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Abstract
The placebo effect has become recognized as an excellent example of mind-body
interaction and as a mechanism of therapeutic action in its own right. Theoretical and
empirical work has shown that one‟s expectations of treatment are important mediators of
the placebo effect, as well as treatment outcomes in diverse areas of health care. Modern
theorists agree that situational and individual factors both contribute to the formation of
positive treatment expectancies; however, only the former has received adequate study.
The current research was designed to investigate the individual psychosocial variables
that are associated with positive treatment expectations, using irritable bowel syndrome
(IBS) as an illness model. People with IBS (n = 289) were recruited online to complete a
survey study. Participants read hypothetical vignettes about state-of-the-art treatments
for IBS and were asked to rate their expectations to benefit from treatment on a
continuous scale. They then completed a series of questionnaires measuring various
individual difference factors, health belief variables and context-specific psychosocial
variables, all identified from the literature as potentially relevant correlates of levels of
expectation. Correlation and regression analyses revealed that several of these variables
were associated with participants‟ ratings of expected treatment benefits, in particular,
perceived somatic focus of treatment and beliefs of personal control over symptoms, as
well as higher levels of optimism and self-focused attention. Weaker relationships were
identified for acute health status, coping self-efficacy, catastrophizing and patientprovider relationship; whereas no relationships were found for trait anxiety, motivational
factors and other health belief variables. Among those with past experience with similar
treatments, previous treatment satisfaction was a strong predictor of current expectations.
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Supplemental analyses revealed that among a sub-sample having previous treatment
experience, along with higher levels of self-focused attention, significant relationships
between treatment expectancies and independent psychosocial variables were more
numerous and more robust. Results are discussed in light of contributions to theory,
directions for future research as well as potential clinical applications.
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Chapter 1
INTRODUCTION
I.

Overview

The ultimate goal of this project is to increase the effectiveness of medical
interventions through identifying the psychosocial factors that contribute to an
individual‟s ability to benefit from treatment. There has been an increasing interest in the
role of psychosocial factors in medicine and health due to the rise of a holistic, nondualistic approach to conceptualizing the human organism, its illness and its healing.
There is one well-known phenomenon in medicine that for years has highlighted the
importance of psychological factors in healing, namely, the placebo effect. Simply, the
placebo effect refers to the situation where an individual shows an improvement in their
symptoms as a result of receiving a secretly inert intervention that the individual believes
to be therapeutic. Many consider the placebo effect as a scientifically validated
phenomenon of „belief becoming biology‟ (Cousins, 1989), and have come to agree that
the belief system of the patient is critically important (Moerman & Jonas, 2000; Ray,
2004). Placebo effects are considered some of the best examples of mind-body
interaction (Ray, 2004; Mayer, 2003), and are now recognized as contributing to
treatment outcome in any therapeutic situation (Benedetti, 2007). Exploring the placebo
effect is thus a useful model within which to begin to explore the contribution of
psychosocial factors to a patient‟s ability to benefit from treatment (Colloca & Benedetti,
2005; Moerman & Harrington, 2005). In this chapter it will be shown that a patient‟s
positive expectancy of treatment outcome is one of the key mediators of the placebo
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effect. On this basis, this project will seek to examine the individual psychosocial factors
that are associated with the magnitude of these integral 'positive outcome expectancies.‟
II.

Introduction to the Placebo Effect

Throughout the history of medicine, the first psychosocial factor recognized to
contribute to health outcomes was the individual‟s beliefs about the effectiveness of a
treatment intervention or provider. Galen, one of the forefathers of modern medicine,
said, “He cures most successfully in whom the people have the most confidence.”
Medical scholars agree that most early medicine was predicated on the power of
individuals‟ belief in treatment, which came to be known as the placebo effect (Shapiro
& Shapiro, 1997).
Before the rise of the biopsychosocial model (Engel, 1977) and the birth of the
field of health psychology, the field of medicine had already identified the importance of
the elusive placebo effect in contributing to health outcomes. Although the term placebo
comes from the Latin phrase „I shall please,‟ the word placebo has had medical
connotations for the last 200 years. An archetypal placebo is a sugar pill given to a
patient with instructions that it is an active substance. Any resulting improvement in the
patient‟s condition is termed the „placebo effect.‟ In practice, a placebo can take almost
any form. Some have suggested that placebos are likely the oldest treatment, as with
very few exceptions, we know that ancient treatments had no intrinsic healing power
(Shapiro, 1960). When successful, what these treatments had in common was that the
person receiving them, and usually the healer himself, believed they might do some good
(Thompson, 2005).
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Early dictionaries (1785) defined a placebo as „a commonplace method of
medicine,‟ and for many years from the early 1800s to the late 1900s, the word placebo
was defined as an inert substance used to „placate‟ a patient‟s need for treatment. With
the rise of the medical model after World War II, the placebo effect came to be
considered a nuisance variable that had to be controlled for in order to ascertain the
genuine effects of supposedly active therapeutic interventions. The „placebo controlled
clinical trial‟ became the gold standard for testing the efficacy of new interventions
(Kaptchuk, 2001), and the definition of the placebo expanded to include „a control
treatment in a clinical trial.‟
As recently as 1999, placebo was defined as an „ineffective substance that may
relieve a condition because a patient has faith in its powers‟ (Oxford Concise Medical
Dictionary). This definition highlights that the patient‟s beliefs play an important role in
the generation of the placebo effect. Current definitions of placebo by scholars in the
field of placebo research remain mum on the mechanisms of the effect (Stewart-Williams
& Podd, 2004). These current definitions state:
A placebo is a substance or procedure that has no inherent power to produce an
effect that is sought or expected.
A placebo effect is a genuine psychological or physiological effect, in a human or
another animal, which is attributable to receiving a substance or undergoing a
procedure, but is not due to the inherent powers of that substance or procedure.
Earnest research into the placebo effect itself has increased over the last halfcentury. Although much of the placebo research has been conducted in the area of pain
and analgesia (see Colloca & Benedetti, 2005; Hoffman, Harrington & Fields, 2005 for
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reviews), it has been demonstrated that the placebo effect is a genuine phenomenon that
has been reported for a variety of health problems, across objective and subjective
parameters (Stewart-Williams & Podd, 2004). Placebos have demonstrated effectiveness
in the treatment of physical symptoms in a variety of medical conditions. Among the
functional disorders and conditions, placebos have produced significant treatment effects
in sexual dysfunction (Cranston-Cuebas, Barlow, Mitchell, & Athanasiou, 1993),
insomnia (Bootzin & Herman, 1976; Kellog & Baron, 1975; Storms & Nisbett, 1970),
hunger states (Heatherton, Polivy, & Herman, 1989), environmental disease (Grandjean,
Guldager, Laresen, Jorgensen, & Holmstrup, 1997), asthma (Joyce, Jackevicius,
Chapman, McIvor & Kesten, 2000), premenstrual syndrome (Freeman & Rickels, 1999),
irritable bowel syndrome (Patel et al., 2005), chronic fatigue syndrome (Cho, Hotopf, &
Wessely, 2005) and nausea (Levine, Stern, & Koch, 2006). There are also substantial
placebo effects reported in the psychiatric literature (see Khan, et al., 2005; Kirsch,
Moore, Scoboria & Nicholls, 2002, as examples). Furthermore, placebo treatment of
medical conditions such as ulcerative colitis (Ilnyckyj, Shanahan, Anton, Cheang, & N.,
1997), hypertension (Hunyor et al., 1997), post-operative swelling (Ho, Hashish, Salmon,
Freeman, & Harvey, 1998), post-operative pain (Levine, Gordon, & Fields, 1978, 1979),
Parkinson's disease (de la Fuente-Fernandez, 2004; Shetty, Friedman, Kieburtz, Marshall,
& Oakes, 1999), infertility (Dunphy, Kay, Robinson, & Cooke, 1990; Garcia et al.,
1985), duodenal ulcer (de Craen et al., 1999), functional dyspepsia (Mearin, Balboa,
Zarate, Cucala, & Malagelada, 1999), inflammatory bowel disease (Hershfield, 1997),
headaches (Roberts, 1994), migraines (Jhee et al., 1997), and warts (Spanos, Sternstrom,
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& Johnston, 1988), has resulted in significant physiological changes and/or amelioration
of symptomology.
Despite these findings, there has still been considerable debate regarding the
veracity of the placebo effect in conditions other than pain (see Hrobjartsson & Gøtzsche,
2001; Wampold, Minami, Tiernery, Baskin, & Bhati, 2005, Wickramasekera, 2001).
Genuine placebo effects have been differentiated from other non-specific effects of
treatment, such as regression to the mean and the natural course of an illness, which are
controlled for in placebo research through the use of a no-treatment control group (Fields
& Levine, 1984; Kirsch, 1997; Stewart-Williams, 2004). Experimental research has also
been instrumental in ruling out artifactual alternatives to genuine placebo responses, such
as sampling biases, reporting biases or demand characteristics (Wager & Nitschke, 2005).
Currently, most researchers agree that placebo effects are partially responsible for
treatment outcomes in almost every area of medicine (Benedetti, 2007; Di Blasi et al.,
2001; Thompson, 2005). Thus, understanding the mechanisms of the placebo
phenomenon has become a crucial scientific endeavor (Crow, Gage, Hampson, Hart,
Kimber & Thomas, 1999; Haour, 2005; Sarinopoulos et al., 2006). From the perspective
of the medical model, the placebo effect was seen as a nuisance variable that can
confound clinical trials. From the more modern biopsychosocial model of health, which
acknowledges that biological, social and psychological factors will each contribute to
health and illness, the placebo effect is viewed as something that might be harnessed to
maximize current levels of clinical efficacy (Chaput de Saintonge & Herxmeimer, 1994;
Hauprich, 1996; Thompson, 2005).
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Early efforts to understand the placebo effect sought to identify individual traits
that may make someone more likely to „succumb‟ to placebo effects, so that these people
could be identified and excluded from controlled clinical trials. Today, the identification
of individuals who respond to placebos seems appealing as it may allow for safer and
more economical health care delivery for those who can benefit from inert treatments.
Unfortunately these early attempts (Beecher, 1955) and those since (e.g., Lasagna,
Mostellar, von Felsinger & Beecher, 1954; Moertel, Taylor, Roth & Tyce, 1976; Shapiro
& Shapiro, 1997) failed to identify people who consistently respond to placebos.
Alternatively, researchers turned to the more fruitful pursuit of studying the situational
factors that may be involved in the placebo effect. These lines of research have
uncovered several interesting situational factors that appear to be related to placebo
effects (Harrington, 1997). For example, placebos have been known to mimic active
agents by producing undesirable side effects. They also commonly follow dose-response
curves, wherein two pills are more effective than one, larger capsules produce stronger
effects than smaller ones, and injections produce greater effects than placebo capsules or
pills (see reviews in Stewart-Williams, 2004 or Kirsch, 2005). However, such research
has not been able to isolate the ideal placebo situation, just as research could not isolate
individuals who consistently respond to placebos.
The placebo effect is certainly a complex phenomenon that eludes simplistic
explanations. Despite its complexity, researchers are still driven to understand the
precursors and mechanisms of placebo effects, due to the recognition that placebo effects
represent a means for therapeutic gain over an above the beneficial effects of an active
intervention, along with the recognition that every therapeutic situation contains the
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potential for placebo responding. This drive has led to some testable models that attempt
to explain the role of situational and personal factors in an individual‟s response to
treatment. It is important to remember that the placebo is by definition „inert,‟ and any
changes occurring within the patient must be due to the interaction of the patient and his
environment (Thompson, 2005).
III. Early Models of the Placebo Effect
A. Biological Model
Our earliest understanding of the placebo effect was that a patient‟s and/or service
provider‟s belief or expectation of outcome was the key element that contributed to
placebo effects (Kupers & Marchand, 2005; Morris, 1997). Early formal models of the
placebo effect, however, focused on biological and conditioning models to explain this
effect. In the late 1970s, researchers discovered that at least some forms of placebo
analgesia were mediated by the brain‟s natural painkillers, i.e., endogenous opioids
(Levine, Gordon & Fields, 1978). This proved an exciting development that spurred
much research into placebo analgesia. Meta-analyses of placebo effects in controlled
clinical trials have now found that placebo analgesia is one of the most common and
potent instances of the placebo effect (Morris, 1997, Hrobjartsson & Gøtzsche, 2001).
Pain research has consistently found that placebo effects account for an average 35% of
any reported therapeutic benefit in relation to pain control (Wall, 1993), over and above
the benefit provided by the active treatment. Although fascinating, these findings offer
an incomplete account of the mechanisms of the placebo effect. For instance, there is no
strictly biological account of how taking a placebo could activate the endogenous opioid
system. Investigators have also discovered that not all placebo analgesia is mediated by
7

endogenous opioid systems (Amanzio & Benedetti, 1999; Gracely et al., 1983).
Furthermore, as reviewed above, placebo effects have been demonstrated in numerous
conditions other than pain (Colloca, Lopiano, Benedetti & Lanotte, 2005; Morris, 1997).
B. Conditioning Model
An early prominent model of the placebo effect is the classical conditioning
model, which posits that in standard treatments, the physical characteristics of the
environment, provider or treatment (conditioned stimulus) become paired with the active
ingredients of the treatment (e.g., morphine, unconditioned stimulus) to elicit
physiological effects (e.g., analgesia, unconditioned response). After „learning‟ that such
characteristics signal physiological changes in the body, a placebo with the same
characteristics (conditioned stimulus) could then elicit the same changes in the organism
(conditioned response) without the presence of the active treatment. This model was
inspired primarily by Ader and colleagues who discovered that they could condition
placebo-induced immunosuppression in rats (Ader & Cohen, 1975). Support for this
model of placebo effects has been demonstrated several times in humans (e.g., Goebel et
al., 2002; Voudouris, Peck & Coleman, 1985, 1989, 1990). A conditioning model
cannot, however, account for all reported aspects of the placebo effect in humans. For
example, this theory cannot explain placebo effects in patients that have never been
exposed to the specific active treatment (Haour, 2005), nor why placebo effects are
resistant to extinction, which is normally seen in classically conditioned learning
(Montgomery & Kirsch, 1997).
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C. Response Expectancy Model
Irving Kirsch‟s (1985) response expectancy model of placebo effects was
considered a main competitor to the conditioning model of the placebo effect. Response
expectancies are anticipations of the occurrence of nonvolitional responses (such as pain,
analgesia, sadness, joy, intoxication, vomiting, alertness, etc) that arise when, in the case
of the placebo effect, an individual is presented with an intervention (Kirsch, 1997a). In
a general treatment scenario where there is a suggestion that a specific treatment would
lead to amelioration in one‟s symptoms, response expectancies (or treatment
expectancies) would refer to one‟s expectation to benefit from that treatment. The
concept of response expectancy was introduced as an extension to social learning theory.
Expectancy was already a central concept in a number of influential theories of learning
and behaviour. Bolles (1972) classified expectancies into two categories. Responsestimulus expectancies are beliefs about the relation between behaviour and environmental
consequences. Stimulus-stimulus expectancies are beliefs that certain stimulus events
predict other stimulus events. In Rotter‟s (1954) social learning theory, which builds on
Tolman's (1932) expectancy model of reinforcement learning, expectancies are
„perceived probabilities that reinforcement will follow behaviour.‟ Behaviour is thus
considered a function of the expectancy that behaviour will bring reinforcement, together
with the perceived value of the reinforcement (an expectancy-value framework). In
Bandura‟s (1977) social learning theory, behaviour is also guided by self-efficacy
expectancies, expectancies regarding one‟s ability to execute behaviour that
reinforcement is contingent upon. In each of these theories, expectancies involve the
occurrence of a voluntary behaviour. Response expectancy theory, on the other hand,

9

refers to expectancies about non-volitional responses, i.e., responses that occur
automatically (Kirsch, 1985). These are the types of expectancies that Kirsch considers
to mediate the placebo effect.
Response expectancies are considered unmediated; this means that no additional
psychological, situational or behavioural factors need be evoked to explain the influence
of response expectancies on placebo responding. They are also considered selfconfirming; for example, if you expect morphine to reduce pain, and you believe you are
taking morphine, then you will experience reduced pain as expected. Early support for
the response expectancy model has been demonstrated in various ways. First, there are
studies wherein the placebo responses are more strongly related to a substance‟s expected
effects than to the substance‟s actual effects. For example, responses to placebo alcohol
have been found to be more closely related to a culture‟s beliefs about the effects of
alcohol rather than its actual physiological effects (MacAndrew & Edgerton, 1969).
Similarly, effects of placebo caffeine often follow individuals‟ beliefs about caffeine‟s
effects (Kirsch & Weixel, 1988; Fillmore et al., 1994).
Second, Montgomery and Kirsch (1997) demonstrated that manipulating subjects‟
conscious expectancies could actually eliminate the effect of conditioned analgesia. In
this important study, Montgomery and Kirsch first employed an established conditioning
paradigm to elicit a placebo analgesia response (Voudouris et al., 1985, 1990). In this
paradigm, subjects are first stimulated on several trials with an electric current to the arm,
in order to determine what intensity of current is subjectively experienced as moderate
pain and low pain for each individual, using a pain intensity scale of 0 (no pain) to 10
(intolerable pain). During a pre-test phase when no placebo intervention is administered,
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subjects are stimulated at a level to generate moderate pain. A placebo „analgesia cream‟
is then applied to certain areas of a subject‟s arm. Then subjects undergo a series of
manipulation trials where stimulus intensity is surreptitiously lowered during placebo
trials so that it generates only „low pain,‟ and kept at a higher level during no-placebo
trials. In the original studies using this paradigm (Voudouris et al., 1985, 1990), these
conditioning manipulations resulted in lower pain reports during placebo trials vs. noplacebo trials in a post-test phase (where the current is kept at the higher level),
demonstrating that placebo responses can be conditioned. To test the contribution of
verbal information to the conditioning of this placebo response, some subjects in
Montgomery & Kirsch‟s study were randomly assigned to an „informed pairing‟ group,
where they were explicitly informed that stimulus intensities were being reduced during
placebo trials in the manipulation phase. As usual, subjects assigned to the „uninformed
pairing‟ group showed a placebo response during post-test, indicating that the
conditioning trials had been successful in eliciting analgesia. In contrast, those subjects
in the „informed pairing‟ group did not show greater placebo responses in the post-test
phase, indicating that the verbal information had eliminated the effect of conditioning.
Montgomery and Kirsch conclude that subjects in the „informed‟ group no longer
expected the placebo cream to produce analgesia.
D. Resolution of the Conditioning – Expectancy Debate
For several years, the conditioning and response expectancy models were
considered opposing models of the placebo effect. However, as evidence accumulated, it
became clear that these models are not mutually exclusive (see Haour, 2005; Kirsch,
2005; Stewart-Williams & Podd, 2004, for reviews). Advances in theories of
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conditioning have aided this shift in conceptualization. It has been recognized that at
least in humans, conditioning involves conscious learning, where the individual comes to
associate or expect certain consequences (the association of the conditioned stimulus with
the unconditioned response, Rescorla, 1988).
There is now almost universal agreement that conditioning involves the
production of expectancies (Benedetti, et al., 2003; Kirsch, Lynn, Vigorito & Miller,
2004). Most contemporary theorists of the placebo effect agree that the majority of
placebo effects are mediated by response expectancies (i.e., expectations to see specific
changes as a result of the intervention; Benedetti et al., 2003; Colloca & Benedetti, 2005;
Kirsch, 2005; Pollo et al., 2001; Vase et al., 2002), although there is evidence that some
placebo effects are mediated by conditioning alone (Benedetti, Pollo, Lopiano, Lanotte,
Vighetti & Rainero, 2003; Pacheco-Lopez, Engler, Niemi & Schedlowski, 2006; Enck,
Benedetti & Schedlowski, 2008). Although expectancies have been shown to be induced
via conditioning procedures, as discussed further later they also can be formed via other
information, such as prior experience, verbal suggestion, observation learning, etc
(Kirsch, 1990, 1997, 2005).
The centrality of expectancies in influencing therapeutic outcomes is a central
assumption of this proposed research. At this point we have reviewed the ubiquity of
placebo effects in the treatment situation, as well as the theory that such placebo effects
are mediated by one‟s expectation to see specific changes as a result of that treatment.
At this point, it will be pertinent to outline the impressive evidence that supports this
theory. First to be presented is the support for response expectancy-mediated outcomes
arising from the placebo literature. This will be followed by evidence in non-placebo
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research that demonstrates the fundamental role of expectations in influencing subjective
and objective health outcomes. Throughout this review and the description of research to
follow, the term „treatment expectancies‟ will be used interchangeably with „response
expectancies,‟ and „treatment expectations.‟ Although an individual could have several
different types of expectations regarding a therapeutic situation or a treatment, herein
„treatment expectancies‟ is used to refer to one‟s expectation to see benefit from
treatment.
IV. Support for the Role of Expectancies
A. Placebo Literature Support
There are several studies from the field of experimental placebo research that
support, either directly or indirectly, the contribution of expectancies to a placebo
response. Indirect support is often demonstrated in studies where explicit expectancies
are not measured, but are either assumed to be induced via verbal suggestion or are
assumed to be present due to experimental procedures.
In an early study of experimental placebo analgesia, Montgomery & Kirsch
(1996) demonstrated that the application of an inert cream accompanied by a verbal
suggestion that the cream was a powerful topical analgesic produced a reduction in pain
(induced via controlled mechanical pain stimuli) at the body site where the placebo was
administered but not at a control body site. Although expectations of analgesia were not
measured, the researchers assumed that verbal suggestion had produced such
expectations.
Similarly, in a study examining the role of conditioning and verbal suggestion in
one clinical condition (motor performance in Parkinson‟s patients) as well as three
13

experimental conditions (placebo analgesia and placebo stimulation of growth hormone
and cortisol release), it was found that verbal suggestion had no effect on hormonal
secretions, whereas it did affect pain reports and motor performance. Verbal suggestions
were also shown to override conditioning procedures to influence pain and motor
performance; however hormonal placebo responses were only responsive to conditioning
(Benedetti, et al., 2003).
In a study of post-operative pain in patients who underwent thoracic surgery for
lung cancer, it was found that different verbal instructions about the certainty of receiving
a painkiller produced different reported analgesic effects, and led to significant
differences in the intake of opioids for pain (Pollo et al., 2001). Following surgery,
every patient received a starting dose of an opioid painkiller, and over the following three
days all patients received intravenous saline, and were treated with the active painkiller
upon request. Patients were randomly assigned to three experimental conditions that
received different verbal instructions about the saline solution that they were receiving.
Those in the „double-blind‟ condition were told that they had a 50% chance of receiving a
placebo or the active painkiller, as in traditional double-blind placebo-controlled trials.
Subjects in the „deceptive‟ condition were deceptively informed that they were receiving
the active painkiller (100% certainty of receiving „active‟ treatment), and those in the
„natural history‟ condition were told that they were simply receiving a rehydrating
solution. The number of doses and total dosage of active painkiller requested by each
group served as the dependent variable. The double-blind group requested a significant
20.8% fewer painkillers than did the natural history group, and the deceptive
administration group requested 33.8% less painkiller. This indicates that a strong placebo
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effect occurred and that it was significantly larger in the deceptive group (those who were
„certain‟ that they were receiving an active painkiller). It is important to note that there
was no difference in the pain intensity ratings of the three groups upon request for
painkiller, further indicating that those who thought that they were receiving a painkiller
were, in fact, experiencing analgesia. The authors highlight that the different placebo
analgesic responses were due to the different verbal instructions, which presumably
induced different expectations for pain relief.
Verbally induced variations in the „certainty‟ of receiving an active treatment
have also been shown to influence the magnitude of placebo responses on a larger scale.
Vase and colleagues (2002) conducted a meta-analysis comparing the magnitude of
placebo analgesia effects in controlled clinical trials (where subjects are informed that
there is a 50% chance of receiving a placebo) versus in placebo analgesia studies (where
subjects are deceptively told that they are certainly receiving an active analgesia). This
study found that placebo effect sizes were modest in clinical trials (d = .15, range = -.95 + .57), but were significantly more robust in placebo studies (d = .95, range = -.64 - 2.29;
p < 01). The authors argue that the main difference between these sets of studies is the
strength of the suggestion for pain relief, and thus presumably the strength of subject‟s
expectations for relief.
Serendipitous support for the powerful role of patients‟ expectations has surfaced
in placebo-controlled trials of acupuncture for post-surgical and chronic pain (Bausell,
Lao, Bergman, Lee, & Berman, 2005; Linde et al., 2007, respectively). In the first study,
investigators preformed a blinding check to ascertain whether subjects thought that they
had been assigned to the active acupuncture group or to the sham acupuncture group
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(Bausell et al., 2005). Although there were no differences in pain reports amongst those
receiving active or placebo treatment, those who believed they were in the active
treatment group reported less pain than those who believed they were receiving the
placebo treatment. In the second study, subjects randomly assigned to active or sham
acupuncture were asked before, and mid-way through several weeks of treatment,
whether they expected to personally benefit from the treatment. At treatment completion,
regardless of group assignment, those who reported high expectations to benefit from
treatment had greater odds of having responded to the treatment. The results of these
studies truly highlight the importance of patients‟ beliefs and expectations about
treatment (Benedetti, 2005, 2007).
Support that is more direct is indicated in several studies where expectations of
treatment outcome are measured directly and found to be positively associated with
actual treatment outcome. Montgomery and Kirsch (1997) first demonstrated a direct
correlation between expected and actual treatment responses in the study that was
described in part above. An additional aspect of this study involved the measurement of
expected pain after conditioning trials and prior to post-test trials using an analogue scale
identical to the one used to measure pain ratings (i.e., „0‟ = no expected pain to „10‟ =
intolerable pain expected). Conditioning trials in the uninformed pairing group altered
participant‟s placebo response expectancies (calculated by subtracting placebo trial
expected pain ratings from no-placebo trial expected pain ratings), as well as their posttest pain reports. Regression analyses found that expected pain levels accounted for 49%
of the variance in reported pain levels. In this study, although conditioning did lead to
placebo analgesia, it appeared to be mediated by expectancies.
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Price and colleagues (1999) conducted a similar experiment of conditioned
placebo analgesia using painful thermal stimulation and a modified within-subjects
design. In this study, separate areas of participant‟s arms were treated with different
„doses‟ of a placebo analgesic, versus a control solution. During conditioning trials,
stimulus intensities at a personal level of 2/10 were delivered to the area treated with a
„strong‟ analgesic. On the area of the „weak‟ analgesic, subjects received stimulation at
an intensity of 5/ 10 and at the „control‟ site intensities were set at 6/ 10. After
manipulation trials, subjects indicated their expected pain intensity and expected pain
unpleasantness on a visual analogue scale (VAS). Placebo effects, manifested both
within sensory and affective dimensions of pain, were shown by reliable reductions in
pain ratings after conditioning trials. Expected levels of pain intensity and
unpleasantness contributed to a large proportion of the variance in sensory and affective
pain ratings within the areas treated with placebo cream, providing further evidence that
the conditioning effect (and the placebo effect) is mediated by expectancy (Price, Milling,
Kirsch, Duff, Montgomery & Nicholls, 1999).
Similar robust associations between expected and concurrent pain intensity and
unpleasantness levels have been demonstrated in other studies of experimental placebo
analgesia, both in clinical (Vase, Robinson, Verne & Price, 2003) and non-clinical
populations (de Jong, van Baast, Arntz & Merckelbach, 1996; De Pascalis, Chiaradia &
Carotenuto, 2002). Together these studies of experimental placebo analgesia support the
expectancy model by indicating that a significant amount of variance in actual pain relief
following placebo treatment can be accounted for by expected pain relief. The proportion
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of variance attributed to expectancies has been reported to vary from 25 to 49% (Vase et
al., 2003).
B. Health Psychology Literature Support
Fascinating studies supporting the role of expectancies in health outcomes have
been reported by an Italian research group, comprising of Benedetti, Amanzio, Pollo and
colleagues, who have been studying the contribution of conscious expectations to
treatment outcomes. For example, Pollo et al., (2002) reported remarkable results
regarding the moderating effect of positive expectations on the motor performance of
Parkinson‟s patients receiving deep brain stimulation via electrodes implanted in
subthalamic nuclei. They found that expectations of good motor performance, induced
by verbal suggestion, actually led to significantly faster hand movements.
This group of researchers have also been studying the contribution of expectations
to health outcomes by using an „open vs. hidden administration‟ paradigm. Here, clinical
patients all receive the active treatment. The „open administration‟ subgroup is made
explicitly aware, through verbal information and observable procedures, that they are
receiving the active treatment. The „hidden administration‟ subgroup receives the active
treatment without their knowledge (e.g., in their intravenous saline). Using this
paradigm, these investigators have been able to truly distinguish the effects of an active
treatment while controlling for the effects of a patient‟s expectations of treatment, and
have contributed valuable support for the role of expectations in the therapeutic context.
This paradigm was first used in the 1980s to study placebo analgesia. In a study
of postoperative pain following oral surgery, it was found that a hidden injection of 6-8
mg of morphine was equivalent to an open injection of placebo morphine (saline). In
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other words, telling a patient that a painkiller is being administered is as potent as 6 –8
mg of morphine (Colloca & Benedetti, 2005)! Benedetti et al., (2003a) reported a study
of the open vs. hidden administration of treatment in three clinical conditions
(postoperative pain, postoperative anxiety, and subthalamic stimulation in Parkinson‟s
patients) and two experimental conditions in healthy subjects (administration of a betablocker and a muscarinic antagonist). In each of these conditions it was found that the
open administration was significantly more effective than the hidden administration.
These results show clearly that a person‟s knowledge about an intervention affects their
response to the intervention.
Several other independent studies where expectations have been measured also
lend support to the central role of expectancies in contributing to various health outcomes
(Mondloch, Cole & Frank, 2001). Briefly, it has been reported that positive treatment
expectancies predict substantial amounts of variance in nurses‟ reports of physical health
status following heart transplants (Leedham et al., 1995), expectations regarding
symptoms have been found to predict symptom severity after oral surgery (McCarthy,
Lyons, Weinman, Talbot & Purnell, 2003), depressed patients with high expectations of
benefit show a greater response to antidepressant medication (Krell, Leuchter, Morgan,
Cook, & Abrams, 2004), and positive outcome expectancies predict several outcome
measures at post-treatment after cognitive-behavioural treatment for chronic fatigue
syndrome (Goosens, Vlaeyen, Hidding, Kole-Snijders, & Evers, 2005). Patient
expectations of the likelihood of experiencing severe nausea during chemotherapy have
been found to be a strong predictor of actual nausea (Montgomery et al., 1998; Roscoe et
al., 2004). Furthermore, negative expectations regarding the course of one‟s illness have
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been found to predict poor outcome for chronic fatigue symptoms in a controlled clinical
trial (Chadler, Godfrey, Ridsdale, King, & Wessely, 2003).
Additional evidence that expectancies play a role in physical symptomotology can
be found in experiments where symptoms have been reduced by manipulating patient
expectancies, usually via suggestion. Such experiments have found that enhancing
expectations for a positive outcome can increase gastrointestinal motility in patients
undergoing abdominal surgery (Disbrow, Bennet & Owings, 1993), reduce blood loss
during elective spinal surgery (Bennett, Benson, & Kuiken, 1986), modulate cellular
immune dysregulation (Kiecolt-Glaser, Marucha, Atkinson & Glaser, 2001), enhance
immune reactions to an injection of tuberculin (Smith & McDaniel, 1983), and potentiate
release of endogenous dopamine (Fuente-Fernandez et al., 2001).
V.

How Expectancies Lead to Placebo Effects

This review has clearly revealed that across a wide range of different therapeutic
contexts, one‟s expectations about their symptoms, their illness and the outcome of their
treatment can have a notable impact on one‟s response to treatment. Having established
the association between a person‟s expectations and their response to interventions (see
also Crow et al., 1999), we are left with the difficult question of how expectancies
influence therapeutic outcomes. Despite Kirsch‟s position that response expectancies are
directly self-confirming, there are several factors that have been proposed to mediate this
relationship, including behavioural change, cognitive-attentional biases, emotional
change and neurobiological change. Although a clear understanding of the mechanisms
by which expectations influence outcome is not integral to the proposed research, they
will be summarized here to satisfy the potential curiosity of the reader and strengthen our
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key assumption that positive treatment expectancies contribute to positive intervention
outcomes.
A. Behavioural Change
Some contend that positive expectations of treatment outcome contribute to better
outcomes via changes in a patient‟s behaviours, such as improved adherence to treatment,
greater activity levels or increased seeking of social support (Stewart-Williams, 2004).
There are at least two studies that have shown that positive expectations are related to
behaviour change. It has been demonstrated that positive expectations are related to
better self-care in chronic disease patients (De Ridder et al., 2004), and that higher preoperative expectations predict later adherence to a complex medical regimen (Leedham,
Meyerowitz, Muirhead, & Frist, 1995). Although there may be a role for behaviour
change, this proposed mediator of expectations cannot account for many instances of
expectation-mediated placebo responding. For example, it is difficult to argue that
behavior change is responsible for the significant placebo analgesia effects demonstrated
using the open versus hidden paradigm for post-operative pain (Colloca & Benedetti,
2005).
B. Cognitive- Attentional Biases
It is suggested that expectations about the effects of a treatment may contribute to
subjective changes through the creation of cognitive-attentional biases (Caspi & Bootzin,
2002). Stewart-Williams (2004) suggests that expectations may induce schematic
processing changes, wherein there is an increased likelihood that subjects may perceive
and recall an effect when none has occurred, or when changes are small. Alternatively,
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subjects with greater expectations may overlook ambiguous or disconfirming symptoms
in post-treatment reports. As discussed by Stewart-Williams (2004), the activation of
these cognitive schemas (e.g., “I will experience analgesia”) may serve to direct one‟s
attention inward towards sensations indicative of analgesia. He notes that there is
evidence that attending to internal experiences such as sensations and emotions can
amplify these experiences (Franzoi, 1996). Some potential support for this theory is
found in a study where individuals with greater expectations of the benefit of elective
surgery reported more perceived improvement in their symptoms, but not fewer
symptoms or better health post-surgically than individuals with lower expectations
(Flood, et al., 1993). These investigators suggest that perhaps those with greater
expectations place more importance on any mild symptom improvements that they
experience.
Further support for the idea that expectations may influence outcomes via
cognitive-attentional biases comes from cases where a reverse placebo effect is found.
An example of a reverse placebo effect is when subjects are given a placebo together
with the suggestion that is a relaxant, yet some subjects report increased arousal relative
to baseline (Duncan & Laird, 1980). It has been suggested that individuals who have a
tendency to attend to internal stimuli, as opposed to external stimuli (e.g., verbal
suggestion), may selectively attend to and notice sensations associated with arousal as
opposed to relaxation, which then produces a reverse placebo effect (Sirois, 2001, 2009).
It could be argued that selectively attending to and reporting disconfirming symptoms
may interact reciprocally with the contingent activation and confirmation of expectations
for arousal. Overall, at this time there is neither strong support nor refutation for the
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account that cognitive-attentional biases mediate the expectancy-outcome relationship.
However, as discussed later, such attentional biases likely modulate the strength of
situationally induced expectations (Sirois, 2001, 2009).
C. Emotional Change
It has been suggested that positive expectations may induce emotional changes,
which then contribute to better health. For example, there is a strong health psychology
literature that shows that lower levels of anxiety, depression or demoralization contribute
to better psychological and physical health, via reduced stress hormone levels, improved
sleep, greater activity, etc. (Stewart-Williams, 2004). There is certainly some evidence
that suggests that expectations may influence subjective health via changes in affective
states. For instance, one study found that positive outcome expectancies (measured on a
general optimism scale) were related to decreased symptom reports in patients with
diabetes, and that this relationship was mediated by decreased negative affectivity
(DeRidder, Fournier, & Bensing, 2004). Another study found that both reduced
expectation of pain and reduced fear of pain contributed to placebo analgesia (de Jong,
van Baast, Arntz, & Merckelbach, 1996), yet here a mediation model was not tested. At
this time, there have been no empirical studies directly testing the role of emotional
change in mediating the relationship between expectations and outcome. There is reason
to believe that this model of mediation is insufficient. Specifically, placebo analgesia
research demonstrating the link between expectation and analgesia (Montgomery &
Kirsch, 1996; Price et al., 1999) has also shown that placebo effects can be found in
specific body zones but not others simultaneously, suggesting that these effects are not
mediated by global mechanisms such as anxiety reduction.

23

D. Neurobiological Change
In Kirsch‟s (1985) response expectancy model of placebo effects, he posits that
expectancies lead to placebo effects directly, (i.e., they are not mediated by other
psychological or behavioural factors). This model implies that expectations induce
neurophysiological events that manifest as placebo effects. This indeed is the „black box‟
of this field of study, yet a lot of headway has been made in the last few years. Research
has shown that placebos can produce changes in the brain similar to those of the drugs
they are „mimicking‟ (Lieberman et al., 2004), and brain imaging studies have shown that
placebo effects are associated with specific and localized changes in brain functioning
(Haour, 2005). For example, placebo dopamine administration is associated with the
release of endogenous dopamine and binding to the corresponding receptors (De la
Fuente-Fernandez, et al., 2001; De la Fuente-Fernandez & Stoessl, 2002). A similar
effect has been shown for caffeine; placebo caffeine seems to stimulate the same
neurochemical actions as does the ingestion of real caffeine (Kaasinen, Aalto, Nagren &
Rinne, 2004).
Considerable progress has been made in our understanding of the neurobiological
mechanisms of the placebo effect, and most of our knowledge originates from the field of
pain and analgesia (see Colloca & Benedetti, 2005 for a review). Petrovic and colleagues
(2002) demonstrated that placebo and opioid analgesia share a neuronal network. It has
also been shown that placebo analgesia operates through both opioid and non-opioid
mechanisms (Gracely et al., 1983; Amanzio & Benedetti, 1999) and researchers have
begun to discuss the distinction between bottom-up pain pathways and top-down
„expectation‟ pathways of drug analgesia (Colloca & Benedetti, 2005). Functional neural
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imaging studies (fMRI) have found that placebo analgesia is related to decreased activity
in pain-sensitive brain regions (Kong et al., 2006; Wager et al., 2004), and it has been
shown that expectations of analgesia correlate with opioid release in some of these areas
(Zubieta, Yau, Scott, & Stohler, 2005). At this time there have been at least two theories
proposed to understand the neural circuitry of expectation-induced analgesia (see Enck,
Benedetti & Schedlowski, 2008; Lieberman et al., 2004; Ploghaus, Becerra, Borras, &
Borsook, 2003).
Research has also begun to uncover the neurophysiological correlates of the
placebo or expectation response in conditions other than pain, such as Parkinson‟s,
depression, immunological and hormonal responses and cardiovascular responses (for
reviews see Colloca, Lopiano, Benedetti & Lanotte, 2005; Pacheco-Lopez, Engler, Niemi
& Schedlowski, 2006). For example, endogenous neurotransmitters released within the
cortex and brain stem in response to expected pharmacologic effects have been shown to
modulate immunologic and end organ function through distinct efferent neural pathways.
Three of these pathways that have been extensively studied are the neocorticalsympathetic-immune axis, the brain stem-vagus-cholinergic pathway, and the
hypothalamus-pituitary-adrenal immune axis, which modulate effects through the release
of norephinephrine, acetylcholine, and adrenocorticotropic hormone, respectively
(Pacheco-Lopez et al., 2006). Additionally, brain-imaging studies have discovered some
of the neural correlates of placebo-induced reductions in taste aversion (Nitschke et al.,
2006; Sarinopoulos, Dixon, Short, Davidson & Nitschke, 2006), and visually induced
anxiety (Petrovic et al., 2005). Advances in understanding the neural circuitry involved
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in expectation-induced autonomic responses are thought to be relevant towards the
understanding of how expectations affect the immune system (Lanotte et al., 2005).
E. Summary
There have been several accounts about how response expectancies may come to
generate objective and subjective changes in people. A fair amount of recent research
has focused on the neurobiological changes that accompany placebo administration.
Despite this recent focus, it is conceivable that in the near future we will see the
integration of cognitive-attentional, affective and neurobiological factors into a dynamic
and reciprocal model of how response expectancies induce therapeutic changes.
VI. Inducing Expectancies
As discussed above, modern models of placebo effects recognize that response
expectancies are central (Stewart-William, 2004), and it has come to be accepted that
expectations can play a role in influencing outcome in any treatment scenario. The
„expectation effect‟ account does not rule out the influence of the therapeutic
relationship, the provider‟s expectations, or sociocultural factors; instead it is thought that
the effects of such factors come through their influence on the recipient‟s expectancies
(Stewart-Williams & Podd, 2004). Those who write about the expectation account of
placebo responding agree that people may acquire expectancies in various ways, for
example through conditioning, observational learning, direct personal experience, or
verbal suggestion (Kirsch et al., 2004; Stewart-Williams, 2004; Vase, Robinson, Verne &
Price, 2003). Other than this general agreement, there has not been much discussion or
investigation regarding the genesis or the correlates of these important response
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expectancies. As outlined above, the focus of work in this area has been on testing the
role and influence of response expectancies, as well as their mechanisms of action. This
line of research is crucial and intellectually interesting, and support for the role of
expectancies and research into their mechanisms of action are certainly accumulating.
However, it is felt that at this point, it can also be clinically relevant to examine the
psychosocial factors that contribute to the magnitude of expectancies (Janzen, Silvius,
Jacobs, Slaughter, Dalzial, & Drummond, 2006). Since we know that expectations
regarding treatment contribute to significant amounts of variance in treatment outcome,
from a clinical point of view it is important that we now begin to understand what factors
contribute to these expectations. This remains an area of study that has not yet been
sufficiently explored, and is the focus of the current research. In order to proceed, we
will first explore theoretical accounts of expectancy formation.
A. Theories of Expectancy Formation
On a basic level, expectancies are defined as beliefs about a future state of affairs.
They are subjective probabilities linking the future with an outcome at some level of
probability ranging from merely possible to virtually certain (Olson, Roese & Zanna,
1996). It is thought that expectancies have evolutionary significance, as one of the
fundamental purposes of the brain is to anticipate the future (Dennett, 1991). The
capacity for memory has survival value in that it allows for the learning of contingencies
between two stimuli/responses; contingencies that can be used to anticipate the future
relationships between these stimuli and responses so that the organism can minimize
punishment and maximize reward. Thus, it follows that evolution must have favoured

27

organisms that managed to construct predictions about future contingencies (i.e.,
expectancies).
As noted above, expectancies are considered one type of belief, namely, beliefs
about the future. Not all beliefs are expectancies, but all beliefs imply expectancies (i.e.,
it is possible to derive an expectancy from any belief). For example, „Fire is hot‟ is a
belief, „If I touch fire I will be burned‟ is an expectancy derived from the belief. „Fire is
hot‟ is not an expectancy itself, but a belief about the world. As expectancies are beliefs
about the future, the question of how expectancies form is really a question of how
beliefs are formed (Olson et al., 1996).
Beliefs themselves can be classified in an innumerable number of ways (e.g.,
beliefs about cats, beliefs about what people do in the spring, etc). As such, it is
sometimes considered more productive to classify the sources from which beliefs are
developed (Olson et al., 1996). Olson et al. outline that beliefs come from three major
sources; namely, a) direct personal experience, b) indirect experience (vicarious learning,
communication from others), and c) other beliefs. Moreover, „other beliefs‟ are
acknowledged to have formed from either direct experience or third-party
communications, and often can be conveniently categorized as beliefs about the self,
beliefs about others and beliefs about the world. Note the similarity here between the
sources of belief development and the sources of response expectancy development
mentioned above. Specifically, in both cases it is agreed that beliefs (and thus
expectancies) can be induced via direct or indirect experience with the world. Although
Kirsch (1985) comments briefly that attributional processes may also be a source of
response expectancies, he doesn‟t elaborate about how „other beliefs‟ may be an
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important source for expectancy development. Luckily, general expectancy theory does
elaborate how other beliefs may also be a source of specific beliefs (and thus
expectancies). For example, causal attributions may be a source of beliefs: if something
is attributed to stable causes, similar outcomes will be expected in the future.
Furthermore, logical inferences are made to derive situation-specific beliefs from other
existing beliefs (e.g., nice doctors are effective doctors, thus the treatment received from
this nice doctor will be effective).
Expectancies are thought to vary on certain dimensions, most notably in level of
certainty, or strength/ magnitude. The source of the belief/ expectancy development is
thought to be one of the determinants of the level of certainty of a particular expectancy.
For instance, if the expectancy was formed based on direct personal experience, it is
thought to be held with more certainty than if developed from indirect experience (Fazio
& Zanna, 1981; Stewart-Williams, 2004). What is harder to predict is the relative level
of certainty for expectancies derived from beliefs that are derived from other beliefs
(Olson et al., 1996). Furthermore, in the general expectancy literature, there seems to be
little theoretical or empirical work focused on how various relevant pieces of information
are integrated to determine the level of certainty of a specific expectation. Since the
strength of treatment outcome expectancy has been found to correlate substantially with
subjective and objective outcome parameters, it may be clinically relevant to begin to
develop an integration model.
Fortunately, there has been some initial work in this direction among placebo
researchers and theorists. For instance, most researchers agree that both situational and
individual factors interact to contribute to the magnitude of a placebo effect (Enck &
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Klosterhalfen, 2005; Geers, Helfer, Kosbab, Weiland & Landry, 2005; Montgomery,
David, DiLorenzo & Erblich, 2003; Patel et al., 2005), and most agree that the placebo
effect is mediated by expectancies. As such, there has been some effort to discuss how
different sources of information are used in the determination of response expectancy and
placebo effects. The Belief-Activation Model, proposed by Sirois (2001, 2009), is a
useful contribution to this discussion.
B. Belief-Activation Model
The Belief-Activation Model (BAM) is the first model of placebo responding to
really integrate the contribution of situational and individual factors to the strength and
direction of treatment expectancies. This model highlights the interaction of contextual
and individual differences in the formation of positive or negative placebo effects.
Contextual differences are considered „placebo-salient cues,‟ which include differences in
the physical, informational, and interactive aspects of the intervention context, including
verbal suggestions. Such placebo-salient cues are thought to activate expectations about
the specific treatment and its context. Presumably, certain aspects of the environment
will activate „other beliefs‟ about what to expect in „this type‟ of environment, beliefs
that were formed previously based on direct or indirect experiences. Sirois‟ BeliefActivation Model acknowledges that expectancies can also be reflections of more
inclusive beliefs about healing outcomes; beliefs that are influenced both by personal
experiences and culturally specific beliefs. This model is unique in that it highlights the
importance of individual difference variables in the generation of a placebo response. In
particular, it is posited that certain individual difference variables can either enhance or
attenuate the strength of the treatment expectancies that are activated by placebo-salient
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cues. This model is useful in that it can explain why there is variability in treatment
expectancies and placebo responses across individuals even when contextual factors
remain constant. It acknowledges that each individual will come to the treatment setting
with a unique set of beliefs about illness and healing (e.g., „I have a weak immune
system‟), as well as unique psychological characteristics (e.g., low levels of self-focused
attention) that can modulate the personal salience of situational cues.
VII. Purpose of Current Research
The current research was inspired by the placebo literature, which has highlighted
the importance of treatment expectancies in the generation of treatment outcomes, both in
experimental and clinical contexts. Given that such treatment expectancies have been
shown to play a central role in the placebo effect, as well as in the outcome of active
treatments, it is thought that anything that helps activate and maintain these positive
expectations may facilitate overall improved treatment outcomes across a variety of
settings and conditions. Understanding the development of such expectancies is thus an
important endeavor, one that has not received much empirical attention (Olson et al.,
1996; Janzen et al., 2006). As noted earlier, the contextual factors that contribute to the
strength of positive treatment expectancies have been well studied in the placebo
literature (Harrington, 1997). However, much less empirical work has examined the
contribution of personal factors. Theoretically, there has been some effort to identify
those person-specific factors that will contribute to the formation of treatment
expectancies. Kirsch‟s Response Expectancy Model of the placebo proposes that both
verbal suggestion and prior learning (via conditioning, observation or direct experience)
will influence the magnitude of one‟s expectations of outcome. Second, the general
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expectancy literature adds that expectancies are derived from beliefs, and that beliefs are
formed based on information garnered through direct experience, third-party
communication, or derived from other beliefs. The Belief-Activation Model of the
placebo acknowledges the influence of contextual factors but also highlights a role for
both individual difference factors and health beliefs in the generation of a placebo
response. The goal of this project was to combine these models of placebo responding
and expectancy formation, to hold the contextual variables constant, and to really focus
on identifying the psychosocial variables that contribute to treatment expectancies. It is
important to note that this research was not designed to test these models, but to
synthesize and extend them by identifying and testing the types of health beliefs, the
range of individual difference factors and the specific context-dependent psychosocial
variables that contribute to one‟s level of expectation to benefit from treatment.
In order to identify potential psychosocial variables that may influence the
magnitude of expectancies, several literatures are reviewed herein. First, the placebo and
health psychology literatures are reviewed to identify individual difference factors that
have been found to contribute either to treatment expectancies, placebo responses or to
health outcomes. This will be followed by a similar review identifying important health
belief factors. Following this, a review will be made of the psychosocial correlates of
symptom report in people with irritable bowel syndrome (IBS), the clinical population
that has been chosen to be a model for this investigation.
VIII. Identifying Individual Difference Variables
In the placebo literature, there have been many individual factors suggested to
contribute to placebo effects in general and outcome expectancies in particular. One‟s
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level of faith, optimism, trust, anxiety, and suggestibility are all concepts associated with
placebo reactivity (Chaput de Saintonge & Herxheimer, 1994; Vase et al., 2003).
However, few of these variables have been tested or verified empirically. Sirois (2001,
2009) reviewed several individual difference factors that have been suggested, over the
years, to influence placebo responding. It was found that factors such as demographics,
hypnotizability, religiosity and acquiescence have not been reliably associated with
placebo responsiveness.
A. Self-Focused Attention
One individual difference factor found to influence placebo responding is selffocused attention, conceptualized as a predisposition to focus on and be aware of internal
states and sensations. Sirois (2001, 2009) reviewed the empirical support for the
influence of self-focused attention on placebo effects and incorporated this factor into the
Belief-Activation Model. Briefly, it has been found that individuals with higher levels of
self-focused attention (either naturally or via induction) are less responsive to placebo
suggestions (Gibbons & Gaeddert, 1984) and sometimes display a reverse placebo
response (Duncan & Laird, 1980; Gibbons, Carver, Scheier, & Hormuth, 1979). The
Belief-Activation Model provides an explanatory framework for understanding how selffocused attention alters placebo responsiveness. Sirois notes that attention is a limited
resource; the more focus directed toward internal stimuli, the less attention is paid to
external information (Carver & Scheier, 1981). Thus, although placebo-salient cues (e.g.,
verbal suggestion) may induce expectations for certain physiological responses, focus on
internal cues may detract from, or contradict, these externally activated expectations. In
order to resolve this belief conflict, it is posited that the individual combines these beliefs
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into a more inclusive expectancy, for example, that „Although the treatment is normally
effective, I will not necessarily benefit from this treatment.‟
In contrast to the findings presented above, recent research suggests that greater
self-focused attention can also increase placebo responding. In particular, Geers and
colleagues (Geers, Helfer, Weiland, & Kosbab, 2006) describe a study wherein selffocused attention was manipulated by having half the participants tally their negative
internal sensations after ingesting a (placebo) drug “known” to produce negative
sensations as a side effect. Participants were also randomly assigned to conditions
differing in their level of placebo suggestion. The „unconditional expectation‟ group was
told that they were receiving the active drug; whereas the „conditional expectation‟ group
was told that there was a 50:50 chance of receiving the „active‟ drug or a placebo, and a
control group was given no placebo suggestion. Placebo responding (increased negative
sensation reporting) was only observed among those in the unconditional expectation
group who received the manipulation designed to increase self-focus. These results
suggest that increased self-focused attention led to increased placebo responding because
participants with stronger expectations directed more of their attention to internal
sensations that confirmed these expectations. Findings such as these are consistent with
the Belief-Activation Model, which posits that an individual‟s predisposition to be
internally focused represents one individual difference factor that moderates the
magnitude of one‟s expectations of treatment outcome. An adaptation to the model that
is suggested by these findings is that self-focused attention seems to be able to either
increase or decrease placebo responding according to whether internal cues either
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confirm or contradict one‟s initial expectations induced via external cues (verbal placebo
suggestions).
An important point to mention is that the Belief-Activation Model proposes that
the level of self-focused attention may alter the strength of the expectation activated by
external information, at a point in time after a placebo has been administered. For
instance, after receiving an intervention accompanied by information that it will result in
relaxation, a highly self-focused individual would be particularly attentive to internal
sensations. This intense internally focused attention may bring to awareness sensations
that either contradict or confirm the initial expectation for relaxation, thus altering the
strength of the expectation that the intervention will lead to relaxation. What remains
unclear is which factors influence a person‟s tendency to attend to internal stimuli that
confirm vs. contradict the initial expectations. The results of the Geers et al., (2006)
study suggest that the strength of the initial expectations may be a factor that influences
the attention to confirmatory or contradictory internal stimuli. This suggestion is based
on their findings that increased self-focused attention was only related to increased
placebo responding among those participants who were „certain‟ that they were receiving
an active drug with negative side effects, whereas there was no effect of increased selffocused attention among those told that they had a 50% chance of receiving the active
drug.
There is evidence from the self-focused attention literature that suggests that this
individual difference variable can indeed influence expectancies. In particular, it has
been found that self-focus increases access to self-knowledge. According to expectancy
theorists, accessibility is one of the determinants of the strength of a belief and its
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corresponding expectancy (Olson et al., 1996). Furthermore, research has shown that
increased self-focus (both trait and state) leads to perseverance of beliefs about self
(Davies, 1982, 1993, 1994). With this in mind, it seems reasonable to suggest that
personal health beliefs may be stronger predictors of treatment outcome beliefs (and
expectancies) among individuals with higher levels of self-focus relative to individuals
with lower levels of self-focus.
B. Anxiety
In relation to health and treatment outcomes, the health psychology literature is
replete with studies indicating that anxiety is negatively related to general health and
recovery from illness (Rozanski, Blumenhal & Kaplan, 1999; Salaffi, Cavalieri, Nolli &
Ferraccioli, 1991; see also Taylor, Kemeny, Reed, Bower & Grunewald, 2000). For
example, anxiety has been found to exacerbate pain (Staats, Hekmat, & Staats, 1998), and
to impair the immune system (Lundh, 2000). Anxiety has also been shown to influence
placebo responsiveness. Studies have found that mild to moderate levels of pre-treatment
state anxiety are predictive of an enhanced placebo response (Coryell & Noyes, 1988;
Rickels, Baumm, Raab, Taylor & Moore, 1965; Rickels & Downing, 1967; Shipman et
al., 1974; Zuckerman, 1974). On the other hand, high levels of trait anxiety have been
found to reduce or eliminate the placebo response (Coryell & Noyes, 1988; Pollack et al.,
1994; Uhlenhuth et al., 1998; Zuckerman, 1974), or contribute to a reverse placebo
response (Loebel, Hyde & Dunner, 1986; Rickels & Downing, 1967; Uhlenhuth et al.,
1998). Sirois (2001, 2009) has incorporated this individual difference variable into the
Belief-Activation Model, specifying that levels of anxiety also act to moderate the
strength of one‟s contextually-cued treatment expectancies. The role of anxiety is
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explained in part by incorporating the well-established relationship between anxiety and
self-focused attention. For example, it has been demonstrated that the state of anxiety is
accompanied by attentional biases; individuals high in anxiety tend to selectively attend
to threatening stimuli (Owens, Asmundson, Hadjistavropoulos & Owens, 2004; Mathers,
May & Eysenck, 1990). Furthermore, it is noted that anxiety is thought to act in concert
with self-focused attention, with the two being mutually enhancing. For example,
Gibbons (1991) has suggested that self-focused attention is a necessary and integral part
of the experience of anxiety, and self-attention promotes anxiety by enhancing awareness
of this emotional state. Empirically, it has been demonstrated that anxiety and selffocused attention do co-occur (Mor & Winquist, 2002) and contribute to increased
negative symptom reporting in medical and student populations (Ahles, Cassens, &
Stalling, 1987; Martin, Ahles & Jeffery, 1991). The Belief-Activation Model proposes
that the attentional deficits and biases involved with high levels of anxiety diminish an
individual‟s ability to attend to placebo-salient cues, and thus diminish the establishment
and/or maintenance of positive treatment expectancies.
Although there seems to be a reliable association between anxiety and health, and
anxiety and placebo outcome (Sirois, 2001, 2009), at this time there are mixed results
regarding the association of anxiety to outcome expectancies. One study found no
relationship between state and trait anxiety and pre-intervention outcome expectancies for
people undergoing oral surgery (McCarthy, et al., 2003); another reported no relationship
between trait anxiety and expectations of nausea during chemotherapy treatment
(Montgomery et al., 1998). On the other hand, fear (of re-injury) has been shown to be
inversely related to expectations of treatment efficacy in a chronic pain sample (Goosens
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et al., 2005). Furthermore, in a study of experimental placebo analgesia in an IBS
sample, it was reported that levels of anxiety regarding upcoming pain was positively
correlated with both expected and actual pain (Vase, Robinson, Verne & Price, 2005).
Although the relationship between anxiety and treatment expectancies has not been
clearly established, the empirically grounded Belief-Activation Model provides good
theoretical support for this relationship.
C. Optimism/ Pessimism
In the general health psychology literature, optimism has been identified as an
individual difference variable that pertains to relatively stable expectations that good
things will happen, whereas pessimism pertains to expectations that bad things will
happen (Steed, 2002). Research has verified that dispositional optimism consists of these
two separate but often negatively correlated dimensions (Bryant & Cvengros, 2004).
Behavioral medicine studies that have examined these dimensions independently,
frequently report that optimism and pessimism show differential relationships to various
measures of health in both clinical and non-clinical samples (Mroczek, Spiro, Aldwin,
Ozer & Bosse, 1993; Robinson-Whelen, Kim, MacCallum & Kiecolt-Glaser, 1997;
Räikkönen & Matthews, 2008). In general, greater optimism has been linked to more
favourable health indicators and outcomes, for example: stronger immune functioning
(Segerstrom, Taylor, Kemeny, & Fahey, 1998), improved survival rates for cancer and
heart disease patients (Allison, Guichard, Fung & Gilain, 2003; Buchanan & Seligman,
1995, respectively); and lower risk of overall mortality in a 30-year study (Maruta,
Colligan, Malinchoc, & Offord, 2000). Perhaps not surprisingly, greater pessimism has
been found to be associated with less favourable health indicators and outcomes, for

38

example: weaker immune functioning (O‟Donovan, et al., 2008), more pain and lower
functionality in post-surgical heart disease patients (Mahler & Kulik, 2000) and increased
mortality rates among cancer patients (Schulz, Bookwala, Knapp, Scheier & Williamson,
1996).
In the placebo literature, optimism and pessimism are two of the individual
difference variables whose influence on placebo responding have been studied directly.
As the personality literature suggests that pessimists are more likely to be influenced by
negatively-toned information, Geers and colleagues (2005) decided to test individuals
identified as optimistic or pessimistic on their responsiveness to a negative placebo
(suggestion of unpleasant sensations). This study reported that although optimists in the
placebo group did not report more unpleasant symptoms than the control group,
individuals identified as pessimistic did show a placebo response (Geers, Helfer, et al.,
2005). To explore the possible interaction of self-focused attention, half of the
participants were encouraged to signal whenever they experienced a change in their level
of unpleasant sensations. It was reported that this manipulation did not affect negative
symptom reporting, suggesting that the influence of pessimism is not just a function of
attentional biases. Geers and his research group (Geers, Kosbab, Helfer, Weiland &
Wellman, 2007) subsequently looked at the relationship of optimism/ pessimism to
placebo responding in a study where the placebo suggestion was positively toned (a
writing task improves sleep quality). Here, it was found that greater levels of optimism
were associated with improved sleep quality, yet only in the placebo group. In two nonplacebo control groups (one completing the writing task without suggestion for sleep
improvement, one with no writing task), optimism was not associated with improved
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sleep quality, suggesting that in this sample, optimism was related to outcome only when
there was a positive placebo suggestion. Although in both of these studies participants‟
expectations were not directly measured, it is likely that optimism/pessimism contributed
to placebo responding by moderating the extent to which participants believed the
experimenter‟s suggestions.
In another study, the relationship between optimism/pessimism and the strength
of expectancies for non-volition responses was studied directly (Montgomery, David,
DiLorenzo & Erblich, 2003). In this study, participants were asked how much they
expected certain non-volitional outcomes (both positive and negative) to occur. For
example, they were asked to rate how much alertness they expected to experience after
drinking coffee (positive) or how much pain they expected to experience after undergoing
surgery (negative). Here again, degree of dispositional pessimism was correlated with
expectancies for negative non-volition occurrences, whereas optimism was not related to
levels of expectancy.
One study has demonstrated that optimism positively influences expectations of
benefit from clinical treatment. Weinfurt and colleagues (2003) conducted an interesting
study examining patient characteristics that were associated with expectations of benefit
from Phase I clinical trials for cancer treatment. Participants indicated their expectations
of benefit on a visual analogue scale, and completed several survey measures regarding
their health beliefs and personal characteristics. The authors reported a moderate positive
correlation (r = .28) between expectation of benefit and a single-item measure of general
dispositional optimism. This suggests that individuals with higher levels of dispositional
optimism also report higher expectations that they will benefit from treatment.
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D. Hope
The predominant conceptualization of dispositional hope is that it is a “cognitive
set that is based on a reciprocally derived sense of successful (a) agency (goal-directed
determination) and (b) pathways (planning of ways to meet goals)” (Snyder et al., 1991,
p. 571). Dispositional hope is a variable that has also been implicated as relevant in
contributing to health outcomes (Scioli et al., 1997; Snyder, 2002; Snyder, Sympson,
Michael & Cheavens, 2001), and has been suggested to play a role in the placebo
response (Yahne & Miller, 1999). Hope is a construct similar to optimism, although
recent research has indicated that hope and optimism are distinct constructs (Bryant &
Cvengros, 2004). In particular, hope has been distinguished from optimism as it
considered more of an affective state, used in situations where outcomes are deemed
more important, less likely and under less personal control (Bruininks & Malle, 2005).
Similarly, expectancies and hope have been shown to be independent but related
constructs, and it has been shown that hope contributes to response expectancies for nonvolitional responses (Montgomery et al., 2003). In a recent qualitative study examining
expectations of benefit in randomized clinical trials, hope was mentioned by almost all
participants as a factor that contributes to their positive treatment expectancies (Stone,
Kerr, Jacobson, Conboy, & Kaptchuk, 2005). Based on the empirical and theoretical
support for the contribution of hope to health, placebo responding, response expectancies
and positive treatment expectancies, this individual difference variable is thought to
warrant further study.
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IX. Identifying Health Belief Variables
The general literature on expectancy formation specifies that an individual‟s
preexisting beliefs can be an important source of information in the generation of specific
current beliefs and thus, expectancies. Furthermore, the Belief-Activation Model
specifies that external cues will interact, either synergistically or competitively, with an
individual‟s personal health beliefs to influence the strength of treatment expectancies.
One of the purposes of the proposed research is to further extend and refine our
understanding of the contribution of these various „health beliefs‟ to the strength of
positive outcome expectancies. As stated above, the placebo, health psychology and IBS
literatures will be reviewed in order to identify additional personal health belief variables
that may contribute to the strength of one‟s outcome expectancies.
A. Perceptions of Health
Subjective perception of one‟s current health is known to be a powerful predictor
of one‟s future health (Idler & Kasl, 1991; Kaplan & Camacho, 1983; Whittaker, Kemp
& House, 2007), and has even been reported to be a better predictor than current
objective health status (Mossey & Shapiro, 1982). In two similar studies, „health-related
quality of life‟ has been identified as a variable correlated with individuals‟ expectations
of benefit in Phase I clinical trials (Cheng et al., 2000; Weinfurt et al., 2003). In both
these studies, the Medical Outcome Study – Short Form 36, which assesses a patient‟s
overall perception of their health and physical functioning, was used to measure healthrelated quality of life. One of these studies also reported that expectations of benefit were
positively correlated with „relative health stock‟ (Weinfurt et al., 2003). This variable
was considered an index of an individual‟s current perceived health, including their
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expected longevity and quality of life. It seems clear from these studies that a person‟s
general perception of how healthy they are exerts an influence on expectations of
treatment efficacy. It is argued here that perceptions of current health can be considered
one aspect of the greater umbrella concept of „personal health beliefs.‟ As such, this
variable will be included in the proposed research in order to ascertain its relative
contribution to positive treatment expectancies.
B. Control beliefs
One‟s belief about their level of control over their illness and healing is another
variable that has been found relevant to health outcomes. Such „control beliefs‟ have
been studied extensively over the years, usually in one of two ways. One popular way is
to measure the level of control attributed to three different sources (Levenson, 1973):
internal (e.g., “I am in control of my health”), external/ powerful others (e.g., “My doctor
is in control of my health), and chance (e.g., “My health status is mostly dependent on
luck”). Other researchers have assessed the relative presence of a sense of perceived
control over one‟s symptoms and illness. Overall, it appears that a greater sense of
personal control over one‟s symptoms and illness contributes to more favourable mental
and physical health outcomes and more favourable symptom reports in chronic illnesses
(Affleck, Tennen, Pfeiffer, & Fifield, 1987; Marshall, 1991; Taylor, Kemeny, Reed,
Bower & Grunewald, 2000; Tennen, et al., 1992). Furthermore, it has been noted that
better outcomes are associated with weaker „powerful others‟ control beliefs (external
locus of control; Härkäpää, et al., 1996; Shelley & Pakenham, 2004; So, 1998).
Here it is suggested that control beliefs are another form of belief that will
influence current expectancies about treatment efficacy. This suggestion is made based

43

on the idea that control beliefs constitute a form of attribution, specifically attributions of
therapeutic change mechanisms with regard to one‟s symptoms or illness. In particular,
Olson et al., (1996) predict that if positive changes are attributed to internal, stable causes
(e.g., „I am in control of my symptom improvement), then future positive changes will be
expected. On the other hand, if changes are attributed to external (and perhaps unstable)
causes, then expectations of benefit may be less certain.
Some preliminary evidence to support the relationship between personal control
beliefs and beliefs about treatment effectiveness has been demonstrated in studies using
the Illness Perception Questionnaire –Revised (Moss-Morris, Weinman, Petrie, Horne,
Cameron & Buick, 2002). This scale contains several subscales, one of which, labeled
„treatment control‟ could be considered as a measure of treatment expectancies. Three of
the five items that load on this subscale refer to beliefs about the ability of one‟s current
treatment to control aspects of one‟s illness (e.g., “My treatment can control my illness”
and “The negative effects of my illness can be prevented (avoided) by my treatment”).
Two other items that load less strongly refer more to feeling of lack of control (e.g.,
“There is little that can be done to improve my illness”). When this scale was validated
using a large sample of mixed illness groups, it was found that the „personal control‟
subscale, which contains six items pertaining to beliefs of personal control over one‟s
illness and symptoms, was strongly positively correlated with the treatment control
subscale.
C. Self-Efficacy
In Bandura‟s (1977) social learning theory (now called social cognitive theory),
he introduced the concept of self-efficacy as an additional type of expectancy that
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contributes to guiding behaviour, in conjunction with the expectancies that a behaviour
will lead to reinforcement and that the reinforcement is valuable (Rotter, 1954). Selfefficacy expectancies reflect one‟s confidence regarding one‟s ability to execute
behaviour that reinforcement is contingent upon. The utility of the concept of selfefficacy in understanding health behaviours has been wide-ranging (O‟Leary, 1992), so
much so that self-efficacy has been adopted into most theories of health behaviour.
Various types of perceived health-related self-efficacy have been found to predict
adjustment to illness (Aarnold et al., 2005; Lev, Paul & Owen, 1999; Shelley &
Pakenham, 2004), better self-care in the context of illness (de Ridder et al., 2004), as well
as better physical health and well-being (Marshall, 1991; Schwarzer & Fuchs, 1995). In
one impressive study of self-management education for arthritis sufferers, it was
demonstrated that over four years, participants enjoyed an increase in their arthritis selfefficacy, which correlated with decreased pain reports and fewer visits to their physicians
(Lorig, Mazonson & Holman, 1993). „Health self-efficacy‟ in particular refers to the
extent to which one feels confident and capable of doing what is necessary to control
one‟s health in general (Sirois, 2003), and has been found to predict health behaviours
among individuals with chronic illness (Sirois, 2008).
Another type of self-efficacy that is relevant in the context of health outcomes is
coping self-efficacy, which refers to beliefs about one‟s ability to cope with the day-today aspects of their symptoms. This health belief variable has been found to be
associated with improved health outcomes in illness groups, primarily through its
relationship with treatment adherence. For example, coping self-efficacy is correlated
with self-care in diabetics (Williams & Bond, 2002), as well as adherence to
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cardiovascular health-promoting behaviors (Ewart, 2002). Although the relationships
between treatment expectancies and health self-efficacy or coping self-efficacy have not
been examined directly, the reported link to health outcomes and health-related variables
flag both these variables as relevant targets of study for the research proposed herein.
Furthermore, Olson et al (1996) note that high self-efficacy implies that success is
expected and that success reflects personal capacities (Bandura, 1977); thus, individuals
with high self-efficacy will attribute positive changes to internal controllable factors and
will expect future positive changes.
X.

Context-dependent Psychosocial Variables

Imagine a situation where an allopathic physician prescribes a pharmacological
intervention to treat fibromyalgia, along with the suggestion that this intervention will
address the generalized aches and pains (myalgia) associated with this condition. The
ability of this specific intervention to elicit strong positive expectations of outcome may
depend on a variety of personal factors that become relevant only in this specific context
(a specific treatment administered by a specific physician); for example, whether an
individual has a previous negative experience with this type of intervention or physician,
or perhaps whether he/she agrees that the pain is best treated through pharmacology.
These types of variables are intrinsic to the individual, but may only become relevant in a
specific context. The potential relevance of several of such context-dependent
psychosocial variables is explored in this section.
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A. Past Experiences with Treatment
An individual‟s previous experience with a specific type of treatment is assumed
to exert a strong influence on their current expectations of treatment (Montgomery &
Bovbjerg, 2000) and on their responsiveness to placebos (Enck & Klosterhalfen, 2005;
Chaput de Saintonge & Herxheimer, 1994). In fact, in the expectancy literature, previous
experiences are considered to be more effective in shaping expectancies than any
informative factors such as verbal suggestion (Olson et al., 1996; Stewart- Williams,
2004). Some research has directly linked previous experience with current expectancies,
both in laboratory and clinical settings. For example, past experiences with nonvolitional responses have been shown to correlate with current expectancies for nonvolitional responses (Montgomery et al., 2003), and in the qualitative study mentioned
above, past experiences with treatment was mentioned by all participants when
discussing their expectation of benefit in a Phase I clinical trial for cancer treatment
(Stone et al., 2005).
Strong support for the role of previous experience has also been found in studies
of placebo analgesia. In one study, some subjects were randomly assigned to receive a
surreptitious lowering of the painful stimuli after receiving what they were told
(deceptively) was an analgesic treatment, in order to make them believe that the treatment
was effective (Colloca & Benedetti, 2006). When later given the same placebo treatment
and exposed to the original higher intensity painful stimuli, a strong placebo effect was
demonstrated. This effect was demonstrated after minutes and also lasted from four to
seven days. In some subjects who did not receive the lowering of the pain stimulus, a
placebo effect was still demonstrated, even days later, but the effect was much smaller.
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Thus, small and large placebo responses were obtained, depending primarily on the
previous negative or positive experience with the analgesic treatment. They emphasize
that in this study, verbally induced expectancies of analgesia alone resulted in either
significant placebo responses, or no response at all, depending on the previous positive or
negative experience of the participant. The authors are not definitive regarding whether
the influence of previous experience in this study was mediated through conditioning or
expectancies, but they suggest that the conditioning procedure they used produced
increased expectations of benefit.
B. Illness Attributions
In general, expectancy theorists view causal attributions as a potential source of
situational expectancies (Kirsch, 1985; Olson et al., 1996). One‟s attributions about the
cause(s) of their symptoms and/or illness are often referred to as illness attributions,
although it is recognized that attributions for one‟s illness may be distinct from
attributions for one‟s symptoms (Robbins & Kirmayer, 1991). Although such
attributions could feasibly be stable over time, they can be considered as contextdependent as their relevance to one‟s current expectancies may vary as a function of the
specific intervention being presented. Such attributions are often categorized as somatic,
psychological, some combination of both, or normalizing (Robbins & Kirmayer, 1991).
A recent meta-analysis has implicated illness attributions as a personal variable that may
influence placebo responding among individuals with chronic fatigue syndrome (CFS;
Cho, Hotopf, & Wessely, 2005). Knowing that there are often strong somatic illness
attributions in patients with CFS, and that these attributions are associated with poorer
health reports over time (Schmaling, Fiedelak, Katon, Bader & Buchwald, 2003) these
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authors speculated that illness attributions (physical, psychological, or both) may
influence patients‟ expectancies of treatment outcome (and thus their placebo
responsiveness) across different types of intervention. Their analyses were designed to
estimate the average placebo response in clinical trials of CFS and to determine whether
intervention type influenced the magnitude of the placebo response. They report a pooled
placebo response of 19.6%, and found that intervention type contributed to the
heterogeneity of placebo responses, with psychological interventions eliciting a lower
placebo response. The authors suggest that these differences across intervention type are
a function of the influence of illness attributions on treatment expectancies. A
complementary, but somewhat distinct explanation for these results can be proffered,
based on the argument that one‟s attributions regarding the cause of their symptoms
(somatic/ psychological) do not necessarily lead directly to one‟s attributions for
symptom change (e.g., via a somatically-focused treatment vs. a psychologically-focused
treatment). For instance, one could attribute symptoms to psychological factors, yet still
prefer a pharmacological treatment to manage one‟s symptoms (e.g., a stress headache
treated with ibuprofen). With this in mind, the results presented by Cho et al (2005)
could indicate that individuals with CFS hold lower expectations for outcome (and show
smaller placebo responses) when offered treatments that focus on psychological targets.
Another study involving participants with CFS demonstrated more directly that
illness attributions were linked with treatment outcomes. In a randomized controlled trial
of cognitive-behavioural therapy for CFS, greater somatic attributions predicted poorer
outcome at follow-up (Chadler et al., 2003). This study seems to provide support for the
idea that one‟s attributions can interfere with verbal suggestions provided by the
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treatment provider. Specifically, individuals who attributed their illness to a physical
problem were less able to benefit from this psychological intervention. These studies
suggest that it is reasonable to hypothesize that illness attributions (for either the cause of
symptoms or the management of symptoms) can alter the magnitude of positive treatment
expectancies.
C. Motivation
Motivational factors, such as desire for relief or desire to please the experimenter
or physician, can also be considered as context-dependent psychosocial variables as they
may fluctuate from one temporal or spatial context to another. In placebo literature in
particular, motivational factors have been of interest as they have been proposed as a
potential mediator of placebo responses. Some authors posit that motivation is a factor
that contributes to placebo responding independently of outcome expectations (Vase et
al., 2003), while others incorporate the two by suggesting that one‟s motivation
(conscious or subconscious) to respond in the suggested direction will moderate the
strength of the outcome expectancy (Geers, Weiland, Kosbab, Landry & Helfer, 2005).
The results of various studies examining the contribution of motivational factors have
been mixed.
A study by Price and colleagues (1999) separately examined the correlations
between desire for pain relief, expectations of pain relief and actual placebo analgesia.
Part of their rationale for examining motivation factors included findings from the
placebo analgesia literature showing that placebo responses in experimental pain increase
as a function of the duration and severity of pain (Jospe, 1978). In the Price et al study, it
was found that desire for pain relief was not related to the magnitude of placebo
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responding. The authors suggest that despite the range of desire ratings reported, this
variable may not be as potent in experimental studies of pain among healthy participants
subjected to brief pain stimuli, compared to its role among populations who report
clinical pain.
Addressing this issue, Vase and colleagues (2003) conducted a placebo analgesia
study using evoked rectal distention in patients with irritable bowel syndrome. After
baseline exposure to the noxious stimuli and treatment with a „powerful analgesic‟
placebo, they asked patients to rate both their desire for pain relief as well as their
expectations of pain relief. These authors report that together, desire for relief and
expectations of pain accounted for over 70% of the variance in actual pain ratings
(although expectancy had the only significant beta weight in a simultaneous regression).
The data from this study was later reanalyzed to examine the contribution of expectancies
and desire to placebo effects (not just pain ratings) by calculating change scores from
baseline measurement to post-placebo measurement (Price, Chung & Robinson, 2005).
Here, the interaction of desire and expectancy was a significant predictor of placebo
effects. Unfortunately, the authors do not offer a description of this interaction; therefore,
it is unclear whether motivation (desire for relief) predicts placebo analgesia
independently of one‟s expectations, or whether motivation contributes to placebo
responding in part by strengthening one‟s expectations for relief.
Others have presented a more elaborated model of how motivation can strengthen
or attenuate the magnitude of one‟s expectations of treatment, and subsequently one‟s
response to a placebo intervention. Specifically, Geers, Weiland and colleagues (2005)
speculate that the placebo effect is most likely to occur when individuals have a goal that
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can be fulfilled by confirmation of the placebo expectation. Their „goal-activation‟
model posits that although situational cues may induce expectations of treatment, if a
person‟s goal for treatment (conscious or subconscious motivation) is incompatible with
the placebo expectations, expectation will be attenuated and have less influence on one‟s
somatic experience. They further speculate that a placebo-compatible goal directs
cognitive processing and behaviour towards the confirmation of placebo expectation.
These authors tested their model in five separate experiments where some subjects were
primed to have a particular goal with respect to the placebo treatment. Overall, they
report that larger placebo effects were found when individuals were primed to have
placebo-compatible goals. As expectations were never directly measured in these
studies, it is difficult to distinguish whether goals to cooperate with the placebo
suggestions enhanced expectancies and thus placebo responding, or whether goals to
cooperate independently influenced placebo responding. Nevertheless, this series of
studies provides support for the importance of motivation factors in the generation of
placebo effects, and furthermore indicates that a closer examination of the influence of
motivations on expectancies is warranted.
D. Patient-Provider Relationship
There is an additional context-dependent psychosocial factor whose contribution
to outcome expectancies will be examined in the proposed research. It is a relational
factor, specifically, the quality of the patient-provider relationship. It has been suggested
in the placebo literature that „common factors in therapy‟ (i.e., the therapeutic alliance)
are additional factors that can shape treatment expectancies (Di Blasi et al., 2001;
Pacheco-Lopez, Engler, Miemi & Schedlowski, 2006; Stewart-Williams, 2004; Turner,
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Deyo, Loeser, Von Korff & Fordyce, 1994). Specific aspects of the patient-provider
interaction that have been researched and found to be related to placebo responding
include the provider‟s interpersonal skills (Oh, 1991), persuasive influence (Shapiro,
1971) and the time spent with the patient (Kaptchuk et al., 2006; Solomon, 2002). In the
expectancy literature it has been noted that positive views about another person are found
to be associated with the acceptance of that person‟s ideas (Harris & Rosenthal, 1985).
Empirically, one study reported that more a positive perception of the patient-provider
relationship contributed to greater expectations of benefiting from treatment (Beach,
Keruly & Moore 2006). With this in mind, it is reasonable to hypothesize that positive
beliefs about a provider would influence the degree to which a patient accepts their
information (i.e., suggestions of treatment efficacy).
In the field of mental health, it is well-known that the therapeutic alliance is a
strong predictor of treatment outcome (Lambert & Barley, 2002). Although this variable
has not been as well studied in field of medical health, there are some reports that the
quality of the patient-provider relationship is related to health outcomes (Beach et al.,
2006; Sans-Corrales, et al., 2006). In the IBS literature, there have also been studies that
indicate that dissatisfaction with one‟s provider is not uncommon and tends to contribute
to negative attitudes regarding treatment (Chang et al., 2006; Dixon-Woods, & Crtichley,
2000; Dhaliwal & Hunt, 2004). As this relationship variable has been identified as
contributing to placebo responding, treatment expectancies and health outcomes, it is
considered a relevant variable to include in the proposed research.
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XI. IBS as the Proposed Illness Model
To give a full account of the background and significance of the proposed
research, it is important at this point to outline the rationale for choosing irritable bowel
syndrome as the specific illness model to be explored herein. Irritable bowel syndrome
(IBS) is a common functional gastrointestinal motility disorder that affects 10-20% of the
general population, both males and females from a wide age-range (Cremonini & Talley,
2005). It is termed a „functional syndrome‟ as the primary pathology is an altered
physiological function (the way the body works), rather than an identifiable structural or
biochemical cause. This disorder is characterized by abnormal stool consistency and
frequency accompanied by abdominal pain. There are three different sub-types of IBS,
including a constipation-predominant subtype (IBS-C), a diarrhea-predominant subtype
(IBS-D) and an alternating sub-type (IBS-A).
IBS is an ideal illness model to study in this type of research for several reasons.
First, IBS is diagnosed using a specific set of self-report symptom criteria and there are
no physical findings or diagnostic tests needed to confirm the diagnosis; this makes it
easier to conduct research online with this illness group. Second, IBS is known to be
responsive to placebo treatment (Enck & Klosterhalfen, 2005; Mertz, 2003; Patel et al.,
2005; Vase, et al., 2003), and thus presumably to variations in treatment expectancies,
making it quite relevant to be studying the psychosocial correlates of treatment
expectations in this sample. Although there have been relatively few studies examining
the psychosocial correlates of placebo responding in people with IBS (Patel et al., 2005),
one study that has directly addressed this research question identified patients‟
expectations as a contributing factor (Vase, et al., 2003).
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A final benefit of studying expectancies in people with IBS stems from the
elusive nature of this syndrome. As there are no known organic indicators present in
IBS, and since it has been shown to be responsive to psychological interventions
(Lackner, Mesmer, Morley, Dowzer & Hamilton, 2004; Matsumoto, Sato, Yokoi,
Yoshinaga, Shimura, & Sakano, 1998), there is a research literature examining the
psychosocial correlates of IBS symptom reporting. In particular, the IBS literature is
somewhat unique in that there has been a specific effort to examine the relationship of
IBS symptomotology to health belief variables. As such, a review of this literature will
be informative in identifying various psychosocial variables that may contribute to the
activation of treatment-specific expectations. Ultimately, the results of this investigation
should be able to contribute valuable information about the correlates of treatment
expectancies in this sample, information that can be used to inform and improve
intervention efforts in the treatment of IBS.
XII. Psychosocial Factors Identified from IBS Literature
A. Self-focused attention & Anxiety
Most research on the psychosocial variables relevant to IBS has focused on
individual attributes that tend to present in people with IBS. Some of this research has
found that individuals who seek treatment for IBS report higher than average levels of
bodily preoccupation (or self-focused attention; Crane & Martin, 2002, 2004b;
Gomborone, Dewsnap, Libby, & Farthing, 1995; Silverman et al., 1997) as well as higher
levels of general and health anxiety (Barahmand, 2008; Crane & Martin, 2004; HazlettStevens, Craske, Mayer, Chang, & Naliboff, 2003). In this literature as well, both selffocused attention and anxiety are associated with less favourable outcomes. It is
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important to note, however, that this literature does not support a causative model. Crane
and Martin (2002) have speculated that the relationship between body preoccupation and
IBS symptomotology may be reciprocal. In particular, it is hypothesized that the
sustained presence of discomforting and unexplained IBS symptoms likely contributes to
increased anxiety as well as vigilance towards internal bodily states and sensations. In
turn, as noted above, there is evidence that attending to internal experiences such as
sensations can amplify these experiences (Franzoi, 1996). Moreover, there is an everexpanding literature concerning the neurobiochemical relationships between
emotionality, hypervigilance and gut motility (see Jones, Dilley, Drossman & Crowell,
2006; Mulak & Bonaz, 2004).
B. Illness Attributions
There have been a handful of studies investigating the illness attributions of
people with IBS. In general, there has been an informal consensus that people with IBS
tend to make somatic attributions for their symptoms, and this has been confirmed in
early research (van Dulmen, Fennis, Mokkink & Bleijenberg, 1996). It has also been
noted that individuals who seek treatment for their IBS make more somatic attributions
for their IBS symptoms (as well as for non-IBS symptoms) than do non-treatment seekers
(Martin & Crane, 2003). More recent research has contradicted this assumption
somewhat; in one study it was found that people with IBS did not make more somatic
interpretations of their symptoms than did other patients presenting to a GI clinic (Bray,
Nicol, Penman & Ford, 2006). Another recent study found that levels of somatic
symptom attribution were unrelated to quality of life in an IBS sample, whereas levels of
psychological symptom attribution were positively correlated with quality of life
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(Barahmand, 2008). The results have also been mixed when attributional styles have
been examined in relation to symptom severity; in one study symptom severity was more
strongly correlated with levels of somatic attributions (Gerson et al., 2006), yet in another
it was more strongly correlated with levels of psychological interpretations (Bray et al.,
2006). Although limited, this research suggests that illness attributions may be a relevant
variable for individuals with IBS, as has been demonstrated for individuals with chronic
fatigue syndrome (reviewed above).
C. Control Beliefs
As in the general health psychology literature, control beliefs have been studied
among individuals seeking treatment for IBS. As we would perhaps expect, it has been
shown that a weaker perception of personal control over one‟s IBS symptoms is
associated with less favourable outcomes (lower quality of life, lower satisfaction with
health; Rutter & Rutter, 2002). Again, it should be noted that this relationship is not
presumed to be unidirectional; on the contrary it is logical that increased symptom
severity can be accompanied by a decreased sense of control over symptoms. Individuals
with IBS have been found to endorse greater external locus of control than healthy
participants (Hobbis, Turpin, & Read, 2003). Thus, here again, control beliefs have been
associated with health status. However, the relationship between control beliefs and
outcome expectancies has not been studied in this illness population.
D. Vulnerability to Illness
Another finding that has emerged is that individuals seeking treatment for IBS
show high levels of what could be called beliefs of „vulnerability to illness.‟ In
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particular, this patient group reports greater levels of disease phobia (fear of contracting a
disease), and perceive themselves as being more at risk of developing health problems
unrelated to their IBS symptoms (Crane & Martin, 2004b; Gomborone et al., 1995;
Martin & Crane, 2003). One study found that an IBS patient group reported greater
perceived illness vulnerability than other groups with chronic health problems, even
while controlling for levels of self-focused attention, anxiety, depression, as well as
levels of recent and current symptoms. Crane and Martin (2002) argue that if these
beliefs are a part of one‟s enduring „illness schema,‟ they are likely to reduce an
individual‟s expectations for their own recovery.
E. Catastrophizing
Similarly, studies report that individuals with IBS often present reporting belief in
the presence of serious pathology, as well as catastrophizing beliefs about their symptoms
(Gomborone et al., 1995; Kolowski, Boyce & Talley, 2005). Such catastrophizing beliefs
have been linked to poorer health outcomes among women with gastrointestinal disorders
(Drossman et al., 2000; Rutter & Rutter, 2002), and have been found to partially mediate
the relationship between depression and pain severity among individuals with IBS
(Lackner, Quigley & Blanchard, 2004). By virtue of the fact that these negative health
beliefs have been found to influence health outcomes, an empirical investigation of their
contribution to outcome expectancies seems warranted.
XIII. Identifying Additional Variables
This study also included a qualitative component, primarily designed to identify
relevant psychosocial variables that may not have been identified in the literature review.

58

An open-ended question format was used, designed to provide participants with the
opportunity to directly communicate their thoughts about their treatment expectancies.
This type of qualitative research can be of great value in uncovering information in new
areas of investigation such as this. Recently there has been one qualitative study
examining factors that influence expectations to benefit from treatment among
individuals participating in a Phase I randomized clinical trial for cancer medication
(Stone et al., 2005). This study was among the first to demonstrate that several different
variables (e.g., past experiences) may affect one‟s expectations of treatment, whereas
previously it was thought that expectations were primarily a function of one‟s hope for
benefit. This example highlights how qualitative research can complement a quantitative
approach in identifying factors that contribute to the strength of treatment expectancies.
XIV. Aims
The global aim of this study was to work towards better and more cost effective
medical interventions by encouraging increased attention to and improvement of a
patient‟s expectations of treatment outcome. To facilitate this global aim, this project has
surveyed several literatures to provide support for the central role of treatment
expectancies in health interventions and to identify psychosocial variables that may
contribute to the formation of such expectancies. Three models of placebo responding/
expectation formation were combined into a single model that was used to guide this
literature review, which has resulted in the identification of several psychosocial
variables that may be relevant correlates of treatment expectancies. Many of these
variables have been shown to directly influence the formation of treatment expectancies,
whereas others are presumed to influence expectancies based on their relationship to
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placebo responding, health outcomes, symptom reporting or to each other. Please refer to
Table 1 for a summary of the type of support available in the literature to inform the
inclusion of each variable in the current study.
Table 1
Summary of the Type of Empirical Results Available in the Literature to Link Each
Independent Variable to Outcome Expectancies
Differential
Placebo
Responses
Yes
Yes
Yes
Yes

Differential
Health
Outcomes

Association with
Outcome
Expectancies

Independent Variable
Self-focused Attention
Anxiety
Yes
Yes / No
Optimism
Yes
Yes
Pessimism
Yes
Yes
Hope
Yes
Yes
Perceptions of Health
Yes
Yes
Control Beliefs
Yes
Yes
Self-Efficacy (Health & Coping)
Yes
Vulnerability Beliefs
Yes
Catastrophizing
Yes
Past Experiences
Yes
Yes
Yes
Illness Attributions
Yes
Yes
Yes
Motivation
Yes
Patient-Provider Relationship
Yes
Yes
Yes
Note. A „Yes‟ in a particular column indicates that the specific variable has been shown
to be associated with the result in that column. A „No‟ indicates that that the specific
variable has been found to not be associated with the result in that column. An empty
cell indicates that the relationship between a specific variable and the result in that
column has not been studied.

Figure 1 displays the resulting complex model that includes each of the variables
identified as potentially relevant contributors to the magnitude of one‟s treatment
expectancies. One of the main purposes of the current investigation was to test the
relationships of each of these variables to the magnitude of one‟s treatment expectancies.
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Figure 1. The full model of potentially relevant psychosocial variables contributing to
treatment expectancies.
A further purpose was to create a more parsimonious list of relevant variables by
ascertaining the relative contributions of each of these variables. The objective of
creating a more parsimonious list of variables was to increase the feasibility of assessing
these relevant factors in a clinical setting. This focus on parsimony and feasibility fits
well with the global aim of increasing the efficiency and effectiveness of medical
interventions.
The qualitative data was used to facilitate the aforementioned aims through
accomplishing two additional specific aims. One specific aim of this component was to
identify any additional psychosocial variables that may influence treatment expectancies
that have not been identified from the literature. Secondly, this data was used to shed
light on null or unexpected quantitative findings.
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XV. Research Questions:
This research was designed to address these aforementioned aims through
addressing the following specific research questions:
1. Which of the identified psychosocial variables are related to the magnitude of
positive treatment expectancies in an IBS sample?
2. What is the relative contribution of these psychosocial variables for predicting
levels of treatment expectancies in an IBS sample?
3. Are there additional psychosocial variables that are commonly cited by IBS
sufferers as contributing to expectations of treatment benefit in this context?
XVI. Design
To address these specific research questions, a sample of individuals meeting
criteria for a diagnosis of irritable bowel syndrome were recruited to participate in this
cross-sectional research by completing an online battery of self-report questionnaires.
Individuals were presented with two vignettes describing hypothetical treatments for
irritable bowel syndrome; they were then asked to rate their expectations of personally
benefiting from the proposed treatments1 on two visual analogue scales (dependent
variables), and asked to identify the treatment that they would hypothetically prefer. The
self-report questionnaire battery that followed contained measures of all independent
variables (identified psychosocial variables). Finally, individuals were asked an openended question regarding factors they felt influenced their expectations of treatment
benefit in this hypothetical context.

1

Also referred to throughout as „treatment expectancies.‟
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XVII. Hypotheses
A number of specific hypotheses, informed by the literature review, follow from
the aforementioned specific research questions.
Research Question 1: Which of the identified psychosocial variables are related to the
magnitude of positive treatment expectancies in an IBS sample?
Hypothesis 1a: Levels of self-focused attention would be correlated with levels of
treatment expectancies2.
Hypothesis 1b: Levels of trait anxiety would be negatively correlated with levels
of treatment expectancies.
Hypothesis 1c: Levels of optimism will be positively correlated with levels of
treatment expectancies and levels of pessimism would be
negatively correlated with levels of treatment expectancies.
Hypothesis 1d: Levels of hope would be positively correlated with levels of
treatment expectancies.
Hypothesis 1e: Levels of perceived current health would be positively correlated
with levels of treatment expectancies. Number of acute health
problems will be negatively correlated with levels of treatment
expectancies.
Hypothesis 1f: Levels of perceived personal control over health and symptoms
would be positively correlated with levels of treatment
expectancies.

2

The direction of this relationship was not specified as findings in the literature have
been mixed.
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Hypothesis 1g: Levels of health and coping self-efficacy would be positively
correlated with levels of treatment expectancies.
Hypothesis 1h: Levels of perceived vulnerability to illness would be negatively
correlated with levels of treatment expectancies.
Hypothesis 1i: Levels of symptom catastrophizing would be negatively correlated
with levels of treatment expectancies.
Hypothesis 1j: Levels of past satisfaction with similar treatments would be
positively correlated to levels of treatment expectancies. Number
of previous treatments attempted would be negatively correlated
with levels of treatment expectancies.
Hypothesis 1k: Levels of illness attribution (somatic and psychological) and the
treatment‟s perceived focus (somatic and psychological) would be
correlated with levels of treatment expectancies3.
Hypothesis 1l: Levels of desire to see relief would be positively correlated with
levels of treatment expectancies. Levels of symptom severity and
interference of IBS symptoms in daily activities would be
negatively correlated with levels of treatment expectancies.
Hypothesis 1m: Levels of social desirable responding would be positively
correlated with levels of treatment expectancies.
Hypothesis 1n: Level of positive perception of treatment provider would be
positively correlated with levels of treatment expectancies.

3

Again, directionality was not hypothesized due to mixed findings in the literature.
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Research Question 2: What is the relative contribution of these psychosocial variables for
predicting levels of treatment expectancies in an IBS sample?
Hypothesis 2: This research question was largely exploratory, as not all variables
had been empirically linked to treatment expectancies at the time
of this study. However, several hypotheses were made based on
the literature review presented above. For example, in accord
with the general expectancy literature, past satisfaction with a
similar treatment was hypothesized to be a strong predictor of
current expectations of treatment. In addition, personal illness
attributions and the perceived focus of the preferred treatment
(i.e., somatic vs. psychological) were hypothesized to be moderate
predictors of current expectations to benefit from treatment.
Research Question 3: Are there additional psychosocial variables that are commonly
cited as contributing to one‟s expectations of treatment benefit in this context?
Hypothesis 3: Due to the exploratory nature of this research question, no specific
hypotheses were generated a priori.
Chapter 2
METHOD
I.

Overview of Studies

Prior to initiation of the main study, a pilot study was conducted to assess the
credibility of three hypothetical treatment vignettes, and to ensure that the outcome
expectancy ratings generated from these vignettes followed a relatively normal
distribution and demonstrated adequate variance. Many features of the two studies were

65

the same, including participant recruitment and inclusion criteria, informed consent
procedures, vignette presentation, and the assessment of treatment expectancies and
treatment preference. These features will thus be described together in more detail in the
following sections of this chapter. Areas of departure in study methods will also be
described. In particular, the main study used only two of the hypothetical treatment
vignettes, chosen based on results of the pilot study, and measured an expanded set of
demographic and psychosocial variables.
II.

Participants

A. Participant Recruitment (Pilot & Main Study)
The current research was focused on individuals with irritable bowel syndrome
(IBS). After securing clearance from the University of Windsor Research Ethics Board,
participants were recruited to participate using recruitment messages posted on three
types of websites, as well as in gastroenterology clinics for the main study. First,
websites designed to provide online support and information to individuals suffering
from IBS were contacted. In this instance, if appropriate, the IBS support site board
moderator was contacted via email and presented with information about the study, a link
to the study website and a request to post recruitment messages. The information
provided to the moderator is presented in Appendix A and contains information regarding
the rationale and aims of the current study, data collection timelines, and informed
consent and anonymity. The board moderator was asked to return an email to the study
investigator providing written „consent to post.‟
The second venue for posting online recruitment messages was on social science
Internet research sites. Such sites usually follow a specific protocol for allowing study
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recruitment messages to be posted; these protocols were observed in attempting to have
this study‟s recruitment message posted. The final Internet recruitment venue was online
sites where researchers can post free classifieds advertisements to recruit participants,
such as „craigslist.com,‟ and „kijiji.com.‟
For the main study, participants were also recruited from gastroenterology clinics
in major urban centres throughout Canada. A list of gastroenterologists in one major city
from each province was compiled from the College of Physicians and Surgeons online
membership lists. These gastroenterologists were contacted by phone in order to access
an email address or fax number where a description of the study procedures, as well as a
recruitment flyer, could be sent. Each physician who provided a contact address was sent
these materials and asked to participate in the study by posting the recruitment flyer in
the waiting area of their office. The phone script, the letter of study description and the
recruitment flyer are presented in Appendix B.
The recruitment messages explained that the study was looking for individuals
with diagnosed IBS to participate in a study interested in assessing factors that contribute
to an individual‟s thoughts and beliefs about particular treatments. The recruitment
message also specified the predicted amount of time to complete the study, as well as the
potential for remuneration. Potential minimal remuneration for participation was offered
in the form of a draw. Participants were informed that at the end of the data collection
period, participants would be selected at random to receive a 20 CAD (18 USD, 14 EUR,
or 10 GBP) gift certificate to a major book retailer (e.g., Amazon.com). The number of
participants selected in the draw was two for the pilot study and ten for the main study.
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Please note that the recruitment messages (for the pilot and main study) can be found in
Appendix C.
Participants were recruited for the pilot study over a 4-month period in early
2007, and over a 9-month period for the main study. Inclusion criteria specified that
participants be over 16 years of age and have a diagnosis of IBS. Verification of illness
status was accomplished by having participants complete a self-report survey of the
Rome III criteria for this diagnosis, which is the standard criteria for making this
diagnosis, created by an international group of experts in functional gastrointestinal
motility disorders. The Rome III questionnaire of IBS criteria is presented in Appendix
D, along with the diagnostic scoring procedures (Appendix E). These criteria also allow
for IBS sub-type diagnosis. Individuals were excluded who a) did not meet criteria for
IBS, b) who clearly responded to the study questionnaires in a random or careless
fashion, or c) did not provide a response for at least 80% of study items. Table 2 presents
the percentage of respondents recruited from each venue for the pilot and main study.
B. Participant Numbers and Characteristics (Pilot and Main)
Of the 35 participants recruited for the pilot study and who completed the survey
online, 31 met criteria for IBS and were retained in the dataset. In the main study, a total
of 358 participants were recruited; however, only 294 met inclusion criteria.4

4

Five participants later excluded during data screening in results section, leaving N =
289.
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Table 2
Source of Participant Recruitment by Percentage in Pilot and Main Study
Study
Source

Pilot

Main

Online classifieds

64.5

73.1

IBS support website

3.2

14.4

Research website

22.6

6.1

Friend / Relative referral

9.7

3.3

0

2.5

n/a

0.6

Undisclosed
Gastroenterology clinic
General demographic characteristics.

Table 3 summarizes the demographic characteristics of the samples for both the
pilot and main study. In both samples, the majority of participants were women,
Caucasian, well educated, employed full-time and residing in North America. In the
main sample, the majority of participants were married, whereas in the pilot sample, more
participants had never been married.
IBS-related demographic characteristics.
Table 4 presents IBS-related demographic characteristics of the pilot and main
samples. Although all participants met the Rome III criteria for a diagnosis of IBS, a
small percentage of participants in both samples reported that they had not been
diagnosed with IBS.
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Table 3
Demographic Characteristics of the Pilot and Main Samples
Sample
Characteristic
N
Sex (% [N])
Women
Age
M (SD)
Range
Country of residence (% [N])
USA
Canada
Europe
Australia
Other
Ethnicity (% [N])
White
Hispanic
Asian
Other
Mixed
East Indian
Black
Marital Status (% [N])
Married/ living with intimate partner
Never married
Separated/ divorced
Widowed
Level of Education (% [N])
High school
College/ university
Graduate
Employment Status (% [N])
Full-time
Not at all
Part-time
Disabled
Student
Retired
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Pilot
31

Main
294

28 (90)

250 (85.0)

37.1 (13.5)
20-63

33.9 (11.4)
16-68

20 (64.5)
7 (22.6)
2 (6.5)
2 (6.5)
0

143 (48.5)
135 (45.9)
13 (4.4)
1 (0.3)
1 (0.3)

25 (80.6)
1 (3.2)
1 (3.2)
1 (3.2)
1 (3.2)
0
2 (6.5)

253 (86.1)
10 (3.4)
8 (2.7)
8 (2.7)
6 (2.0)
5 (1.7)
3 (1.0)

11 (35.5)
14 (45.2)
5 (16.1)
1 (3.2)

149 (50.7)
116 (39.5)
25 (8.5)
3 (1.0)

5 (16.1)
20 (64.5)
6 (19.4)

38 (12.9)
190 (64.6)
65 (22.1)

14 (45.2)
3 (9.7)
7 (22.6)
2 (6.5)
5 (16.1)
0

152 (51.7)
46 (15.6)
42 (14.3)
24 (8.2)
24 (8.2)
5 (1.7)

The majority of participants reported being diagnosed by a physician and having diarrhea
predominant IBS (43.0%). Interestingly, when IBS subtype was diagnosed based on the
Rome III diagnostic criteria, the majority of both samples met criteria for alternating
subtype IBS. On average, in the main sample participants reported that they had
symptoms of IBS for 11.4 years (SD = 9.18; range = 1-51) and had been diagnosed with
IBS for 6.56 years (SD = 6.80; range = 1-18).
Table 4
IBS –Related Demographic Characteristics of the Pilot and Main Samples
Sample
Characteristic
IBS diagnosis (% [N])
Yes
No
Undisclosed
Source of diagnosis (% [N])
Physician
Self
History of misdiagnosis (% [N])
Yes
No
Undisclosed
Self-report IBS subtype (% [N])
Constipation predominant
Diarrhea predominant
Alternating subtype
Unknown
Rome III IBS subtype (% [N])
Constipation predominant
Diarrhea predominant
Alternating subtype
Years with symptoms
M (SD)
Range
Years since diagnosed
M (SD)
Range
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Pilot

Main

27 (87.1)
3 (9.7)
1 (3.2)

269 (91.5)
24 (8.2)
1 (0.3)

26 (83.9)
5 (16.1)

251 (85.4)
43 (14.6)

12 (38.7)
19 (61.3)
0

76 (25.9)
214 (72.8)
4 (1.3)

4 (12.9)
17 (54.8)
9 (29.0)
1 (3.2)

56 (19.0)
129 (43.9)
91 (31.0)
18 (6.1)

3 (9.7)
8 (25.8)
20 (64.5)

23 (7.8)
60 (20.4)
211 (71.8)

12.6 (8.47)
1 -35

11.4 (9.2)
1-51

10.0 (9.5)
1-35

6.5 (6.8)
1-18

III. Procedures
After receiving permission to recruit participants on the target websites, brief
recruitment messages were posted on each website. The brief recruitment messages
included a link to the University of Windsor server where the online survey study was
hosted. Interested individuals could click on the link provided in the recruitment message
and be directed to the study homepage. Here, potential participants were first informed
that should they wish to participate in the study using hardcopy forms and surveys, they
should indicate so by sending an email, containing their mailing address, to the principal
investigator with „IBS Study‟ written in the subject line. A study package (consent form
and study survey) was then mailed to the participant along with a self-addressed postage
paid return envelope. In the main study, 11 participants requested a paper version of the
survey; only one was returned and included in the dataset.
Participants willing to participate in the online version of the study were directed
to click on the „continue‟ button, which directed them to the consent form. Participants
were asked to read the informed consent form for the proposed study. The consent forms
(presented in Appendix F) contained information regarding the purpose of the study, the
procedure, potential risks and benefits of participating, and the rights of the participant
including withdrawal from the study without penalty. In addition, participants were
informed about the potential for remuneration, the exclusion criteria, the anonymous
nature of the study, and the researcher‟s identity and contact information. Participants
were instructed that in order to participate, they must „click‟ on the box provided to
indicate their informed consent. After indicating their consent to participate, they were
automatically directed to the first page of one of two versions of the survey that were
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counterbalanced in terms of the order of presentation of the treatment vignettes and the
study scales. The link to the survey was set up to direct participants to one version of the
two versions of the survey in a random fashion.
The following is an overview of the procedures involved in the current studies;
more detailed descriptions of the specific measures and components are provided in the
following section. After providing information regarding their general and IBS-related
demographic characteristics (Appendix G), participants were then asked to read vignettes
detailing hypothetical treatment protocols for irritable bowel syndrome. Following these
vignettes there were several questions specifically regarding the treatment vignettes,
including their expectation of benefiting from each treatment, and the treatment option
that they would personally prefer. In the pilot study, participants rated the credibility
levels for each treatment vignette. In the main study, participants were asked to complete
a series of questionnaires (counterbalanced and each on their own webpage) that
measured the independent variables of interest in the current study. They were also
presented with the opportunity to express, in a narrative fashion, their thoughts about
what factors they felt contribute to their expectations of benefit for the treatment that they
had chosen as their preference. This is described further in the next section.
At the end of the survey participants in both studies were then given the
opportunity to be included in the draw for potential remuneration. It was explained that
participation would remain anonymous even if they choose to be entered in the draw. If
they chose not to participate in the draw by clicking on the „No Thanks‟ button, they
were thanked for their time and consideration, and participation was over. An individual
could choose to participate in the draw by clicking on the „Sign me up!‟ button. This
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action caused a pop-up window to open describing the options for draw participation.
Specifically, participants were asked whether they would prefer to be contacted via mail
or email should they be selected for remuneration. It was described that at the time of the
draw, the draw winners would be contacted by their preferred method to ascertain how
they would prefer to receive remuneration. Individuals who preferred to be contacted by
email were asked to provide their email address. Individuals who preferred to be
contacted by mail were asked to provide their address, but to withhold their name. In the
latter case, a letter was sent to the „Study Participant‟ at the given address. In either case,
this first contact was used to inform selected individuals of their „winning status,‟ and to
request that an email be sent to the study administrator indicating whether an electronic
or a hard copy of the gift certificate was preferred, and in what currency (USD, CAD,
GBP, Euro). Participants were reassured that their contact information would be stored
separately from their survey information to maintain the anonymity of their responses.
Once contact information was entered, clicking the „submit‟ button registered this
information in a designated data file on the server, and participants were directed to the
„letter of explanation‟ page, which was designed to debrief participants about the purpose
of the study. At the end of the letter of explanation, participants were thanked for their
time and consideration, thus ending study participation. The letter of explanation can be
found in Appendix H.
IV. Measures
A. Treatment Vignettes
Participants were asked to read hypothetical treatment vignettes while imagining
they were participating personally in the scenario. Treatment vignettes are presented in
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Appendix I. These vignettes were created by the author, and designed to represent a
thorough and credible treatment planning and procedure scenario. The first part of the
vignette described a thorough clinical interview by a gastroenterologist, as well as the
possibility for additional data collection as needed. Research has found that individuals
with IBS often feel that their treatment provider does not pay adequate attention to their
illness experience (Chang et al., 2006; Dixon-Woods & Critchley, 2000), thus efforts
were made to present the hypothetical specialist as being thorough. Efforts were also
made to describe the hypothetical provider and the interaction in a way as to minimize
affective aspects of the relationship, in order to a) reduce demand characteristics (e.g.,
desire to please the provider) and b) allow participants to potentially project their own
perceptions of such a provider into the scenario.
It was then described that based on all the information that is provided, the
participant would be assigned to one of the possible treatments for their IBS. Each of the
three treatment vignettes included a dietary consult along with dietary recommendations,
as well as an educational component relating to what is currently understood about the
biopsychosocial contributors to IBS symptom presentation (Barahmand, 2008). These
treatment components were emphasized in each treatment to increase treatment
credibility, as they are accepted as the first plan of action in any treatment of IBS. Over
and above the dietary and educational components, each treatment vignette described a
detailed treatment plan that contained a pharmacological approach, a psychological
approach, or a combined pharmacological and psychological approach. More than one
treatment vignette was used as there are no accepted prescribed treatments for IBS at this
time, and it is fairly well known that both pharmacological and psychological approaches
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can be beneficial. All treatment plans included comparable treatment timelines and
regular monitoring by the provider, and were designed to provide equal amounts of
information. Each treatment was labeled using only a letter (i.e., Treatment A). Three
vignettes were presented in the pilot study, with the aim of choosing two vignettes to use
in the main study (to reduce sample fragmentation).
The „pharmacological treatment‟ involved the prescription of one of two state-ofthe-art pharmaceutical drugs (depending on IBS subtype) designed to provide global
symptom improvements. The descriptions of the drugs included information about the
drug‟s performance in clinical testing and potential side effects. The drug information in
this vignette was taken directly from reviews of current promising drug treatments for
IBS (Gilkin, 2005; Tack, Fried, Houghton, Spicak & Fisher, 2006). The drugs that were
offered have been tested for use with either the diarrhea – predominant subtype (IBS-D)
or the constipation – predominant subtype (IBS-C). At the time of the study, there were
no drugs of this caliber designed for use specifically with the alternating subtype (IBS-A;
Gilken, 2005). However, in the treatment vignette, it is indicated that one drug is
designed for use with both IBS-C and IBS-A. Although this is somewhat counterfactual,
it is not incredible. For example, research has found that individuals with alternating
subtype IBS (25% of IBS sufferers), typically report symptoms very similar to those
reported by IBS-C sufferers, with the exception of reporting defecatory urgency (Mearin,
et al., 2003). In addition, there have been very few pharmacological studies aimed at
treating IBS-A specifically, and often the same agent is tested among IBS-C and IBS-A
groups (Tack, et al., 2006).
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The „psychological treatment‟ involved a combined trial of cognitive-behavioural
therapy and hypnotherapy. The latter treatment was described only as relaxation training
with guided imagery, as the term „hypnotherapy‟ has been found to produce biased
responses in other studies (see Gandhi & Oakley, 2005). These treatments were chosen
as they have both been found to be effective in treating IBS in quantitative and narrative
reviews of the literature (Blanchard, 2001; Blanchard & Scharff, 2002; Lackner, Mesmer,
Morley, Dowzer & Hamilton, 2004; Whitehead, 2006). The vignette provided
information about the empirical support for this approach, and a description of the
specific components of the treatment, modified slightly from a paper describing the
successful use of this approach (Taylor, Read & Hills, 2004). These first vignettes were
counterbalanced in both studies.
The „combined treatment‟ involved the prescription of a pharmaceutical drug as
well as a trial of cognitive-behavioural therapy. This option was presented as it is
accepted that a multimodal approach can be helpful (Levy et al., 2006; Spanier, Howden
& Jones, 2003). To minimize a false advantage to this treatment due to a dose-response
phenomenon (i.e., larger expectations for this treatment because it provides more
treatment than either of the others), this treatment offered the combination of smaller
„doses‟ of the other treatments. In particular, the subtype-specific drug was offered at a
lower dose, specifically 50% of the dose offered in the pharmacological only treatment.
The „relaxation training with guided imagery‟ component of the psychological treatment
was removed, and fewer sessions of therapy were offered. This vignette was used only in
the pilot study; the rationale for excluding it is described in the results section.
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B. Expectancy Ratings
After reading treatment vignettes, participants were asked to rate how much they
expected those specific treatments to ameliorate their symptoms of IBS. As is often done
in placebo research (De Pascalis et al., 2002; Goosens et al., 2005; Price et al., 1999;
Vase et al., 2003; Weinfurt et al., 2003), expectations were measured on a visual
analogue scale (VAS). The VAS is a horizontal line drawn from 0 (no expected benefit)
to 10 (excellent expected benefit). Participants indicated their level of expectation of
benefit for each treatment by making a mark along such lines. The expectancy rating
scales are presented in Appendix J.
C. Treatment Credibility
Treatment credibility, assessed only in the pilot study, was also measured using a
VAS from 0 (not at all credible) to 11 (completely credible). Participants were asked to
rate the credibility of each treatment vignette by making a mark on the appropriate scale.
The credibility rating scales are presented in Appendix K.
D. Treatment Preference
Both in the pilot study and in the main study, participants were asked to indicate
what their treatment preference would be, should they actually be participating in the
hypothetical treatment scenario. The rationale for this question was as follows.
Hypothetically, the sample could be divided as to their preferred treatment scenario. It is
likely that preferred treatment would vary as a function of an individual‟s illness
attributions, i.e., what they consider to be causing their IBS symptoms, or their recovery
attributions, i.e., what type of treatment they consider to be the best approach to treating
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their IBS symptoms. It is also likely that these attribution variables could influence one‟s
expectations to benefit from a particular treatment. For example, for an individual who
considers their symptoms to be caused mainly by psychological factors, a
pharmacological treatment may not be expected to be of much benefit. On the other
hand, for those who feel their symptoms are influenced mainly by organic causes, a
psychological treatment may not be expected to be of benefit. Without controlling for
these likely important contributors to expectations of benefit, there is a risk that the
majority of the variance in expectancies could be predicted by illness and/ or recovery
attributions. This would significantly limit the variance in expectations that may be
predicted by other independent variables, and thus limit the utility of the study to
accomplish its aims. In order to avoid this situation, participants were given a choice of
preferred treatment, and their expectations of benefit for this preferred treatment then
served as the main dependent variable. Furthermore, by using „expectations of benefit
for preferred treatment‟ as the main outcome variable, data from the entire sample could
be collated for analysis, preserving statistical power.
E. Individual Difference Variables
Self-focused attention.
Self-focused attention was measured using the Revised Self-Consciousness Scale
(SCS-R; Scheier & Carver, 1985). The original scale (Fenigstein, Scheier & Buss, 1975)
was comprised of 23 items that loaded on three subscales, the private self-consciousness
subscale, the public self-consciousness subscale and a social anxiety subscale. This scale
was revised as it was found that the original wording was too abstract for non-college
samples, thus it was revised for use with non-college samples. For the purposes of the
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present study, only the private self-consciousness subscale was used. This subscale is
designed to measure one‟s dispositional tendency to attend to inner thoughts and feelings,
with higher scores indicating greater levels of self-focused attention. There have been
several studies examining the factor structure of the total scale, as well as the private selfconsciousness subscale (for a review see Martin & Debus, 1999). Each study has
confirmed that the private self-consciousness subscale can be divided into two related
factors, although there is disagreement regarding how the items on the subscale should be
divided and conceptualized. The most commonly used factor structure contains a „Selfreflectiveness‟ factor and an „Internal state awareness‟ factor. Self-reflectiveness is seen
as a disposition to think about the self; it contains 4 items thought to reflect negative
private self-consciousness (Anderson, Bohon & Berrigan, 1996; Ben-Artzi, &
Hamburger, 2001-2002). Internal state awareness is seen as a dispositional awareness of
one‟s inner feelings and states; it contains 3 items thought to reflect neutral or positive
private self-consciousness.
This is the most popular measure of dispositional self-focused attention in the
literature and the only one to differentiate between public and private self-focused
attention. It has been found to have adequate psychometric properties, with internal
reliability ranging from .73 to .84, and test-retest reliability ranging from .77 to .79
(Govern & Marsch, 2001; Martin & Debus, 1999; Mor & Winquist, 2002). The Private
Self-Consciousness Scale is presented in Appendix L.
Trait anxiety.
Two separate scales were used to measure trait anxiety in the current study. The
Anxious Arousal subscale of the Mood and Anxiety Symptom Questionnaire (MASQ;
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Watson & Clark, 1991) was used to capture the somatic anxiety symptoms that are
unique to the construct of anxiety. To capture the cognitive aspect of the anxiety
disorders, the Penn State Worry Questionnaire was employed (PSWQ; Meyer, Miller,
Metzger, & Borkovec, 1990). The decision to use these two scales was based on two
trends emerging in a growing literature regarding the measurement of anxiety and
depression. First, several studies have found that common measures of anxiety typically
do not have adequate discriminant validity to distinguish between the constructs of
anxiety and depression (e.g., Watson et al., 1995; Nitschke, Heller, Imig, McDonald &
Miller, 2001). For example, the commonly used State-Trait Anxiety Inventory (STAI;
Spielberger, Gorsuch, Lushene, Vagg & Jacobs, 1983) has been shown to be more
strongly related to general symptoms of distress, depression and negative affect than to
measures more specific to anxiety (Nitschke et al., 2001). In contrast, the Anxious
Arousal subscale of the Mood and Anxiety Symptom Questionnaire has been found to
have excellent discriminant validity across several samples (Keogh & Reidy, 2000;
Nitschke et al., 2001; Ruth & Mehrotra, 2001; Watson et al., 1995). Secondly, analysis
of the symptom patterns among the anxiety disorders have demonstrated that cognitive
anxiety (anxious apprehension or worry) is more characteristic of certain anxiety
disorders (i.e., generalized anxiety disorder and obsessive-compulsive disorder), whereas
somatic anxiety (anxious arousal) is more characteristic of other anxiety disorders (e.g.,
panic disorder, specific phobias; Andrews & Borkovec, 1988; Nitschke, Heller, Palmieri
& Miller, 2000). A recent study has confirmed that anxious apprehension (as measured
by the PSWQ) is relatively unrelated to anxious arousal (measured using the MASQ-AA)
and Anhedonic Depression (depression-specific symptom subscale of the MASQ;

81

Nitschke et al., 2001). In light of these findings, it is reasoned that the use of these two
separate anxiety subscales was best able to capture the specific symptom clusters of trait
anxiety that present in various anxiety disorders and have also been found to be distinct
from symptoms that are unique to the presentation of depression.
The Anxious Arousal subscale of the MASQ (MASQ-AA) consists of 17 items
that represent symptoms that, as mentioned, are relatively unique to the somatic arousal
aspects of the construct of anxiety. Respondents indicated to what extent they have
experienced each symptom on a 5-point scale ranging from 1 (not at all) to 5 (extremely),
with a higher score indicating more anxious arousal. To capture a more stable „trait‟
aspect of anxious arousal, respondents were asked to complete each item while
considering to what extent they experience each symptom „generally.5‟ This subscale has
been found to have good internal reliability (Cronbach‟s alpha = .86 - .90; Watson et al.,
1995). The MASQ-AA is presented is Appendix M.
The Penn State Worry Questionnaire (PSWQ) was designed as a measure of trait
worry for general use. It contains 16 items; respondents indicate to what extent each
statement applies to them on a 5-point scale ranging from 1 (not typical of me) to 5 (very
typical of me). Several items are reverse scored and a higher sum score represents
greater levels of trait anxious apprehension. The scale has been found to have excellent
psychometric properties (internal reliability = .93; test-retest = .92) and good convergent
and discriminant validity (Meyer et al., 1990; Nitschke et al., 2001). The PSWQ is also
presented in Appendix M.

5

Using a „general‟ frame as opposed to a specific time frame (i.e. in the last week) is how
the STAI distinguishes the trait versus the state version of the scale.
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Optimism / Pessimism.
Dispositional optimism and pessimism were measured using the popular Life
Orientation Test – Revised (LOT-R; Scheier, Carver & Bridges, 1994). The scale was
originally designed to assess optimism and pessimism as a bipolar unidimensional
construct with high scores representing optimism and low scores representing pessimism.
However, the authors of the LOT-R also reported that the optimism and pessimism items
could be used in analyses as separate constructs. There has been a fair amount of
research that confirms that the LOT-R is best considered to measure optimism and
pessimism as two related but distinct constructs (e.g., Creed, Patton, Wendy & Bartrum,
2002), including a large sample confirmatory factor analysis with findings consistent
across gender, age and medical diagnosis (Herzberg, Glaesmer & Hoyer, 2006).
This scale has 10 items; three positively worded optimism items, three negatively
worded pessimism items and four filler items. Respondents indicated their level of
agreement with each item on a four-point scale from 1 (strongly disagree) to 4 (strongly
agree). Subscale (optimism or pessimism) scores were calculated by summing the scores
for each item on that subscale. These subscales have demonstrated only adequate internal
reliability (Cronbach‟s alpha = .71 & .68 for optimism and pessimism, respectively;
Herzberg et al., 2006). The LOT-R is presented in Appendix N.
Hope.
Hope was measured using the Adult Hope Scale – Trait version, considered a
measure of dispositional hope (AHS; Snyder et al., 1991). The scale represents the
conceptualization of hope as consisting of a successful sense of agency (goal-related
determinism; 4 items) and pathways (ability to generate means to reach goals, 4 items).
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Respondents indicated the veracity of each statement (including 4 filler items) on an 8point scale ranging from 1 (definitely false) to 8 (definitely true). A total hope score was
calculated by summing the scores for each of the 8 hope items. Factor analytic studies
have confirmed that the scale consists of an overarching hope construct and two
underlying factors (Babyak, Snyder & Yoshinoba, 1993). Internal consistency has been
found to be good (Cronbach‟s alpha = .74 to .84) and the scale has been reported to have
good test-retest reliability (.85). The two subscales are moderately correlated in clinical
samples (r = .46 - .57; Steed, 2002). The Adult Hope Scale is presented in Appendix O.
F. Health Belief Variables
Current health.
Current health was assessed by asking about participants‟ perception of their
health as well as about their current health problems. To measure „Perceptions of
Health,‟ three questions were used, adapted from questions used in previous research
with illness groups (Sirois, 2003). These questions asked participants to rate: 1) How
good their health is relative to others their age, 2) How good their health is relative to
others with IBS, and 3) In general how they would rate their health. Participants
indicated their perceived health for each item on a 5-point scale ranging from 1 (very
poor) to 5 (excellent). A total score was calculated by summing scores for the individual
items. It has been established that brief measures of overall health such as this are highly
reliable and strongly correlated with other measures of health, such as physicians‟
assessments (Kubzansky, Kubzansky & Maselko, 2004). These items are presented in
Appendix P.
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As another measure of current health, participants were asked to complete a brief
health history checklist. This measure had participants indicate with a check the presence
of acute / transitory health problems experienced in the last six months. This second
current health variable, „Acute health problems‟ represented the sum of the health
problems endorsed on this checklist. The Brief Health History Checklist (Sirois & Gick,
2002) is presented in Appendix Q.
Control Beliefs.
Health-related control beliefs were measured using two subscales of the Control
Beliefs Inventory (CBI; Sirois, 2003). The six-item general control subscale measured
perceived control over health in general. A sample item from this subscale is “If I set my
mind to it, I can improve my health.” This subscale correlates highly (r = .73) with the
internal locus of control subscale of the Multidimensional Health Locus of Control Scale
(Wallston, Wallston & De Vellis, 1978), but it is free from the self-blame bias found in
the traditional scale. Internal consistency has been found to be good in samples with
various chronic health conditions (Cronbach‟s alpha = .85 - .91; Sirois, 2003; Sirois,
Davis & Morgan, 2006).
Perceived control over symptoms was assessed with the five-item symptom
control subscale of the CBI. This scale assessed the perceptions that one can manage the
symptoms of a specific illness (here, IBS). For this study, participants were instructed
that the term „symptoms‟ refers specifically to IBS symptoms. Sample items include „If I
make the effort, I can manage my symptoms‟ and „There are things that I can do to make
my symptoms easier to deal with.‟ This scale has demonstrated good internal consistency
with alphas ranging from .80 to .89 in chronic health samples (Sirois, 2003). For both
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subscales, participants were asked to rate their agreement with each item on a six-point
scale ranging from 1 (strongly disagree) to 6 (strongly agree). Higher scores represent
greater perceived control over one‟s health in general and one‟s symptoms, respectively.
These two subscales are presented in Appendix R.
Self-Efficacy.
Health-related self-efficacy was measured using the Health Efficacy subscale of
the Control Beliefs Inventory (CBI; Sirois, 2003). This 8-item scale assessed feelings of
competence and confidence to carry out actions important for maintaining and taking care
of one‟s health. Five items are scored in the positive direction and three items are
reversed scored. Respondents rate the extent to which each statement applies to them on
a 6-point scale ranging from 1 (strongly disagree) to 6 (strongly agree). This scale has
been found to have good psychometric properties; internal consistency is high in various
chronic health conditions (Cronbach‟s alpha = .82 - .86), and it shows good convergent
validity (Sirois, 2003; Sirois, Davis & Morgan, 2006). A total self-efficacy score was
calculated by summing the scores for each item, with higher scores representing higher
levels of self-efficacy. The Health Efficacy subscale is presented along with the other
Control Beliefs Inventory subscales in Appendix R.
Coping self-efficacy was assessed using three questions regarding how well
participants were coping with their IBS. This Coping Efficacy scale (Gignac, Cott &
Badley, 2000) has been used in research regarding adaptation to chronic illness, and was
found to have adequate internal reliability (Cronbach‟s alpha = .79). Respondents rated
their agreement with each coping question on a 5-point scale ranging from 1 (strongly
disagree) to 5 (strongly agree). Total scores were calculated by summing the score for
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each item, with higher scores representing greater levels of coping. The Coping Selfefficacy scale is presented in Appendix S.
Vulnerability to Illness.
Beliefs about vulnerability to illness refer to the extent that individual feels that
they are vulnerable to health problems. To measure this health belief variable, the
Resistance to Illness subscale of the Health Perceptions Questionnaire was used (Ware,
1976). Participants rated their agreement with each of four items (e.g., „I seem to get sick
a little easier than other people) on a 5-point scale from 1 (definitely false) to 5 (definitely
true). Two of the items are reversed scored; a total score is the sum of scores on each
item, with higher scores indicating greater „vulnerability to illness.‟ Although the
psychometric properties of this scale are only adequate (internal consistency = .71; testretest reliability = .73), this subscale is the only published English scale to measure
general beliefs about perceived vulnerability to illness. This subscale is presented in
Appendix T.
Catastrophizing.
The tendency to catastrophize about bodily sensations and symptoms was
measured by the Catastrophizing Interpretation of Bodily Complaints (CIBC) subscale of
the Cognitions about Body and Health Questionnaire (Rief, Hiller & Margraf, 1998).
This 14-item scale contains a series of statements about the interpretation of bodily
complaints and asks the respondent to indicate the accuracy of such statements on a 5 point scale from 0 (completely wrong) to 4 (completely right). A total score was
obtained by summing the scores for each item, with higher scores representing an
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increased tendency to catastrophize about bodily sensations and symptoms. This scale
has been shown to have good internal consistency in a clinical sample (Cronbach‟s alpha
= .88), and to have good construct validity (Rief et al., 1998). The CIBC subscale is
presented in Appendix U.
G. Context-Dependent Variables
Treatment Experience.
Participants‟ previous experiences with treatment were measured using several
author-created questions. The main measure of the influence of previous treatment
experience was labeled Previous satisfaction with preferred treatment. First participants
were asked to recall one of the treatment plans presented in the vignettes (e.g., drug
treatment), and were asked if they had previous experience with a similar treatment. If
they responded in the affirmative, they were directed to rate their satisfaction with that
treatment on a visual analogue scale from 0 (not at all successful) to 10 (completely
successful). They were also asked a similar question about the other treatment plan (e.g.,
psychological treatment). The response that corresponded to the treatment they chose as
their „preferred‟ treatment was then used to create the variable Previous satisfaction with
preferred treatment.
As a second measure of treatment experience, participants were also asked
about current and past treatments. A list of common treatments for IBS was presented
and participants were asked to check off any treatments they were currently using.
Participants were also asked to rate their satisfaction with each treatment on a 6-point
scale ranging from 1 (very dissatisfied) to 6 (very satisfied). Following this section was
an identical section pertaining to past treatments. Several indices were calculated from
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these items, including: Number of current treatments and Satisfaction with current
treatments, Number of past treatments and Satisfaction with past treatments. Finally,
participants were asked whether or not they had previously been treated by a
gastroenterologist, and to rate satisfaction with this treatment on a 5-point scale ranging
from 1 (not satisfied) to 5 (extremely satisfied). These items are presented in Appendix
V.
IBS Symptom Attributions.
Symptom attributions refer to what an individual perceives to be the cause(s) of
their illness-specific symptoms. For example, illness-specific symptoms may be
attributed to physical/ somatic causes (such as genetics, bacteria, viruses, structural
abnormalities, etc) or to psychological causes (such as stress or anxiety). Individuals
may also attribute their symptoms to a combination of somatic and psychological causes,
or to more transitory causes (poor sleep, diet changes, lack of exercise, etc). Two
questions were used to assess participants‟ personal illness attributions for their
symptoms of IBS. These questions present a particular symptom of IBS and are followed
by three explanatory statements that describe a somatic, psychological or transitory
reason for the symptom. (Two filler questions also were presented that describe non-IBS
symptoms). For each statement, respondents indicated on a 10-point VAS how much
they felt that the reason explained each symptom from 0 (Not at all true) to 10 (Very
much true). Averaging ratings across the two questions resulted in two variables labeled
Somatic symptom attribution and Psychological symptom attribution. These symptom
attribution items are presented in Appendix W.
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Perception of Treatment Focus.
Further taking into account individuals‟ different illness / symptom attributions,
participants were asked to identify how much they perceived their preferred treatment as
targeting the somatic or psychological causes of IBS. Two 10-point visual analogue
scales were used to measure these perceptions. On one scale, labeled „Perceived somatic
focus of treatment,‟ participants were asked to indicate how much they believed that the
treatment targeted the physical causes of IBS from 0 (not at all true) to 10 (very much
true). On another scale, labeled „Perceived psychological focus of treatment,‟ they were
asked to indicate how much they perceived that their preferred treatment targeted the
psychological causes of IBS. These items are presented in Appendix X.
Motivation.
There are three aspects of motivation that were assessed in the current study. The
first aspect is motivation to benefit from treatment, or Desire for relief. This was
measured similarly to how it has been measured in placebo research, on a visual analogue
scale (VAS; Price et al., 1999; Vase et al., 2003). Participants were asked to indicate on a
10-point VAS: „How strong is your desire to see relief from your IBS symptoms at this
time?‟
As a second measure of motivation/ desire for relief, current IBS Symptom
Severity was also assessed. A 7-item scale was used to assess the severity of participant‟s
IBS symptoms within the last week (Dancey, Whitehouse, Painter & Backhouse, 1995)
on a 8-point scale ranging from 0 (no symptoms) to 7 (extremely severe). A mean score
was calculated, with higher scores indicating more severe IBS symptomotology. Internal
consistency has been found to be acceptable, Cronbach‟s alpha = .74. To complement
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this aspect of motivation, participants were also asked, “To what extent has IBS affected
your daily activities” and were directed to respond on a 4-point scale from 1 (not at all) to
4 (a lot). These items are presented in Appendix Y.
The third aspect of motivation that was examined concerns the general area of
demand characteristics. This refers to a subject‟s perception of what the experimenter‟s
hypotheses might be, along with the participants‟ desire to help confirm those
hypotheses, or otherwise „please the experimenter.‟ There are currently no self-report
survey measures to assess the impact of demand characteristics. To approximate an
assessment of this motivational factor, this study first attempted to minimize demand
characteristics, and second measured participants‟ tendency towards socially desirable
responding. Demand characteristics were minimized through the use of neutral language
in the recruitment messages, consent forms and treatment vignettes.
Socially desirable responding was measured using the newly developed Social
Desirability Scale – 17 (SDS-17; Stober, 1999). This scale was developed to address
criticisms and overcome the limitations of the two currently most popular measures of
social desirability, the Marlowe-Crowne Social Desirability Scale (Crowne & Marlowe,
1960) and the Balanced Inventory of Desirable Responding (Paulhus, 1998). Although
popular, both of these measures have been criticized for having weak psychometric
properties (see Barger, 2002; Leite & Beretvas, 2005; Pauls & Crost, 2004). The SDS-17
contains 16 true-false items. High scores represent a greater tendency to present oneself
in a desirable light. It has been found to be internally reliable (KR-20 = .70 to .92) and to
have good construct validity (Blake, Valdiseei, Neuendorf & Nemeth, 2006; Stober,
2001). This scale is presented in Appendix Z.
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Patient-Provider Relationship.
Perceived quality of the patient-provider relationship was measured using a
modified version of the Patient Reactions Assessment (PRA; Galassi, Schanberg, &
Ware, 1992). This 15-item measure contains three subscales, each of which is designed
to assess an important component of the patient-provider relationship. The Patient
Information Index (PII) contains items concerning the quality and clarity of the
information provided to the patient with regards to a specific treatment. For example,
items query whether the patient feels that the treatment procedure has been clearly
explained, whether potential side effects are adequately understood. The Patient
Affective Index (PAI) assesses socio-emotional aspects of the relationship and includes
items regarding the perceived warmth and interest of the provider, and the patient‟s
comfort discussing personal issues, etc. The Patient Communication Index (PCI)
contains items assessing the perceived ease with which the patient can solicit or provide
additional information regarding symptoms or the treatment. Coefficient alpha for the
15-item PRA was .91. For the PII, PCI, and PAI, the values are .91, .90, & .87,
respectively. Respondents were asked to respond to each item on a 5-point scale ranging
from 1(strongly disagree) to 5 (strongly agree), and total scores are computed by
summing the item scores.
For the proposed research, this measure was modified to reflect the hypothetical
nature of the treatment scenario. Participants were asked to respond to items while
considering how they imagine the patient-provider interaction would occur. Because the
treatment vignettes do not provide enough information to respond to each item, it is likely
that participants‟ implicit beliefs were activated in completing this measure, or their
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beliefs formed through previous treatment experiences, if applicable. The modified
version of the PRA is presented in Appendix AA.
H. Qualitative Component
In the main study, a narrative regarding factors that may contribute to
expectations of benefit was requested from participants. A single open-ended question
was used. The purpose of this question was to have participants express, in a narrative
format, what they thought influenced their expectations of treatment benefit. The
question was designed to elicit responses that do not only focus on treatment or situationspecific variables (e.g., preference for the treatment type), but also on personal
psychosocial variables. Participants were provided with a blank space in which to write
their responses. There was no word limit for this question. The specific question was as
follows:
People have different reasons for why they expect treatments to work.
Often people have unique characteristics, such as their personal history,
personality or beliefs that affect their expectations about whether treatment will
work. Some characteristics may increase expectations while some may decrease
expectations. Either way, we think it is important to learn more about these
unique characteristics so we can better understand people‟s expectations about
treatment.

Think back to the treatment that you chose earlier as the one that you preferred.
Think back to whether you thought it would work well for you or not.
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In the space provided, we would appreciate if you could share your thoughts by
answering the following question: Why did you think that that treatment may or
may not work for you? Try to keep in mind how your personal characteristics
may influence your opinion.
V.

Data Analyses

A. Preliminary Analyses
After data screening, descriptive analyses were run on all main variables and tests
of mean differences were run on the main dependent variable to assess for possible order,
gender, IBS subtype and recruitment source effects. Simple analyses were conducted to
compare the mean expectations of benefit for the preferred treatment among those who
prefer one treatment or the other. There were no mean differences on levels of
expectation for preferred treatment between those preferring one treatment vs. the other.
Thus, a new dependent variable was created capturing participant‟s expectations to
benefit from their preferred treatment, also referred to as „treatment expectancies.‟
B. Analysis of Hypothesis One
A series of Pearson zero-order correlations between the independent and
dependent variables were used to test the hypotheses that each of the measured
independent variables would be correlated with the main dependent variable.
C. Analysis of Hypothesis Two
Hierarchical multiple regression analysis was used to answer the second research
question regarding the relevant contributions of these psychosocial variables for
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predicting levels of treatment expectancies. All independent variables identified as
having a significant zero-order correlation with the dependent variable were included in
the regression in three steps. Relevant individual difference variables were entered in the
first step, relevant health belief variables were entered in the second step, and relevant
context- specific psychosocial variables were entered in the last step. The rationale
behind this hierarchy is as follows. Individual difference variables are thought to be the
most stable of the psychosocial variables being tested in the model. These are the
variables that are presumed to be context-independent and have been theorized to alter
treatment-specific expectations through their effects on cognitive processing, particularly
attention. Health belief variables were entered in the second step as they are presumed to
exert an influence on context-specific expectations in conjunction with/ conditional upon
the role of individual difference variables (Sirois, 2001, 2009). Furthermore, there is also
the least amount of empirical support for the relationship between these variables and
treatment expectations; including them in the second step allows for an assessment of
what they contribute over and above the stable individual difference variables. The
context-dependent variables (e.g., previous treatment experiences, perception of
treatment focus, patient-provider relationship) were entered in the final step of the
regression. These variables were hypothesized to be strongly related to treatment
expectancies, due in part to their context-specific relevance to „expectations about the
current treatment‟ and based on prior theory and research. Including them in the last step
allows for this research to identify which of the more internal psychosocial variables
remain significant predictors of treatment expectancies after these presumably strongly
relevant variables are included in the model.
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In order to ascertain the relative importance of each independent variable in
predicting variance in the dependent variable, a number of indicators were examined.
The standardized regression coefficients (beta weights) and the associated significance
levels were examined to ascertain the contribution of each IV to the DV while the other
IVs are held constant. This allowed for a comparison of the relative predictive power of
each IV. The squared semipartial correlations (and their significant levels) were also
examined, as they reflect the amount of unique and joint variance explained by each IV
when other IVs are held constant. The joint variance is important to consider, as some of
these variables will likely be correlated with each other and thus contribute joint variance
to the DV.
D. Analysis of Research Question Three
The third main research question concerned the narrative data that was solicited
from participants regarding their thoughts about what influenced their expectations of
treatment benefit. Two independent raters examined the qualitative responses from a
random sample of 100 participants from the total sample. Responses ranged in length
from a few words to a few sentences. The transcripts were read multiple times by the
principle investigator and a trained graduate student, guided by the research question
regarding whether there were additional psychosocial variables, over and above the
variables identified as potentially relevant throughout the literature review in Chapter 1,
that are commonly cited as contributing to one‟s expectations of treatment benefit. The
responses were first explored deductively through a qualitative content analysis.
Responses were deductively tagged for common themes and placed in pre-defined
conceptual categories, specifically corresponding to the pre-identified independent
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variables. In addition, responses were reviewed in search of emergent categories that
became apparent in the data but that did not fit into any of the preset categories. The goal
of this conceptual analysis was to a) enumerate the number of references made to each of
the pre-set categories and to b) identify themes as they emerged from the data that
represented „additional psychosocial variables‟ related to treatment expectations.
Discrepancies were discussed and consensus about category codes was reached. Cohen‟s
(1960) kappa (K), which corrects for agreement by chance, was used to assess inter-rater
reliability of the coding categories. The percent agreement was 88.9%, with Cohen‟s
kappa = .88, which indicates very good agreements beyond chance (Fleiss, 1981). The
final coding manual includes (a) a list of all categories (independent variables plus
emergent categories), (b) definitions of each category, and (c) examples of each category
(see Appendix AB).
Chapter 3
RESULTS
The results of the statistical analyses are presented in four sections of this chapter.
The first section presents results of the pilot study. The second section presents the steps
taken to clean and normalize the dataset. The third section outlines preliminary analyses
conducted to assess scale reliability, order and gender effects, the identification of
potential confounds and the creation of one main dependent variable. This section
includes information about participant treatment experiences. The analysis of the main
hypotheses is presented in the fourth section, and includes supplementary analyses.
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I.

Pilot Study Results

A. Selection of Treatment Vignettes
The selection of two treatment vignettes for use in the main study was informed
through the examination of the distribution of treatment expectancy scores for each of the
three treatment vignettes and of the treatment preferences of the pilot sample.
Exploratory analyses were conducted to examine the distribution of expectancy ratings
for each treatment vignette. Descriptive statistics, presented in Table 5, indicate that
expectancy ratings were normally distributed for each treatment vignette. Shapiro-Wilk
tests for normality confirmed the normality of these distributions.
Table 5
Descriptive Statistics for Treatment Expectancy Scores Across Pilot Treatment Condition
Treatment
Condition

M

SD

Variance

Skew/ SE

Kurtosis/ SE

Pharmacological

5.52

2.48

6.12

-.55

-1.17

Psychological

5.23

2.76

7.65

.32

-1.31

Combined

6.03

2.87

8.23

-.56

-1.37

Frequency analyses were then conducted to examine participants‟ preferences
among the three possible hypothetical treatments. Figure 2 illustrates that only 3% of the
sample chose the combined treatment as their least preferred treatment (shown in the
right-most cluster on the graph).
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Figure 2. Treatment preferences in order of choice in pilot sample.
Thus, the majority of participants chose the combined treatment as either their
first or second choice. Although it may seem counterintuitive, this is the vignette that
was excluded from the main study. The rationale for this choice is as follows. It was
preferable that the two vignettes employed in the main study generate an approximately
equal split in the sample of participants preferring one or the other treatment. Also, it
was desired that the treatment vignettes generate a full distribution of treatment
expectancy scores and scores on the measures of „perceived somatic/ psychological
focus‟ of treatment. Therefore, it was decided to employ the pharmacological (Drug) and
psychological (CBT plus relaxation) treatment vignettes as the two vignettes in the main
study. It was thought that if the combined treatment (strongly preferred in the pilot
study) was presented in the main study, this treatment would be again strongly preferred,
potentially creating skewed distributions of treatment expectancies, losing some variance
in the dependent variable and inhibiting to power to examine the influence of attributions
on expectations of treatment benefit.
B. Examining Treatment Credibility
Another component of the pilot study analyses was looking at the relationship
between treatment credibility and expectation to benefit from treatment. The purpose of
this analysis was to serve as a manipulation check to confirm that the treatment vignettes
were credible as veritable potential IBS treatment scenarios.
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The distributions of treatment credibility ratings for each treatment were first
examined and all were normally distributed. Correlation analyses revealed that
credibility ratings (range = 1- 11) were moderately to strongly positively correlated with
ratings of expectation of benefit (Drug treatment: r = .625, p < .001; CBT: r = .739, p <
.001; Combined treatment: r = .871, p < .001). These results indicate that an individual‟s
expectation of benefiting from treatment is related to the individual‟s judgment regarding
the credibility of that treatment for their condition, and confirm the credibility of the
treatment vignettes.
II.

Participant and Dataset Screening

A. Participant Screening
An initial sample of 358 participants provided data. All subjects were over 16
years of age. A total of 62 participants did not meet the inclusion criteria and were
excluded from the study. Specifically, 53 respondents were removed from the dataset as
they did not meet the Rome III criteria to qualify for a diagnosis of IBS. In addition, 8
participants failed to complete at least 80% of survey items and 1 participant who had
clearly responded in a careless fashion were removed from the dataset. This left 296
participants in the dataset (17.3% bad data).
B. Data Screening
All main variables were examined through various SPSS programs for accuracy
of data entry, missing values, and fit between their distributions and the assumptions of
multivariate analysis. The majority of variables were missing values on some cases. For
variables missing less than 5% of cases (all but two variables, described below), SPSS
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missing value analysis (MVA) was run and values for missing cases were imputed using
expectation maximization (EM) method. As part of this procedure, Little‟s MCAR Chisquare statistic was found to be non-significant, indicating that missing values on these
variables were indeed missing in a random fashion.
The two variables missing values on more than 5% of cases were „Years since
diagnosis‟ and „Years with symptoms.‟ As these two variables were not main variables
of interest, the decision was made to exclude these variables from the analysis of main
hypotheses.
Exploring the distributions of the main variables revealed that several variables
displayed significant skew and /or kurtosis, and that many also contained univariate
outliers. Variables that displayed both departures from normality as well as outliers were
transformed to improve normality before addressing outliers. Reflection and square root
transformation was applied to 8 variables to improve moderate negative skew6.
Reflection and inverse transformation was applied to one variable to correct severe
negative skew (Desire for relief). One variable with moderate positive skew was
transformed using square root transformation (Number of current treatments used).
Finally, three variables with substantial positive skew were corrected using logarithmic
transformation (Number of past treatments used, Satisfaction with gastroenterologists,
Anxious arousal). For seven of these variables, transformation eliminated univariate
outliers, whereas for five variables, outliers remained despite improvements in normality
(Number of current treatments used, Number of past treatments used, Satisfaction with
6

Variables include: Treatment expectancy: CBT, Treatment expectancy: Drug, Perceived
somatic focus of treatment, Perceived psychological focus of treatment, IBS: Interference
in daily activities, Satisfaction with current treatments, Control over health, Control over
symptoms.
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current treatments, Control over health, Control over symptoms). Standardized (z) scores
were calculated for these univariate outliers and none were found to be in excess of 3.29,
the criterion recommended Tabachnick and Fidell (2001). Thus these outliers were left in
the dataset as is.
Univariate outliers were also identified on seven variables that were otherwise
normal7. Again, a standardized (z) score was calculated for each outlier; five cases with
standardized scores greater than 3.29 were identified. To improve variable distributions
while maintaining sample size, the „deviance‟ of these cases was minimized, as
recommended by Tabachnick and Fidell (2001). This was accomplished by assigning the
outlying cases a raw score on the offending variable that was one unit larger (or smaller)
then the next most extreme score in the distribution. Variables containing cases that were
minimized include: Patient-provider relationship (2), Socially desirable responding (1),
Hope (1) and Symptom severity (1).
With transformed variables in the variable set, two cases were identified as
multivariate outliers by using Mahalanobis distance with p < .01. Both cases were
deleted, leaving 294 cases in the dataset. Pairwise linearity and homoscedasticity was
checked using bivariate and residual scatterplots and was found satisfactory.
III. Preliminary Analyses
Before proceeding to analyses of main hypotheses, several preliminary analyses
were performed. This included creating new variables that would control for treatment
preference, further examining the distributional and psychometric properties of main

7

Variables include: IBS symptom severity, Perception of health, Socially desirable
responding, Hope, Health self-efficacy, Catastrophizing, Patient-provider relationship.
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variables in the dataset, and checking for possible confounding variables (e.g., gender and
order effects). These analyses are presented in this section.
A. Treatment Preference Variables
To minimize the impact of treatment preference while exploring the relationships
between treatment expectancies and individual psychosocial variables, a new dependent
variable was created, labeled Expectancy for preferred treatment. This variable
represents participants‟ treatment expectancy ratings for the treatment that they reported
that they would prefer based on the two treatment vignettes. Participant treatment
preference was split nearly equally between those preferring psychological treatment
(CBT; 48.6%) and those preferring the pharmacological treatment (Drug; 51.1%). A
univariate GLM (general linear model) was run to test for mean differences in preferred
treatment expectancy ratings across groups preferring one or the other treatment. This
confirmed the null hypothesis that the mean treatment expectancy rating among those
preferring CBT (M = 6.75, SD = 2.11) was not significantly different from the mean
rating among those preferring the Drug treatment (M = 7.00, SD = 1.81), F (1,292) =
1.25, p = ns. The two treatment preference groups were thus combined into one main
sample with Expectancy for preferred treatment as the main dependent variable. The
distribution of Expectancy for preferred treatment was found to be negatively skewed
(skew/ SE of skew = -5.00) and to contain outliers (9 > = 3.00). Reflection and square
root transformation was applied to this variable, which improved skewness (skew/ SE of
skew = 0.36) but did not eliminate outliers. Five of these outliers with standardized (z)
score greater than 3.29 were deleted from the dataset, leaving a total sample size of 289.
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As described above, based on participants‟ reports of past experience and
satisfaction with their preferred treatment, a variable labeled „Previous satisfaction with
treatment‟ was created. Although 120 participants had reported experience with drug
treatment, and 68 participants had reported experience with CBT treatment, only 93
participants reported that they had had experience with their „preferred‟ treatment. The
distribution of this variable (Previous satisfaction with treatment) was adequate and
contained no outliers.
B. Participant Treatment Experiences
Table 6 provides a summary of participants‟ treatment experiences. Participants
reported that they used an average of 2.74 current treatments (SD = 2.00; range = 0-12)
and 2.42 past treatments (SD = 2.42; range = 0-12).

The most popular treatments were

„diet changes‟ (current = 78.9%; past = 57.8%) and the use of „laxative/ antidiarrheals‟
(current = 43.5%; past = 48.3%). Average satisfaction ratings were calculated among
those who reported current or past treatment use (n = 254, n = 230, respectively).
Participant‟s average satisfaction with their current treatments was between „mildly
dissatisfied‟ and „mildly satisfied‟ (M = 3.64; SD = 1.23; range = 1-6) and their
satisfaction with past treatment was between „dissatisfied‟ and „mildly dissatisfied‟ (M =
2.89; SD = 1.39; range = 1-6). The highest satisfaction ratings among both current and
past treatments were for „diet changes,‟ making this treatment strategy both the most
common and perceived as most successful. Participants were also asked about their
experience and satisfaction being treated by a gastroenterologist. Just over half of the
participants (55.4%) reported having been treated by a gastroenterologist, and on average
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participants rated their satisfaction with that treatment as „mildly satisfied‟ (M = 1.97; SD
= 1.07; range = 1-5).
Table 6
Participant Treatment Experiences

Treatment
Diet changes
Relaxation training
Biofeedback training
Laxative/ antidiarrheals
Herbal/ mineral/ vitamin
supplements
Probiotics
Acupuncture
Antispasmotics
Serotonin (ant)agonists
Hypnotherapy
Psychotherapy
Antidepressants

Current
Use
Satisfaction
n (%)
M (SD)
232 (78.9)
3.62 (1.36)
74 (25.2)
3.45 (1.36)
17 (5.8)
2.59 (1.46)
128 (43.5)
3.45 (1.59)
96 (32.7)
3.59 (1.62)

Past
Use
Satisfaction
n (%)
M (SD)
170 (57.8) 3.28 (1.55)
46 (15.6) 2.89 (1.64)
16 (5.4) 2.38 (1.78)
142 (48.3) 2.94 (1.62)
75 (25.5) 2.77 (1.55)

83
13
53
14
9
18
69

60
20
66
17
6
28
66

(28.2)
(4.4)
(18.0)
(4.8)
(3.1)
(6.1)
(23.5)

3.54 (1.45)
3.08 (1.89)
3.21 (1.66)
2.29 (1.90)
3.67 (1.94)
2.83 (1.92)
3.07 (1.56)

(20.4)
(6.8)
(22.4)
(5.8)
(2.0)
(9.5)
(22.4)

2.42 (1.43)
2.05 (1.47)
2.61 (1.50)
1.94 (1.56)
2.83 (1.72)
2.43 (1.64)
2.29 (1.58)

C. Checking the Variables
Table 7 provides a description of all main variables, including: number of items
on the scale, mean, standard deviation, range and Cronbach‟s alpha for internal
reliability. It was noted that the symptom attribution scales had low values of internal
reliability (Cronbach‟s alpha = .30 and .59, for somatic symptom attribution and
psychological symptom attribution, respectively). A number of steps were taken to
attempt to validate these symptom attribution variables. Analyses examining the
relationships between participants‟ symptom attribution scores, treatment preferences and
expectations to benefit from both the CBT and drug treatments, found that neither
Somatic symptom attribution nor Psychological symptom attribution were significantly
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related to Treatment expectations (transformed) for the CBT or drug treatment.8
Furthermore, contrary to conventional wisdom, levels of psychological and somatic
symptom attributions were not different among those who chose the psychological t(287)
= 1.35, p = ns or the drug treatment t(287) = -.98, p = ns. Although it is feasible that the
lack of relationships between symptom attributions and treatment preferences or
expectancies is a valid finding, clearly any results generated using these variables would
be inconclusive. These symptom attribution variables were thus dropped from the main
analyses.
Univariate GLM (general linear model) analyses were conducted to assess for any
order or gender effects on the main dependent variable (Expectancy for preferred
treatment – transformed). There were no main effects for either order, F(1, 287) = .03, p
= ns, or gender, F(2, 286) = .31, p = ns.
Several other univariate GLM tests were conducted to ascertain whether there
were any significant relationships between demographic variables and the main
dependent variable. Variables tested included: Referral source, Source of diagnosis, IBS
subtype (self-report and Rome III criteria), Country of residence, Marital status,
Ethnicity, Education, or Employment status. No significant main effects were identified.
For continuous demographic variables (i.e., age,) a correlation was run to check for a
significant relationship to expectations for preferred treatment (transformed). No
significant relationship was identified at the .05 level.

8

Correlation of Treatment expectation: drug with Somatic symptom attribution (r = .045, p = ns). Correlation of Psychological symptom attribution with Treatment
expectation: CBT (r = -.11, p = ns).
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Table 7
Description of Main Variables
No.
Cronbach‟s
Variable
items
M
SD
Range
alpha
Treatment expectancy
CBT
1
5.42
2.63
1-10
Drug
1
6.03
2.37
1-10
Preferred
1
6.88
1.97
1-10
Self-focused attention
7
17.71 5.07
7-28
.844
Trait anxiety
Trait worry
16
53.38 14.13 20-80
.930
Anxious arousal
16
32.18 10.76 16-72
.868
Optimism
3
7.53
1.89
3-12
.727
Pessimism
3
7.13
2.16
2-12
.849
Hope
8
45.50 9.34
19-64
.856
Current Health
Perception of health
3
9.44
2.38
3-15
.851
Acute health problems
12
5.15
2.52
0-10
Control Beliefs
Health
6
26.53 6.00
6-30
.884
Symptoms
5
22.01 5.62
5-25
.925
Health self-efficacy
8
31.22 6.43
14-47
.737
Coping self-efficacy
3
9.17
3.06
3-15
.883
Vulnerability to illness
4
12.35 3.94
4-20
.874
Catastrophizing
14
26.89 5.49
14-42
.798
Treatment experience
Previous satisfaction with preferred txa
1
6.19
2.75
0-11
Number of current treatments
2.74
2.00
0-12
c
b
Satisfaction with current treatments
3.64
1.23
1-6
Number of past treatments
2.42
2.42
0-12
b
Satisfaction with past treatmentsd
2.89
1.39
1-6
IBS symptom attribution
Somatic
2
5.76
2.05
1-10
.302
Psychological
2
4.83
2.38
1-10
.594
Perceived focus of treatment
Somatic
1
7.02
2.39
1-10
Psychological
1
6.23
3.04
1-10
Motivation
Desire for relief
1
8.80
1.69
1-10
Symptom Severity
7
33.40 7.95
9-56
.592
Interference in daily activities
1
3.13
.76
1-4
Socially desirable responding
16
6.94
1.98
0-14
Patient- provider relationship
15
54.71 8.42
15-75
.878
Note. Statistics presented are for untransformed variables. tx = treatment.
a
n= 93. bNumber of items used to create average varied by participant. cn = 254. dn = 230.
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IV. Analysis of Main Hypotheses
A. Testing Hypothesis 1
The first main hypothesis was that each of the measured independent variables
would be correlated with the main dependent variable (DV; Expectancy for preferred
treatment – transformed)9. To test this hypothesis, a series of zero-order Pearson
correlations were run to test for linear relationships between the main dependent variable
and each independent variable.
Self-focused attention.
Hypothesis 1a proposed that levels of self-focused attention would be correlated
with treatment expectancies.10 Results of the correlational analysis for the total sample
(N = 289) support this hypothesis, as it was found that higher levels of self-focused
attention were positively correlated with higher levels of treatment expectancies (r = .16,
p < .01). In other words, it was found that participants who report a greater dispositional
tendency to attend to their inner thoughts and feelings also reported greater expectations
to benefit from treatment.
Trait anxiety.
Hypothesis 1b proposed that levels of trait anxiety would be negatively correlated
with positive treatment expectancies. To test this hypothesis, separate correlations were
run examining the relationship between treatment expectancies and both levels of anxious
arousal (transformed) and trait worry. This hypothesis was not supported, as levels of

9

All analyses with this variable were done using the transformed variable.
The DV will alternatively be called „treatment expectancies/ expectancy‟

10
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treatment expectancy were not related to either Anxious arousal (r = -.01, p = ns) or Trait
worry (r = .03, p = ns).
Optimism / Pessimism.
Hypothesis 1c proposed that levels of optimism would be positively correlated
with levels of treatment expectancy and that levels of pessimism would be negatively
correlated with treatment expectancy. This hypothesis was partially supported; levels of
optimism were positively correlated with levels of treatment expectancy (r = .17, p <
.01). However, levels of pessimism were not significantly correlated with levels of
treatment expectancy (r = -.10, p = ns). Thus, respondents who reported greater levels of
optimism also reported higher positive expectations of benefiting from their preferred
treatment, whereas levels of pessimism were not related to positive treatment
expectancies.
Hope.
Hypothesis 1d proposed that levels of hope would be positively related to levels
of treatment expectancy. This hypothesis was unsupported as hope was found to be
unrelated to levels of treatment expectancy (r = .07, p = ns).
Current health.
Hypothesis 1e proposed that levels of treatment expectation would be positively
correlated with Perceived current health and negatively correlated with number of Acute
health problems. This hypothesis was not supported as analyses revealed that levels of
treatment expectancy were not related to either Perception of health (r = .10, p = ns), nor
Acute health problems (r = -.05, p = ns). These results suggest that in this sample, one‟s
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perceived level of current health is not related to one‟s expectation of benefiting from
treatment.
Control beliefs.
Hypothesis 1f proposed that treatment expectancies would be positively
correlated with both Control over health and Control over symptoms. Correlational
analyses supported these hypotheses, as it was found that greater levels of treatment
expectancies were positively correlated with both Control over health (transformed; r =
.22, p < .01) and Control over symptoms (transformed; r = .27, p < .01). This suggests
that in this sample, greater expectations to benefit from treatment were related to greater
level of perceived control over health and perceived control over IBS symptoms.
Self-efficacy.
Hypothesis 1g proposed that levels of health self-efficacy and coping self-efficacy
would be positively correlated with treatment expectancies. This hypothesis was
unsupported as neither levels of health self-efficacy nor coping self-efficacy were related
to treatment expectancies (r = .03, p = ns; r = .11, p = ns).
Perceived vulnerability to illness.
Hypothesis 1h proposed that levels of perceived vulnerability to illness would be
negatively correlated with treatment expectancies. This hypothesis was unsupported as
the zero-order correlation between these variables was non-significant (r = .03, p = ns).
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Catastrophizing.
Hypothesis 1i proposed that levels of symptom catastrophizing would be
negatively correlated with treatment expectancies. Correlational analysis did not support
this hypothesis. In contrast, it was found that levels of symptom catastrophizing were
positively related to treatment expectancies (r = .12, p < .05). This suggests that in this
sample, the tendency to catastrophize about bodily symptoms and sensations was related
to higher levels of treatment expectancies.
Treatment Experiences.
Hypothesis 1j proposed that levels of satisfaction with previous similar treatments
would be positively correlated with current treatment expectancies. Among the 93
participants who did report previous experience with their preferred treatment, there was
a strong positive correlation between Previous satisfaction with preferred treatment and
current treatment expectancies (r = .50, p < .01). Thus, greater satisfaction with similar
treatments in the past was strongly related to one‟s level of expected benefit from their
preferred hypothetical treatment.
Also relevant to treatment experiences, Hypothesis 1j proposed that past treatment
history (Number of past treatments, transformed) would be negatively correlated with
current treatment expectancies. Using the full sample (including those who report using
zero treatments in the past), this hypothesis was not supported, (r = .02, p = ns).
Similarly, there was no relationship found between current treatment expectancies and
Number of current treatments (transformed; r = .00, p = ns).
Unplanned analyses examined the relationships between treatment expectancies
and average satisfaction levels for past (n = 230) and current treatments (transformed; n =
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254). Neither relationship with was significant (current: r = .11, past: r = .05, p‟s = ns).
These results suggest that treatment experiences, particularly past satisfaction with
treatment, are relevant only in the context of a treatment situation that is similar to the
one previously experienced. Also unplanned, the relationship between treatment
expectancies and Satisfaction with gastroenterologists (transformed; n = 159) was nonsignificant (r = .06, p = ns).
Illness attributions.
Hypothesis 1k proposed that illness attribution variables, particularly IBS
Symptom attributions (level of somatic or psychological attribution) and Perceived
somatic/ psychological focus of treatment, would be correlated with expectancies for
preferred treatment. The relationships with IBS Symptom attributions could not be tested
due to the poor psychometric properties of the scale used to measure these constructs.
This hypothesis was supported, however, when tested using the variables tapping the
levels to which participants perceived their preferred treatment as focusing on the somatic
or psychological aspects of their IBS symptoms. Specifically, Expectation to benefit
from preferred treatment was moderately positively correlated with Perceived somatic
focus of treatment (transformed; r = .51, p < .01) and weakly positively correlated with
Perceived psychological focus of treatment (transformed; r = .16, p < .01). These
findings suggest that overall, participants‟ treatment expectations were influenced by how
much they perceived their preferred treatment as targeting the somatic or psychological
roots of their IBS symptoms, but more so by the perceived degree of somatic focus of the
treatment.
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Motivation.
Hypothesis 1l proposed that various measures of motivation would be positively
correlated with positive treatment expectancies. Correlational analyses revealed that this
hypothesis was unsupported, as treatment expectancies were not related to levels of
desire for relief (transformed; r = -.01, p = ns), Symptom severity (r = -.03, p = ns), or
IBS: Interference in daily activities (transformed; r = -.04, p = ns). Hypothesis 1m
proposed that levels of socially desirable responding would be positively related to levels
of treatment expectancy. This hypothesis was also unsupported, as these variables were
uncorrelated in this sample (r = -.04, p = ns).
Patient-provider relationship.
Hypothesis 1n proposed that a more positive perception of the treatment provider
would be positively correlated to treatment expectancies. Results from correlation
analysis supported this hypothesis; more positive perceptions of the treatment provider
were positively correlated with treatment expectancies (r = .12, p < .05).
Summary for Findings of Hypothesis 1.
In the full sample the following variables were significantly correlated with
treatment expectancies (transformed) as hypothesized: Optimism, Self-focused attention,
Control over health (transformed), Control over symptoms (transformed), Perceived
somatic focus of treatment (transformed) and Perceived psychological focus of treatment
(transformed) and Positive perception of the treatment provider. Among those who had
past experience with their preferred treatment (n = 93), there was a strong positive
correlation identified between treatment expectancies and Previous satisfaction with
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treatment. One variable was identified as having significant relationship with treatment
expectancies, although not in the hypothesized direction. Specifically, tendency towards
catastrophizing over symptoms demonstrated a weak positive correlation with treatment
expectancies.
The following variables did not show a significant linear relationship to levels of
treatment expectancy: Trait anxiety (both trait worry and anxious arousal), motivation
(including Desire for relief, Symptom Severity, IBS: Interference with daily activities and
Socially desirable responding), Pessimism, Hope, Number of past treatments, perceived
current health (including Perception of health and number of Acute health problems),
Health self-efficacy, Coping self-efficacy and beliefs of Vulnerability to illness.
B. Testing Hypothesis 2
Research question 2 asked: What are the relative contributions of these
psychosocial variables for predicting levels of treatment expectancies in an IBS sample?
As only some of the psychosocial variables included in the current study had been
previously empirically linked with treatment expectancies, the hypotheses made
regarding this research question were limited. Based on the literature review, two
specific hypotheses were made: 1) Past satisfaction with a similar treatment was
hypothesized to be a strong predictor of current expectations of treatment, and 2) illness
attribution variables (now Perceived somatic/ psychological focus of treatment) were
hypothesized to be strong predictors of current expectations of treatment.
As described above, in testing the various hypotheses under Hypothesis 1, several
other variables were found to demonstrate linear relationships to treatment expectancies.
In order to answer research question 2, a hierarchical regression was conducted using the
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relevant variables identified from research question 1 as predictor variables and
Expectancies for preferred treatment (transformed) as the criterion variable. In the first
step of the regression, the following individual difference variables were entered: Selffocused attention and Optimism. In the second step of the regression, the following
health belief variables were entered: Control over health (transformed), Control over
symptoms (transformed), and tendency to Catastrophize over symptoms. In the final
step, the context-specific variables were entered: Perceived somatic focus of the
preferred treatment (transformed), Perceived psychological focus of the preferred
treatment (transformed) and Patient-provider relationship.
Unfortunately, the main treatment experience variable (Previous satisfaction with
treatment) contained data from only 93 participants. Thus, initial regression analyses
proceeded using the full sample (N = 289), without including a treatment experience
variable. Subsequent to the results from the analyses with the full sample, a supplemental
analyses section provides the results of conducting these analyses using a sample with
previous experience versus a sample without previous experience.
Table 8 displays the results of this hierarchical regression, including the
unstandardized regression coefficients and their standard errors (B and SE B), the
standardized regression coefficients (), the squared semipartial correlations (sr2), and R2
after each step. R was significantly different from zero at the end of each step. After step
3, with all IVs in the equation, R = .63, F (8, 280) = 22.88, p < .01, with R2 = .40
indicating that 40% of the variance (37.8% adjusted) in the criterion variable was
explained using these 8 independent variables.

115

After step 1, with Self-focused attention and Optimism in the equation, R = .24, F
(2, 286) = 8.73, p < .01. Beta weights for each predictor variable were examined to
assess their relative importance in the prediction of treatment expectancies. Both Selffocused attention ( = .17) and Optimism ( = .18) were significant predictors of
treatment expectancies (p’s < .01), together accounting for 6% of the variance in the
dependent variable.
When the health belief variables were entered in step 2, the proportion of
explained variance increased significantly, to 13% (∆R2 = .07; F (3, 283) = 7.64, p < .01).
Among the health belief variables, the two significant predictors were: Control over
symptoms (transformed) ( = .21, p < .05) and Catastrophizing ( = .17, p < .01); Control
over health was not a significant predictor ( = .04, p = .65). Both individual difference
variables remained significant during this second step, although their predictive power
decreased somewhat (Self-focused attention:  = .12, p < .05; Optimism:  = .14, p <
.05).
The addition of the context-specific variables in the third step contributed to
significant amounts of explained variance (∆R2 = .27; ∆F (3, 280) = 41.23, p < .01).
Patient-provider relationship was not a significant predictor of treatment expectancies,
both Perceived focus of treatment variables were. Perceived somatic focus of treatment
was a much stronger predictor than Perceived psychological focus of treatment ( = .55,
p < .01 and  = .27, p < .01, respectively).
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Table 8
Summary of Hierarchical Regression Analysis for Variables Predicting Treatment
Expectanciesa in Total Sample (N = 289)

Variable
Step 1
Self-focused attention
Optimism
Step 2
Self-focused attention
Optimism
Control over healtha
Control over symptomsa
Catastrophizing

B

SE
B

.02
.05

.00
.01

.01
.04
.02
.10
.01

.00
.02
.04
.04
.00



sr2

R2b
.06**

 R2

.13**

.07**

.17** .03
.18** .03
.12*
.14*
.04
.21*

.02
.02
.00
.02
.03

.15**
Step 3
.40** .27**
Self-focused attention
.00
.00
.07 .01
Optimism
.02
.01
.10* .01
a
Control over health
.01
.04
.03 .00
Control over symptomsa
.04
.03
.08 .00
Catastrophizing
.01
.00 .13** .03
Patient- provider relationship
.00
.00
.00 .00
Perceived somatic focus of txa
.42
.04 .55** .30
Perceived psychological focus of txa .18
.03 .27** .09
Note. tx = treatment
a
Transformed. bAdjusted R2 after step 1 = .05, after step 2 = .11, after step 3 = .38.
*p < .05. **p < .01.

In the full model, Optimism was the only remaining significant predictor among
the individual difference variables ( = .10, p < .05). Among the health belief variables,
Catastrophizing remained the only significant predictor ( = .13, p < .01).
Squared semi-partial correlations (sr2) were examined to ascertain the proportion
of variance each significant predictor contributed uniquely to treatment expectancies,
controlling for joint variance shared between variables. As hypothesized, the illness
attribution variables contributed the most unique variance to the model, with the somatic
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attribution variable contributing uniquely to 30% of the variance in treatment
expectancies and Perceived psychological focus of treatment contributing to 9%. The
tendency to catastrophize about symptoms independently accounted for 3% of the
variance in treatment expectancies, while Optimism uniquely contributed to 1% of the
variance. The total amount of unique variance contributed by these independent
variables was 43%.
C. Supplemental Quantitative Analyses: By Experience
Analyses presented above do not consider the important contribution of previous
treatment experiences in predicting levels of treatment expectancies. Thus, the analyses
were repeated using the sample of those who reported having previous experience with
their preferred treatment (n = 93; Experienced group) as well as with a sub-sample of
participants reporting no prior experience with either treatment (n = 134; Inexperienced
group).
Preliminary analyses.
Prior to repeating the analyses from Hypothesis 1 and 2 with these two samples,
preliminary analyses were conducted to assess whether the two samples differed on any
demographic variables, on the dependent variable or treatment preference or on any of
the main independent variables. These analyses were done using SPSS Univariate GLM
and independent sample t-tests for mean comparisons, as well as Crosstabs for frequency
comparisons. The groups were found to differ on three variables. First, the Experienced
group reported greater numbers of current treatments (M = 3.49, SD = 2.38) than the
Inexperienced group (M = 2.06, SD = 2.36), Kruskal-Wallis Chi-square (1) = 27.42, p <
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.01. Similarly, the Experienced group reported greater numbers of past treatments (M =
329, SD = 2.77) than the Inexperienced group (M = 1.79, SD = 1.34), Kruskal-Wallis
Chi-square (1) = 19.13, p < .01. Thus, it appears that the Experienced was not only more
experienced with respect to the preferred treatment, but was also more experienced with
treatment overall. Note that the groups did not differ in the number of years that they had
been experiencing IBS symptoms or the number of years since diagnosis. Thus, they
were not necessarily more experienced with IBS despite being more experienced with
IBS treatments. The only other significant difference identified was that those in the
Experienced group reported significantly higher levels of self-focused attention than
those in the Inexperienced group (t(225) = 2.79, p < .01). It is important to note that
these groups did not differ in their levels of expectations to benefit from their preferred
treatment.
Correlational analyses.
The correlational analyses of Hypothesis 1 were repeated with the two new subsamples. These results are presented in Table 9, along with the correlation results from
the full sample. In terms of the individual difference variables, analyses revealed that the
Inexperienced group had no significant relationships, compared to the Experienced group
that showed three significant relationships. Specifically, it was found that levels of
treatment expectancies were positively correlated with levels of self-focused attention (r
= .32, p < .01), Optimism (r = .27, p < .01), as well as levels of hope (r = .22, p < .05). It
is interesting to note that the size of the correlations found in this sub-sample (n = 93)
were noticeably larger than the size of the correlations found in the full sample, and in the
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case of Hope, a significant relationship emerged among the Experienced that wasn‟t
identified in the full sample.
Among the health belief variables, the significant relationships identified among
the Experienced group were more numerous then those in the Inexperienced group. In
the Experienced sample only, levels of treatment expectancies were negatively correlated
with Acute health problems (r = -.21, p < .05), and positively correlated and with Coping
self-efficacy (r = .42, p < .01). Significant relationships between treatment expectancies
and the control belief variables (transformed) were identified in both samples; the
magnitudes of these associations were larger in the Experienced group (Control over
health: r = .32, p < .01; Control over symptoms: r = .42, p < .01) than in the
Inexperienced group (Control over health: r = .23, p < .01; Control over symptoms: r =
.21, p < .01). In fact, the 21-point difference between the correlations with Control over
symptoms in the two groups reached statistical significance (z = 1.71, p < .05). The
difference in the correlations with Control over health did not (z = 0.71, p = .24).
Finally, when looking at the context-dependent psychosocial variables, both
groups showed significant positive relationships between treatment expectancies and
Perceived somatic focus of treatment (transformed). In the Experienced sample, Previous
satisfaction with preferred treatment displayed a robust positive correlation with levels of
positive treatment expectancies (r = .50, p < .01). None of the other treatment experience
variables were related to treatment expectancies in either of the sub-samples.
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Table 9
Zero-order Correlations between Treatment Expectanciesa and Independent Variables in
Three Samples.
Sample name (n)
Inexperienced
Experienced
(134)
(93)

Full
Variable
(289)
Individual difference variables
Self-focused attention
.16*
-.03
Trait Anxiety
Anxious apprehensiona
-.01
-.02
Trait worry
.03
-.01
Optimism
.17*
.11
Pessimism
-.10
-.08
Hope
.07
-.02
Health Belief Variables
Current Health
Perception of health
.10
.12
Acute health problems
-.05
.02
Control Beliefs
Healtha
.22**
.23**
Symptomsa
.27**
.21*
Health self-efficacy
.03
-.05
Coping self-efficacy
.11
.04
Vulnerability to illness
.03
.03
Catastrophizing
.12*
.06
Context-dependent variables
Treatment Experience
Previous satisfaction with tx
n/a
n/a
Number of current txa
-.02
-.11
Number of past txa
.00
-.06
Satisfaction with current txa
.13b
.16d
c
Satisfaction with past tx
.05
.13e
Perceived treatment focus
Somatica
.51**
.55**
Psychologicala
.16**
.16
Motivation
Desire for reliefa
-.01
.12
Symptom severity
-.03
-.15
IBS: Interference with daily activitiesa
-.04
.02
Socially desirable responding
-.04
.03
Patient-provider relationship
.12*
.11
Note. tx = treatment(s)
a
Transformed. bn = 254. cn= 230. dn = 111. en= 98. fn = 86. gn = 80.
*p < .05. **p < .01.
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.32**
-.06
-.00
.27**
-.14
.22*

.14
-.21*
.32**
.42**
.14
.42**
-.03
.19

.50**
-.08
-.06
.17f
.05g
.40**
.15
.10
.15
.18
-.12
.11

Regression analyses.
The regression analyses used in testing Hypothesis 2 with the full sample were
repeated for both the Experienced and Inexperienced sample. In order to compensate for
the relatively small sample sizes of both samples, the bootstrap method was used when
performing these regression analyses. The bootstrap method was described by Efron in
1979 and is defined as a general procedure that mimics the sampling distribution of a
statistic through successive resampling (Dalgleish & Chant, 1995). This procedure is a
means of estimating statistical accuracy from a single sample (Diaconis & Efron, 1983).
That is, bootstrapping mimics the process of selecting many samples when it actually
uses only one sample to find the probability that the values of a given test statistic fall
within a certain interval. Bootstrapping is a method that resamples with replacement,
meaning that each time an observation is taken to resample it, the procedure replaces it
before taking the next observation. Because each observation is replaced, it means that
the same observation can appear in the sample more than once. Thus, the empirical
distribution that consists of the bootstrapped samples can be treated as if it were a
distribution constructed from many samples (Dianconis & Efron). The bootstrap method
produces a 95% confidence interval for each statistic of interest (e.g., regression
coefficients and R2); if this interval contains „0,‟ the statistic cannot be considered
significantly different from zero.
For the Experienced sample, as there were significant correlations identified for
variables from each category, a three-step hierarchical regression was used, as with the
full sample, with treatment expectancies (transformed) as the criterion variable. The
results of the hierarchical regression are presented in Table 10. The amount of variance
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explained (R2) was significant after each step. After step 1, with the three individual
difference variables (Self-focused attention, Optimism and Hope) in the equation, an
average of 22% of the criteria was explained (mean R2 = .22, 95% CI = .09-.31). Only
Self-focused attention and Optimism had significant beta values (Self-focused attention:
mean  = .32, 95% CI = .11-.45; Optimism:  = .31, 95% CI = .10-.45). When the health
belief variables (Control over health, Control over symptoms, Catastrophizing and
Coping self-efficacy) were entered in step 2, the proportion of explained variance
increased to 43% (38% adjusted). Among the health belief variables, Control over
symptoms and Acute health problems had significant beta values. In the full model
(including Previous satisfaction with treatment and Perceived somatic focus of treatment)
the average R2 = .62 (SD = .04; 95% CI = .52 -.68), indicating that 62% (57% adjusted)
of the variance in treatment expectancies was explained by these 10 variables.
Beta weights for each predictor variable were again examined to assess their
relative importance in the prediction of treatment expectancies. In the full model, there
were five variables that were significant predictors of treatment expectancies, including
(in descending order) Previous satisfaction with treatment ( = .36, 95% CI = .20-.50),
Perceived somatic focus of treatment ( = .27, 95% CI = .12-.38), Self-focused attention
( = .26, 95% CI = .13- .33), Optimism ( = .21, 95% CI = .04-.46) and Acute health
problems ( = -.12, 95% CI = -.28 - -.01). Control over symptoms was not a significant
predictor of variance in this full model.
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Table 10
Summary of Hierarchical Regression Analysis for Variables Predicting Treatment
Expectanciesa in Sample with Previous Experience with Preferred Treatment (N = 93)

Variable

B

SE B



sr2

R2b
.22*

Step 1
Self-focused attention
.04
.01
.32* .11
Optimism
.09 .03
.31* .08
Hope
.00
.00
.00
.00
Step 2
.43*
Self-focused attention
.03
.01
.27* .11
Optimism
.05
.03
.18
.03
Hope
-.01
.01
-.14
.02
Control over healtha
-.05
.08
-.08
.00
a
Control over symptoms
.19
.08
.36* .07
Coping self-efficacy
.04
.02
.22
.05
Acute health problems
-.02
.01
-.11* .02
Step 3
.62*
Self-focused attention
.03
.01
.26* .12
Optimism
.06
.02
.21* .05
Hope
.00
.00
-.08
.01
Control over healtha
.00
.07
.02
.00
Control over symptomsa
.14
.06
.14
.05
Coping self-efficacy
.00
.02
.05
.00
Acute health problems
-.02
.02
-.12* .02
Previous satisfaction with preferred tx
.07
.02
.36* .18
Perceived somatic focus of treatmenta
.22
.06
.27* .13
Note. tx = treatment.
a
Transformed. bAdjusted R2 after step 1 = .19, after step 2 = .38, after step 3 = .57.
*95% confidence interval does not include zero.

Examining squared semi-partial correlations identified Previous satisfaction with
treatment as predicting the most amount of unique variance in current treatment
expectancies (18%), as predicted in the original hypotheses. Perceived somatic focus of
treatment was the second most important unique predictor (sr2 = 13). Self-focused
attention uniquely accounted for 12% of variance in levels of treatment expectancies.
Although Optimism and Control over symptoms both uniquely accounted for 5% of
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variance in the criterion variable, only Optimism was a significant predictor in the full
model. Acute health problems uniquely contributed to 2.0% of variance. The total
unique variance contributed by these independent variables was 50%.
Table 11
Summary of Hierarchical Regression Analysis for Variables Predicting Treatment
Expectanciesa in Sample without Previous Experience with Preferred Treatment (N =
134)
Variable

B

SE B



sr2

Step 1

.09*

Control over healtha

.08

.05

.17

.02

Control over symptomsa

.06

.05

.13

.01

Step 2

a

R2

.32*

Control over healtha

.05

.05

.10

.01

Control over symptomsa

.01

.06

.02

.00

Perceived somatic focus of treatmenta

.38

.05

.52**

.27

Transformed. Adjusted R2 after step 1 = .08, after step 2 = .31.

*95% confidence interval does not include zero.
The results for the Inexperienced group were quite different, and are presented in
Table 11. A two-step hierarchical regression was used for this analysis, as there was no
individual difference variables identified as significant correlates of treatment
expectancies in this sample. Although the two control belief variables predicted a
significant amount of variance when entered alone in step 1 (R2 = .09, 95% CI = .03-.16),
neither had significant beta weights. This suggests that individually, neither contributes
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enough unique variance in the criterion variable. In step two, the somatic illness
attribution variable uniquely contributed to 27% of the variance in treatment expectancies
(R2 = .32, 95% CI = .20-.44; Adjusted R2 = .31).
Comparing regression results between the three samples.
The purpose of these analyses was to use a hierarchical regression to identify the
best predictors of treatment expectancies (TE) from among those variables identified as
having significant zero-order correlations with this criterion variable. However,
comparing the results of the full sample with the results from the two sub-samples has
revealed differential findings regarding which variables are the best predictors, based on
which sample is examined. Although some variables were identified as significant
correlates and/or predictors of treatment expectancies in all three samples (e.g., Perceived
somatic focus of treatment and the two control belief variables), the relevance of several
variables (the size of their correlation with TE or their significance in a regression model
predicting TE) was found to vary based on which sample was used in the analysis. For
instance, three variables that were not significant correlates in the full sample emerged as
such when considering only those participants with previous experience with their
preferred treatment (i.e., Hope, Acute health, and Coping self-efficacy). In addition, two
of the individual difference variables that were identified as having a significant but weak
relationship with TE in the full sample (Self-focused attention and Optimism) displayed
more robust relationships in the Experienced group. As none of the variables were
significant correlates among those in the Inexperienced group, these results suggest that
the inclusion in the full sample of participants without previous treatment experience has,
for lack of a better term, diluted the relationships that are relevant among the
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Experienced. In contrast, three variables were identified as significant correlates of
treatment expectancies in the full sample, but were not significant correlates in either of
the two sub-samples (i.e., Catastrophizing, Perceived psychological focus of treatment
and Patient-provider relationship). This suggests a sort of additive effect, where trends
towards significance in either one or both sub-samples are combined in the full sample to
reach a level of statistical significance. Alternatively, this finding could be a function of
increased power to detect a significant effect provided by the larger sample size of the
full sample. Overall, these differential results suggest that previous experience with
treatment had some influence on the number of psychosocial variables that were found to
show a significant relationship to the dependent variable.
Testing for Moderation.
A series of hierarchical regressions were conducted to assess whether Previous
experience with preferred treatment truly moderated some of the relationships between
the DV and the IVs, as suggested by the results presented above. To test for moderation,
first Previous experience with preferred treatment was coded as a dichotomous variable
(0= Inexperienced; 1 = Experienced), and interaction terms were created to represent the
interaction between Previous experience and the IV of interest (e.g., Experience*SFA).
The IVs of interest included those variables that displayed significant relationships with
the DV in the Experienced group but not the Inexperienced group (i.e., SFA, Optimism,
Hope, Acute health problems and Coping self-efficacy). Other variables of interest were
those where the size of the correlations with the DV were notably larger or smaller in one
group or the other (Control over symptoms, Perceived somatic focus of treatment). In
each hierarchical regression, the IV of interest and the dichotomous Experience variable
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were entered into the model predicting treatment expectancies in the first step, and then
their interaction term was entered into the second step. Moderation is confirmed if the
interaction term is significant.
The full results of these analyses can be found in Appendix AC. In brief,
Previous experience with preferred treatment was confirmed as moderating the
relationship between Treatment expectancies and i) SFA, ii) Coping self-efficacy
(interaction terms significant at .05 level). The interaction between Experience and
Control over symptoms was almost significant (p = .06), whereas Treatment experience
was not found to moderate the relationships between TE and Optimism, Hope, Acute
health problems, or Perceived somatic focus of treatment.
V.

Examining the Qualitative Data

Qualitative analysis was conducted using responses from 100 participants chosen
randomly from the total sample. The examination of the qualitative data was guided by
the question of whether there were additional psychosocial variables, beyond those
independent variables identified in the literature review, which were commonly cited as
contributing to one‟s expectations of treatment benefit. Among the 100 participants, 98
participants offered at least one factor contributing to their expectations that could be
coded. The average number of factors generated was 1.96 (S.D. = .90), and the
maximum number of factors mentioned was four. The specific factors, both pre-set and
emergent, are presented in Table 12.
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A. Emergent Categories
After coding the qualitative responses using the pre-set categories established in
the introduction as potentially relevant psychosocial variables, the narrative responses
were reviewed to identify additional psychosocial variables that may be mentioned as
contributing to participants‟ expectations of benefiting from treatment. These emergent
categories captured statements provided by participants that were not appropriate for any
of the pre-set categories. Seven of such emergent categories were identified, falling
under five general categories. Although „treatment experiences‟ was a pre-set umbrella
category, two new sub-categories Treatment experience: Vicarious and Treatment
experience: Inexperience emerged from the qualitative data. Similarly, two new subcategories, Attribution: Holistic and Attribution: Situational emerged to join the other two
pre-set Illness Attribution categories. Three emergent categories were original, not
having been measured in the quantitative analysis. These three categories were
Convenience, Aversion and Side effects.
Treatment Experience.
Several participants made statements that can be considered to fall under the
broader category of past treatment experiences, but were not appropriate for the pre-set
categories of Past experience with similar treatment or Number of treatments previously
attempted. In particular, three participants cited vicarious experience with certain
treatments as factors influencing their treatment expectancies. The Treatment
experience: Vicarious emergent category included statements such as „I have seen a lot of
drug treatment in my family and friends be unsuccessful…‟ and „I have worked in the
medical field in the past, and basically lost most confidence in medications.‟ Another
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five participants made reference to previous inexperience with a treatment when asked to
comment on why they thought a treatment may work for them. Statements such as „It is
one that I have not tried…‟ and „I have never tried cognitive/relaxation therapy and feel
that this might help me‟ were coded on the emergent Treatment experience: Inexperience
category.
Attribution.
The second most commonly cited emergent factor encompassed statements
considered to refer to participants‟ attributions regarding the cause of their IBS
symptoms. It was found that some participants made attributional statements that did not
fit into the pre-set categories of Attribution: Somatic and Attribution: Psychological, but
instead made reference to either the holistic/ mind-body aspects (Attribution: Holistic) or
the situational aspects (Attribution: Situational) of the treatments and/or their IBS
symptoms. Fourteen participant statements (14%) were coded as belonging to one of the
two new attribution categories, with 11 (78%) coded as Attribution: Holistic statements
and 3 (22%) coded as Attribution: Situational statements. Examples of Attribution:
Holistic statements include: „I believe all treatments should deal with the mind and
body,‟ or „I feel that my IBS is not only a symptom of my intestines but rather a symptom
of my body as a whole,‟ or „I do not believe this can be cured by counseling or thoughts
alone, I think that you need to combine both treatments together to get the best results.‟
The statements coded as Attribution: Situational include: „I believe firmly that the
symptoms of IBS can be best treated through diet and lifestyle…‟ and „…it is mostly the
behaviours that make IBS “attacks” somewhat more frequent,‟ and „When a lot is going
on in my life, I do have more stomach pain…‟
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Table 12
Number of Qualitative Statements in Each of the Pre-set and Emergent Categories
Category
Pre-set Categories
Self-focused attention
Trait Anxiety
Optimism/ Pessimism
Hope
Current health
Perception of self as „healthy‟ or „sick‟
Other acute health problems
Control beliefs
General health
Symptoms
Health self-efficacy
Perceived vulnerability to illness
Catastrophizing
Treatment Experience
Previous experience with similar treatments
Number of treatments attempted
Illness Attributions
Somatic
Psychological
Motivation
Desire to see relief/ Symptom Severity
Socially desirable responding
Perceptions of the treatment provider
Emergent Categories
Aversion
Side effects
Illness Attributions
Holistic
Situational
Convenience
Treatment Experience
Vicarious
Inexperience

n
0
11
6
4
10
4
6
6
1
5
6
0
2
42
34
8
29
10
19
12
11
1
11
17
5
14
11
3
11
8
3
5

Convenience.
Another category to emerge captured statements referring to the convenience or
inconvenience associated with a certain treatment regimen. Examples of these statements
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include: „Seems user friendly,‟ Fits into my lifestyle better,‟ „It may be too difficult to
maintain if it involves strict dietary restrictions,‟ and „I sometimes do not have the time or
finances to go through relaxation therapy.‟ A total of 11 participants made statements
that were coded in this category.
Aversion.
The emergent variable most commonly cited by participants was labeled
Aversion, which was endorsed by 17 (17%) participants. This category encompasses
statements regarding a participant‟s aversion to or bias against certain treatments, either
drug treatments or psychological treatments. Examples of statements coded as Aversion
include: “I prefer treatments without the use of drugs,‟ or „I am sometimes resistant to
therapy,‟ or „If I could solve the problem with drugs I would,‟ or „I feel medications only
mask the symptoms and don‟t provide a cure.‟ Of the 17 statements coded as Aversion,
11 of those (65%) were coded as aversion to drug treatment while 6 (35%) were coded as
aversion to psychological treatment.
Side effects.
Another five percent of participants mentioned side effects in their narrative
statements. Examples include: „I have had negative side effects from conventional
medications thus far...‟ and „My experience with drugs is … they can have side effects or
be unpleasant or intrusive.‟ Statements in this category are somewhat similar to ones in
the Aversion category. However, these statements contained explicit mention of „side
effects‟ and were noted not to occur exclusively in the context of an Aversion statement.
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For example, „I think medication would probably be the route to go as long as side effects
did not interfere more with my life…‟
B. Exploring Illness Attributions
The second specific aim of including a qualitative component in the current
research was to use participants‟ narrative responses to shed light on null or unexpected
quantitative findings. The following is a brief exploration of one instance where the
qualitative data was useful in clarifying the nature of the relationships between the preidentified psychosocial variables and expectations to benefit from treatment.
In the narrative data, illness attributions in general were mentioned by 29% of
respondents (n = 29), making this general category the second most frequently
referenced. Including the statements coded into the emergent Illness Attribution
categories (Holistic and Situational) raises the count to 43 statements that made reference
to illness attributions. In the quantitative analyses reported above, it was found that
Perceived somatic focus of treatment was moderately related to treatment expectancies,
whereas Perceived psychological focus of treatment was only weakly related. In contrast,
narrative statements regarding psychological illness attributions were somewhat more
common than statements regarding the somatic aspects of symptoms/ treatments (19 and
10 statements, respectively).
Examination of the statements themselves speculatively sheds some light on this
apparent discrepancy between the relevance of the perceived somatic vs. psychological
focus of treatment. For one, all of the Attribution: Somatic statements seemed to make
reference to how the perceived somatic aspects of treatment or symptoms positively
influence expectations of benefit (e.g., “Medications are geared specifically towards the
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illness, therefore should work better than anything else” and “To me, physical symptoms
are to be treated with physical remedies”). In contrast, while some statements coded as
Attribution: Psychological seemed to reference psychological aspects of treatment/
symptoms as positive influences on treatment expectancies (e.g., “I think the treatment
may work because my IBS symptoms are mostly triggered by stress…), other statements
in this category seemed to refer to factors that diminished one‟s expectation of benefiting
from treatment (e.g., “I think I already have enough basic grasp of stress management
and hearing a re-hash of it won‟t improve my ability to chill out… I believe there is a
psychological aspect, but…”). Still other statements in this category suggest some
participants feel that the psychological contributors to their symptoms actually would
impinge on their ability to benefit from a psychological treatment (e.g., “Sometimes my
nerves and my poor ability to reason with stress affect me harshly. It is easier on me to
take medication to get through my issue”). This variety in statements regarding the
psychological aspects of attributions / treatments seem to suggest that for some, the
psychological foci of a treatment may contribute to greater expectations to benefit from a
psychologically-based treatment, whereas for others, this perception may contribute to
lower expectations from such a treatment.
Chapter 4
DISCUSSION
I.

Overview

In the last fifty years, our conceptualization and understanding of the placebo
effect has come a long way. We have gone from considering a placebo as a „sham‟ or
„inert‟ treatment that must be „controlled for‟ in clinical trials, to discovering that a
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placebo response is largely mediated by expectations and viewing the placebo (or
expectation) effect as playing an active role in any treatment context (Papakostas &
Daras, 2001). The goal of much placebo research is not to ultimately justify the ethical
use of placebos in medicine, but to understand the neurological, contextual and
psychosocial correlates of placebo responding so that these factors can be targeted and
enhanced to promote greater responsiveness to any therapeutic intervention (Price,
Finniss & Benedetti, 2008). Historically, much of this research has focused on
identifying the contextual or „placebo-salient‟ factors that contribute to a greater placebo
response. In the last several years, there has also been increasingly more research
focused on the neurophysiological processes that mediate placebo/ expectation effects.
Although recent reviews now emphasize that the study of placebo responding and
expectations effects should be focused on understanding the role of the individual in the
context (Miller & Kaptchuk, 2008), there has been relatively little empirical research
dedicated to this end. The current research has been successful in contributing to our
understanding of these processes by identifying a set of personal psychosocial factors that
are associated with expectations for treatment benefit in an IBS sample.
To accomplish this, two models of placebo responding (Kirsch, 1985; Sirois,
2001, 2009) and one model of expectancy formation (Olson et al., 1996) were combined
into a broad model that encompasses the contextual and psychosocial factors thought to
contribute to expectation formation in the context of therapeutic interventions. The
psychosocial variables suggested by these combined models included the broad category
of health beliefs, some specific individual difference factors (individual differences and
anxiety) as well as certain context-dependent variables (such as previous learning and
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attributions). This combined model was used to guide a thorough literature review
designed to identify the range of individual difference factors, the types of health beliefs,
and the important context-dependent variables that, through their association with either
placebo responding, health outcomes or expectations of treatment, could be considered as
potentially relevant correlates of treatment expectancies (see figure 1). The current
research was then focused on empirically testing which of these psychosocial factors
contribute to expectations regarding a hypothetical treatment in a sample of individuals
with irritable bowel syndrome.
The first research question asked which of the psychosocial factors, identified as
relevant from the literature review, would be correlated with treatment expectancies (TE)
in this sample. The second research question asked which of these correlated variables
would be the best predictors of treatment expectancies in a regression model. The
qualitative research question asked whether there were additional factors that participants
reported as relevant. Together these research questions were focused on identifying a
parsimonious set of relevant psychosocial variables that had the strongest relationships to
treatment expectancies in this sample. Interestingly, the analyses associated with the first
two research questions resulted in somewhat disparate findings when repeated in two
sub-samples of the main sample, namely those with experience with their preferred
treatment and those without experience with the hypothetical treatments.
Figure 3 provides a visual summary of the main findings of the current research.
In terms of psychosocial variables, this research has been successful in identifying a
range of individual difference variables, the types of health belief variables as well as the
important context-dependent variables that are associated with one‟s expectations to
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benefit from treatment (research question 1), as well as their relative ability to predict
variance in treatment expectancies (research question 2).

Figure 3. Summary of results. Variables that were identified as having a relatively greater
contribution to the magnitude of one‟s treatment expectancies are displayed higher in the
figure, and in text boxes of increased shading. Directional arrows specify proposed
interactions that will be discussed herein. Briefly, treatment-specific cues are proposed to
activate specific health beliefs, and when one has previous experience with a similar
treatment, specific related health beliefs are proposed to be activated more strongly.
Increased self-focused attention is also proposed to enhance the association of specific
health beliefs to treatment expectancies. Any influence of motivation and anxiety on
placebo responding is proposed to occur unmediated by expectancies.

In keeping with the study goal of identifying the psychosocial variables that are
the best predictors of treatment expectancies, the discussion will first focus on those
variables that were relevant across each of the samples (full sample, Experienced sample
and Inexperienced sample), and next turn to examine those variables found to be relevant
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correlates and/or predictors of TE in at least two samples, as so on. Possible explanations
for the disparate findings across samples will also be explored.
II.

Discussion of Main Findings

A. Attributions for Symptom Improvement.
One variable that stood out as an important correlate and predictor of treatment
expectancies in all three samples was Perceived somatic focus of treatment. In addition,
both in the full sample and the Inexperienced sample, this variable explained the largest
amount of unique variance in levels of treatment expectancies. These results suggest that
in this IBS sample, there was a strong relationship between how much one perceived
their preferred treatment as focusing on the somatic roots of their IBS symptoms and how
much one expected that treatment to work, with a greater somatic focus being associated
with a greater expectation to benefit. In comparison, Perceived psychological focus of
treatment was a significant but weaker correlate and predictor of treatment expectancies
in the full sample, but not in the other samples. These variables cannot be considered
direct measures of how much one attributes their IBS symptoms to somatic or
psychological causes; instead they may capture participants‟ recovery attributions, or
perhaps more aptly, their attributions for symptom improvement. The specific question
used to measure Perceived somatic/psychological focus of treatment asked participants to
rate to what extent they agreed that their preferred treatment „targeted the physical/
psychological causes of IBS.‟ As the questions referred specifically to one‟s preferred
treatment, it may be that participants‟ responses to these items were indeed inspired by
their causal attributions for their symptoms of IBS. On the other hand, it may be that
participants‟ responses were inspired more by their preference for a treatment that
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targeted somatic vs. psychological contributors to IBS, regardless of what causal
attributions they use to understand their own symptoms. It should also be noted that it is
impossible to determine, using the current data, how much a person considered the
dietary recommendations (offered in both treatment scenarios) as targeting the „somatic
causes of IBS.‟ As diet changes are commonly accepted to be the first and most effective
approach to managing IBS symptoms, it makes sense that greater level of perceived focus
on these aspects of symptom management would be associated with greater expectations
to benefit from these treatments. Given the sizable amount of variance in treatment
expectancies that was predicted by Perceived somatic focus of treatment (up to 27%), it
seems that these relationships should be considered more closely.
If we consider these findings as representing, at least to a certain extent, a link
between illness attributions and treatment expectancies, they would be consistent with a
large study of mixed illness groups wherein expectations regarding treatments in general
were correlated with both organic and psychological illness attributions, although less so
with the latter (Moss-Morris et al., 2002). Without the need to make such a conceptual
leap, these results echo the findings of a meta-analysis of placebo-controlled treatment
studies for chronic fatigue syndrome (Cho et al., 2005), where it was found that on
average, psychological interventions elicited lower placebo responses than somaticallyfocused interventions. The authors speculated that participant illness attributions
influenced their expectations to benefit from the different types of treatment and thus
their therapeutic response to placebo interventions. Here also, it cannot be determined
whether patients expectations to benefit were influenced more so by personal symptom
attributions, attributions for improvement, or even preferences for certain types of
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treatment perhaps based on factors such as aversion or convenience (as suggested by the
qualitative data analysis).
Nevertheless, the current results are unique as they represent the first empirical
findings linking treatment expectations with perceived somatic/ psychological focus of
treatment in an IBS sample. They are important results as they clearly suggest that for
individuals with IBS, one‟s positive expectations to benefit from treatment (and thus
one‟s ability to benefit from the expectation effect) are related to the perceived somatic,
and to a lesser extent psychological, focus of the proposed treatment. The implications
for the treatment of IBS that seem to follow from these findings are that in order to
maximize positive expectations of treatment, practitioners should consider the patients‟
perspectives on what type of intervention and/ or what type of causal factor (somatic or
psychological) is worth targeting, and in what degree.
An interesting result of this study was the discrepancy between the influences of
somatic attributions versus psychological attributions (be them attributions for the cause
of symptoms or the improvement of symptoms). This discrepancy is not unique to an
IBS sample, as it has also been found in other research, such as the stronger associations
between somatic attributions and treatment expectations in a mixed illness group (MossMorris et al., 2002), as well as the stronger influence of somatic attributions to treatment
success in a chronic fatigue sample (Chadler et al., 2003). Results from a recent study of
health attributions among laypersons suggest that this discrepancy is not necessarily
unique to certain illness populations (Shiloh, Peretz, Iss & Kiedan, 2007). In the Shiloh
et al. study, four groups of healthy students were asked to estimate the chances of
recovery of a hypothetical person with an unnamed severe disease on a scale from 0 to
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100. Groups were presented with different vignettes that varied by the quality of medical
care (high/low) or the quality of the person‟s psychosocial resources (both personal and
social; high/low). Their ratings of „chance for recovery‟ were considered an indirect
assessment of recovery attributions. The same participants were then asked to rate (from
0 to 100) the relative importance of a) biomedical factors, and b) psychosocial resources
in effecting the recovery of a different hypothetical person with the same illness. This
was considered an explicit measure of participants‟ recovery attributions. Comparing
ratings derived from the indirect assessment of recovery attributions across groups, there
was only a main effect of psychosocial resources, with higher psychosocial resources
being related to higher ratings of chance for recovery. In fact, the effect size for the
influence of psychosocial factors on recovery was 60 times stronger than the effect size
for biomedical factors. On the explicit measure of recovery attributions, the importance
of quality biomedical care was rated as twice as important as the quality of psychosocial
resources. This interesting study highlights, among other things, the tendency of people
to overestimate the influence of medical/organic factors, and underestimate the
importance of psychosocial factors, when asked explicitly to communicate their
attributions for improvement. This tendency may have been at play in the current
research, as individuals were explicitly asked to rate the perceived somatic/psychological
foci of their preferred treatment. Interestingly, when asked to comment freely about
factors they perceived as contributing to their expectations of benefit, there were a greater
number of references made to psychological attributions or holistic attributions than to
medical/organic attributions of illness/ recovery.
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B. Control Beliefs
The control belief variables were also correlated with expectations to benefit from
treatment across all three samples. Furthermore, in both the full sample and the
Experienced sample, Control over symptoms was a significant predictor of treatment
expectancies when entered with other health belief variables in the second step of the
regression. Thus, in this IBS sample, the greater one‟s beliefs about having control over
one‟s symptoms, and to a lesser extent, control over one‟s health, the higher one‟s
expectations to benefit from the treatment. The general link between control beliefs and
expectations of treatment has previously been demonstrated in a large sample of mixed
illness groups (Moss-Morris et al., 2002), but this is the first empirical evidence to
support a link between treatment expectancies and control beliefs in an IBS sample.
These results regarding the general influence of control beliefs on expectations of
treatment fit nicely with theories of expectancy formation (e.g., Olson et al, 1996) if we
consider variations in control beliefs as constituting a form of change attribution, from
more internal (I am in control of my symptoms) to less internal (low scores on control
belief measures). Olson and colleagues propose that if changes are attributed to internal,
stable causes, then future positive changes will be expected. With less personal and
internal change attributions, expectations of benefit are less certain. Health psychology
research has emphasized that better adjustment to chronic illness is related not only to
possessing more internal causal attributions, but also to having stronger attributions
regarding the controllability of symptoms (Roesch & Weiner, 2001). In other words,
better adjustment has been noted among those who attribute to themselves a greater
amount of control over their illness. These results are also in line with findings that
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greater control beliefs are inversely related to symptom severity in certain chronic
illnesses (e.g., tinnitus; Sirois, Davis & Morgan, 2006), and that weaker personal control
over symptoms are associated with less favourable outcomes in IBS samples (Rutter &
Rutter, 2002).
The finding that beliefs of control over symptoms are more strongly related to
outcome (here expectations of outcome) than are beliefs of control over health in general
is consistent with both theory and research (Sirois et al., 2006). Folkman (1984) suggests
that different types of control beliefs influence cognitive appraisals in different ways.
General control beliefs may lead someone to consistently perceive ambiguous situations
as more manageable, but situation-specific control beliefs can be considered as coping
resources to be drawn on only under certain conditions. It follows that control over IBS
symptoms would be more relevant when considering expectations regarding a treatment
designed to improve IBS symptoms; in this case control over health in general is
obviously not as specific and not as relevant.
It is possible that these findings may not generalize to other illness populations, or
that the magnitude of the relationships would vary across samples or treatment contexts.
Moss-Morris and colleagues (2002) suggest that beliefs about personal control may be
more relevant in situations where treatment choices themselves can be seen as a personal
decision of how best to manage or control symptoms. For example, in situations where
there is no one proscribed treatment (e.g., in IBS), treatment choices themselves can be
seen as a personal decision of how best to manage or control symptoms. In contrast, in
chronic illnesses like HIV or diabetes where treatment is very prescriptive, beliefs about
treatment effectiveness may be conceptually distinct from beliefs about personal ways of
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controlling or managing symptoms. One can also consider how symptom-specific
control beliefs could overlap or combine with beliefs about self-efficacy to carry out or
adhere to treatment recommendations (French & Weinman, 2008). For example, if
following diet recommendations is an important part of a treatment plan for IBS, then
one‟s expectations to benefit from the treatment should vary with one‟s sense of their
ability to manage their symptoms by following the diet recommendations. References to
these types of self-efficacy concerns did surface in the qualitative data as statements in
the emergent category labeled Convenience. Examples include „Fits better into my
lifestyle‟ and „I sometimes do not have the time or finances to go through relaxation
therapy‟ or „It may be too difficult to maintain if it involves strict dietary restrictions.‟
Following from these findings, it may be desirable in future research to more explicitly
examine the relationship between treatment expectancies and one‟s level of self-efficacy
to adhere to specific aspects of the proposed treatment.
Although these results may not be as robust in another illness group, this study
has clearly shown that in this sample of individuals with IBS, control beliefs, particularly
beliefs of control over symptoms, are important psychosocial variables to consider when
aiming to strengthen expectations of treatment benefit.
C. Optimism
Optimism is one of two individual difference variables that were identified as
relevant in both the full sample and the sub-sample of participants who had more
experience with treatment. In particular, in the Experienced sample, optimism was found
to be a moderate predictor of variance in treatment expectancies and to retain its
significance in the full regression model. The results were the same, although less robust,
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in the full sample. It was found that greater levels of reported optimism were associated
with greater expectations about benefiting from the proposed treatment.
This is the first time that optimism has been linked with treatment expectancies in
an IBS sample. This result is consistent with research where treatment expectancies have
been correlated with optimism in cancer patients (Weinfurt et al., 2003) as well as in nonclinical populations (Hyland, Whalley & Geraghty, 2007). Furthermore, it corresponds
with the results from a recent study where levels of optimism were correlated with levels
of positive placebo responding (Geers et al., 2007). Thus this finding is an important
contribution to a growing literature regarding the importance of dispositional optimism
and its relationship to expectations of treatment.
The fact that optimism was linked with treatment expectancies while pessimism
was not is also consistent with empirical research wherein pessimism is only linked to
negative outcome expectancies (Montgomery et al., 2003) and related to negative placebo
suggestions (Geers, Helfer, et al., 2005). Overall, it seems that dispositional optimism is
relevant in the context of a suggestion for positive outcomes. It has been suggested that
optimists are more likely to be persuaded by positively framed suggestions (Geers,
Helfer, et al., 2005), for example information regarding treatment benefits, as optimism
itself pertains to relatively stable expectations that good things will happen. Perhaps
dispositional optimism can be considered as an information processing bias towards
information that confirms and strengthens initial positive expectations. This theory of
how optimism may affect the magnitude of expectancies is similar to cognitiveattentional bias theories of how expectations may lead to placebo responses (Sirois, 2001,
2009; Stewart-Williams, 2004).
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D. Self-Focused Attention
Self-focused attention (SFA) is another individual difference variable
hypothesized to influence levels of expectation of benefit through its effect on cognitiveattentional processing. In the present study, this variable was found to be just as relevant
as optimism in its association to expectations to benefit from treatment, if not more so. In
particular, in addition to displaying a modest correlation and regression coefficient in
relation to treatment expectancies in the full sample, one‟s level of self-focused attention
was found to be a fairly robust positive correlate in the Experienced sample, and to
remain a significant predictor in the full regression model, uniquely accounting for 12%
of the variance in the criterion. These findings indicate that those who reported being
more internally focused also reported greater expectations to benefit from treatment.
This strong finding needs to be replicated in another IBS sample and in other illness
groups, as it seems that this is the first finding of a positive correlation between levels of
self-focused attention and levels of expectations of treatment benefit.
Despite its novelty, this finding is consistent with both placebo research and
theory. In particular, the Belief-Activation Model of placebo responding posits that
levels of self-focused attention influence placebo responding as those with higher levels
of SFA may direct attention away from external information (i.e., placebo suggestions)
towards more internal sensations and cues, which may contradict externally introduced
expectations, thus moderating the degree or direction of one‟s expectations regarding the
intervention (Sirois, 2001, 2009). In one study of placebo responding (Geers at al.,
2006), it has been demonstrated that greater levels of induced self-focused attention are
associated with increased placebo responding. However, this relationship was found only
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among those in the deceptive placebo group (versus the conditional placebo group). To
explain this latter finding, Geers and his colleagues speculated that among those with
stronger (or more certain) initial placebo expectations (the deceptive placebo group),
greater SFA guided information processing towards internal stimuli that confirmed these
initial expectations.
It is possible that this explanation regarding the results of the „certainty‟
manipulation could be used to explain the current differential results regarding selffocused attention found across groups, in particular that self-focused attention (among
other variables) displayed a stronger relationship to treatment expectancies in the
Experienced group than in the full sample or the Inexperienced sub-sample. In particular,
it could be that those with previous treatment experience also had „stronger‟ or „more
certain‟ initial expectations. If this was the case, then the results of this study mirror
those from the Geers study; specifically, level of self-focused attention displayed a
relationship with treatment expectancies, but only among those with more
certain/stronger initial expectations.
According to expectancy theory, previous experience is considered to be the most
effective factor in shaping expectancies, much more effective than other informative
factors, such as third-party communication (Olson et al., 1996). One can imagine that
qualitatively, the „strength‟ or „level of certainty‟ of a specific expectation can vary from
little more than a guess or hunch (no prior experience), to a moderate level of certainty
(some prior experience) to the point where an expectation is subjectively equivalent to
knowledge (extensive prior experience). With this in mind, we would predict that those
with previous experience with a similar treatment would likely have developed the most
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„certain‟ or strongest expectations regarding the benefits of that specific treatment,
regardless of the „level of benefit‟ that is expected. Note that the „strength‟ of
participants‟ treatment expectancies was not measured, but only the level of the expected
benefit (from no expected benefit to excellent expected benefit). It may have been useful
to also have asked participants to rate how certain they felt about achieving that level of
benefit or „how strong is your expectation to benefit at this level?‟
Why would the strength of one‟s initial expectations influence whether selffocused attention has an impact on placebo responding or level of treatment expectation?
As described above, it has been suggested that stronger initial expectations guide
information processing to confirm themselves; this, along with greater SFA (induced or
trait) may lead to even stronger internally-directed expectation-confirmation biases.
Before exploring this possibility further, it seems timely to discuss the relevance of
previous treatment experience to current treatment expectancies in this sample.
E. Previous Experience with Treatment
In terms of the relevance of psychosocial variables in the prediction of treatment
expectancies, it seems that „previous experience with treatment‟ has been found herein to
be relevant in more than one way. First is the strong positive correlation between
Previous satisfaction with preferred treatment and current expectations of treatment,
along with the fact that this variable uniquely contributed to almost 20% of variance in
treatment expectancies in the full regression model, among those who reported having
had previous experience with their preferred treatment. The second way that previous
experience stands out as potentially quite relevant is that it was found to moderate the
relationships of TE to two of the psychosocial variables, and by way of the observation
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that several other relationships that this study has attempted to quantify seem to vary
based on whether the sample has had more or less previous experience with treatment.
These findings will be addressed in turn.
The strong relationship identified between previous satisfaction and current
expectations is fully consistent with both theory and empirical literature. Both
expectancy and placebo theorists posit that previous personal experience has the strongest
influence on a person‟s beliefs and thus on their expectations about the outcomes of
similar experiences (Olson et al., 1996; Price et al., 2008; Stewart-Williams, 2004).
Quantitative research has confirmed that previous experience is an important correlate of
outcome expectancies (Montgomery et al., 2003; Montgomery & Bovbjerg, 2003;
Whalley, Hyland & Kirsch, 2008) and can have a strong and sustained influence on
placebo responding (Colloca & Benedetti, 2006). The qualitative findings are similar to
those found in other studies, wherein past experience is mentioned in a narrative by most
participants who are asked about expectations to benefit from treatment (Liddle et al.,
2007; Stone et al., 2005). Together these results suggest that previous experience is an
important factor to consider if one is interested in maximizing treatment expectancies in a
therapeutic context.
Other than this direct relationship between previous treatment satisfaction and
current treatment expectations, also of interest and potential relevance is how the
significance of many relationships in the full sample fall out (are teased apart) when the
full sample was examined as those with treatment experience versus those without. Note
that the experience level of the two groups differed in several ways. For one, the
Experienced sample had previous experience with the preferred treatment, while the
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Inexperienced sample did not have previous experience with either treatment. Also, the
Experienced sample reported higher average numbers of current treatments and higher
average numbers of past treatments. With respect to the differential results, recall that
previous treatment experience was shown in regression analyses to moderate the
relationship between treatment expectancies and both Self-focused attention and Coping
self-efficacy. In both cases, a significant positive relationship was found in the
Experienced group while no relationship was found in the Inexperienced group. Three
other variables displayed a significant relationship to treatment expectancies only in the
Experienced group (Optimism, Acute health problems, and Hope), although regression
analyses did not confirm a true moderating effect of treatment experience for these
relationships. It thus appears that having had previous experience with a similar
treatment may create a context wherein certain psychosocial variables become more or
less relevant in their associations with levels of treatment expectancy. This again
highlights the importance of considering one‟s previous treatment experiences, yet leaves
us pondering the explanation.
Turning back to theories of expectancy formation suggests a possible explanation.
In particular, Olson and colleagues (1996) describe how previous experience can shape
expectations also by influencing „other beliefs.‟ Perhaps among those whose memories
of a previous similar treatment experience are activated, the beliefs that were influenced
by/ are associated with that experience are also more strongly activated and thus more
available to influence current expectations of treatment. This model also fits with
theories of illness representations (Leventhal, Meyer & Nerenz, 1980), which posit that
people have a collection of beliefs (sometimes implicit) about their illness that are formed
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and later activated in response to stimulus information about the illness (which could
include practitioner suggestions, proposed treatments, etc). It has been found that the
activation of a certain illness representation (e.g., one associated with a particular
previous treatment) depends on the specificity of the stimulus information that is
presented (Henderson, Hagger & Orbell, 2007), with very specific illness representations
being activated by specific stimuli. Thus, in the current context, it is possible that a
specific treatment could activate a specific illness representation containing not only
memories of one‟s previous experience with that treatment, but also the beliefs that were
influenced by that experience. Once those associated beliefs are activated, they are
accessible to influence current beliefs and expectations.
There is an alternative, but not incompatible, explanation of why stronger
associations between psychosocial variables and treatment expectancies are found among
those with more treatment experience. Returning to the concept that prior experience
with a specific treatment can result in „stronger‟ or „more certain‟ expectations about
being able to benefit from that treatment, it is suggested that the beliefs that may be
associated with that treatment (e.g., control beliefs, self-efficacy beliefs) may also
become stronger or come to be held with greater certainty. In that case, it may be that
those who „know‟ more about treatments also know more about their ability to control
and cope with their symptoms in the context of those treatments. Whereas for the less
experienced, whose beliefs and expectations may be less certain, the task of rating one‟s
expectations and beliefs may involve more guess work leading overall to weaker
relationships between these variables.
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It is estimated that approximately 50% of individuals with IBS seek treatment for
their symptoms (Cremonini & Talley, 2005). Specifically taking into account the greater
treatment experience of the Experienced group, it should be noted that there have been
some studies documenting differences among individuals with IBS who seek treatment
vs. those who do not. For example, individuals who seek treatment for IBS have been
found to make more somatic attributions for their IBS symptoms (Martin & Crane, 2003),
and to report higher levels of bodily preoccupation (Crane & Martin, 2002, 2004b) higher
levels of general anxiety and symptom-specific anxiety (Crane & Martin, 2004; HazlettStevens et al., 2003), as well as lower levels of quality of life and coping resources
(Ringström, Abrahamsson, Strid & Simrén, 2007) than do non treatment seekers.
Although these findings should be taken into account when considering the more
numerous relationships identified herein in the Experienced vs. Inexperienced groups,
this explanation on its own cannot be used to explain the current results. For one, having
less experience with treatment cannot be considered the equivalent of being a „non
treatment seeker.‟ Furthermore, in the current study, SFA was the only psychosocial
variable found to differ between these groups.
F. Interaction of Previous Experience and SFA
Returning for a moment to considering the role of SFA, both Geers and
colleagues (2006) and the Belief-Activation Model suggest that greater levels of SFA
guide information processing toward internally generated information (e.g., sensations,
cues) which then influence one‟s expectations, and thus placebo responding. It is
important to note that both models discuss how SFA should influence outcome
expectations at a point in time after the intervention. However, in the current study, trait
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SFA was examined (and found to be relevant) at a point prior to intervention, and thus
would not be guiding information processing towards expectation-confirming or
disconfirming sensations, per se.
In this case it is plausible that greater self-focused attention would guide
information processing towards other internal aspects of the self, (such as beliefs about
the self or beliefs about treatments) for confirmation or disconfirmation (and thus
modulation) of externally-derived expectations for the current situation (e.g., “This
treatment will work for you”). Indeed it has been shown that greater self-focus increases
access to self-knowledge (Gibbons, 2006) and according to expectancy theorists,
accessibility is one of the determinants of the strength of a belief and its corresponding
expectancy (Olson et al., 1996). With this in mind, it seems reasonable to suggest that
personal health beliefs may be stronger predictors of treatment outcome beliefs (and
expectancies) among individuals with higher levels of self-focus relative to individuals
with lower levels of self-focus. Consistent with this hypothesis, recall that SFA was the
only variable (other than the treatment experience variables) on which the Experienced
and Inexperienced groups differed, with those with previous experience reporting higher
average levels of SFA. Thus, it could be that differential levels of SFA can account for
the fact that among the Inexperienced very few individual difference and health belief
variables contributed to TE, whereas among the Experienced there were several
significant variables.
There may be a third, more inclusive, possible explanation. Namely, it is
proposed that in the Experienced sub-sample, a combination of previous experience and
increased self-focused attention was responsible for the greater number of relevant
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relationships between psychosocial variables and current treatment expectancies. As
described above, it has been proposed that previous experience with a certain treatment
would create a) stronger initial expectations that may then guide information processing
towards their confirmation, and b) the activation of treatment-specific associated beliefs
in one‟s illness representation, and c) more certain treatment-related beliefs and more
certain associations between those beliefs and treatment expectations. It may also be, as
in the Geers et al study, that presumably „stronger‟ or „more certain‟ and more specific
initial expectations then combine with greater SFA to produce these differential results.
In other words, among those with previous experience with their preferred treatment,
their stronger and more specific initial expectations, coupled with greater SFA, led to a
situation where individuals had more access to, more certainty regarding, and thus
consulted their related illness and treatment beliefs when asked to explicitly rate their
level of expectation. As „strength‟ or „certainty‟ of treatment expectancies were not
manipulated or assessed in the current study, this model remains only speculative and in
need of further study.
G. Current Health
Returning to an examination of the relative importance of different psychosocial
variables in the prediction of treatment expectancies, first we will examine the factors
that were significant in the Experienced group only, potentially as a result of the action of
the just-proposed mechanisms. Current health, measured by totaling the number of acute
common health problems endorsed by the participant, did show a significant inverse
relationship with TE in the Experienced sample. Despite a relatively modest zero-order
correlation, this was the only health belief variable to remain a significant predictor of TE
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in the full regression model. As hypothesized, those who reported experiencing more
acute health problems in the last six months also reported lower expectations to benefit
from the current treatment. These results are consistent with research reporting that one‟s
relative health stock is positively correlated with expectations regarding treatment
outcome (Weinfurt et al., 2003).
H. Self-Efficacy
Coping self-efficacy was another variable found to be a modest positive correlate
of TE in the Experienced sample, but not in the other samples. It was not a significant
predictor in the regression model, however. This variable was included to capture an
aspect of symptom management to complement the measure of symptom severity. This
coping self-efficacy scale assesses the belief that one is successfully coping with the dayto-day aspects of one‟s condition. Although coping self-efficacy has been previously
linked to health outcomes in illness populations, such as quality of life (Henderson, 2003)
and overall functioning (Strahl, Kleinknecht, & Dinnel, 2000) this is the first time that
this variable has been linked specifically with expectations to benefit from treatment.
This result fits with expectancy theory in a manner similar to how control beliefs are
thought to influence expectancies. In particular, Olson et al. (1996) note that high selfefficacy implies that success is expected and that success reflects personal capacities;
thus, individuals with high self-efficacy will attribute positive changes to internal factors
and will expect future positive changes. In addition, as described above with reference to
control beliefs, it may be that confidence about managing one‟s symptoms is related to
expectations to benefit from treatment by way of treatment adherence self-efficacy
(French & Weinman, 2008). For example, if relaxation exercises are a part of the
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treatment plan and one is confident about engaging in relaxation, then one may report
higher levels of confidence in being able to cope with the day-to-day aspects of one‟s
condition (coping self-efficacy) as well as higher levels of expectation to benefit from
treatment.
Interestingly, scores on the health self-efficacy scale, which assessed feelings of
competence and confidence to carry out actions important for maintaining and taking care
of one‟s health in general, were not related to TE in any sample. These results confirm
that self-efficacy regarding one‟s ability to do what needs to be done to be healthy in
general are distinct from self-efficacy beliefs that are specific to coping with one‟s illness
(Chesney, Neilands, Chambers, Taylor, & Folkman, 2006), and suggest that the latter
beliefs are more relevant with regards to expectations regarding specific treatments. This
pattern is similar to the one noted above regarding the relatively stronger influence of
symptom-specific control beliefs versus general health control beliefs on TE.
I. Hope
The final variable found to be positively correlated with expectations of benefit in
the Experienced sample was Hope. It did not however, contribute to significant amounts
of variance in TE when in a model with the other individual difference variables. The
finding that higher levels of dispositional hope were correlated with more positive
treatment expectancies is consistent with one other study where levels of hope were
correlated with expectancies for positive non-volitional outcomes (Montgomery et al,
2003). The relatively weak relationship identified herein between levels of hope and
levels of positive expectation for treatment suggests that although hope may be somewhat
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relevant among those with greater self-focused attention and previous treatment
experience, it is not as relevant as its conceptual cousin, optimism.
J. Catastrophizing
Two other variables to be discussed are those for which there was a significant
correlation with the dependent variable in the full sample only. One of these is
„catastrophizing,‟ which was the only other health belief variable to show a significant
correlation to treatment expectancies in the full sample and to remain a significant
predictor of TE in the full regression model. Its relationship with expectations was fairly
weak, it uniquely contributed to only 3% of the variance; yet this was more than was
contributed by optimism in the full sample. The direction of the relationship was
surprisingly in the opposite direction to what was hypothesized. It was found that those
who endorsed more catastrophizing beliefs about their symptoms also reported higher
levels of TE. This is the first time that catastrophizing has been linked with treatment
expectancies, thus the directionality of this relationship cannot be compared with findings
from other studies. It was included in the current research because it has been studied in
samples with gastrointestinal disorders, and found to be related to less favourable health
outcomes (Drossman, et al., 2000; Rutter & Rutter, 2002). „Catastrophizing‟ is the short
title used herein for the „catastrophizing interpretation of bodily complaints‟ scale, which
measured the tendency to interpret physical symptoms and sensations as indicators of
serious illness. It could perhaps be argued that this scale assesses a tendency to be
anxious about one‟s symptoms (i.e., trait symptom anxiety). If so, this finding may echo
the mixed findings that have been described regarding the influence of anxiety on
expectations and placebo responding.
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K. Patient-Provider Relationship
Perceived quality of the patient-provider relationship was one context-dependent
psychosocial variable that was positively correlated with TE in the full sample, but not a
significant predictor when entered with the context-dependent variables in the full
regression model. This factor was not correlated with TE in either of the other samples,
suggesting that very weak effects in both the Experienced and Inexperienced group may
have combined additively to result in a weak but statistically significant finding in the full
sample. These weak relationships between treatment expectancies and the patientprovider relationship is likely an artifact of a) the hypothetical nature of the provider, and
b) efforts to minimize the emotional/ relational aspects of the provider in the treatment
vignettes.
The finding that higher levels of perceived quality in the patient-provider
relationship was related to greater expectations to benefit from treatment is consistent
with theory in both the placebo (Miller & Kaptchuk, 2008) and expectancy literatures
(Harris & Rosenthal, 1985). Empirically, provider interactions have been linked with
both greater expectations to benefit from treatment (Beach et al., 2006) and greater
placebo responding (e.g., Colloca et al., 2004; Kaptchuk et al., 2008). Some authors have
even suggested that the placebo effect be renamed the „contextual healing‟ effect and
have emphasized that placebo research should focus its efforts on examining the
contextual aspects of the therapeutic situation, especially aspects of the relationship
(Miller & Kaptchuk, 2008).
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L. Variables Not Related to Treatment Expectancies
Before moving on to summarize and discuss the potential implications of the
significant findings found in the current study, it is important to note that several of the
psychosocial variables hypothesized to be correlated with levels of treatment expectations
were not found to be relevant correlates in this sample. For some of these variables, these
findings are not a great surprise; in particular, the non-significant relationships of TE with
Perceptions of health, Health self-efficacy and beliefs of Vulnerability to illness. Both
Health self-efficacy and Vulnerability to illness were included in the current study as
potentially relevant psychosocial variables based on some demonstrated relationships
with health outcomes. Neither had been previously associated with placebo responding
or treatment expectancies themselves. Perceived levels of general health had been
previously documented to show a relationship to treatment outcome expectancies in
studies using different measures of overall health, particularly „relative health stock‟ and
the Medical Outcome Scale –Short Form 36 (Cheng et al., 2000; Weinfurt et al., 2003).
Seeing that in this study, treatment expectancies were related to current health using the
other index (number of acute health problems), suggests that perhaps the three authorcreated questions used to measure „perception of health‟ did not accurately capture
participant‟s overall sense of their general health.
The null findings regarding both trait anxiety and motivation are of more interest
in the context of understanding placebo mechanisms, as both have been linked with
placebo responding and have been frequently cited as potential mediators of the placebo
effect. The finding that trait anxiety was unrelated to treatment expectancies is consistent
with some studies that have reported no relationships between trait anxiety and treatment
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expectancies (McCarthy et al., 2003; Montgomery et al., 1998). It is inconsistent,
however, with the results of an experimental placebo study with an IBS sample where
levels of anxiety regarding experimental pain were positively correlated with levels of
expectation of pain, and where together anxiety and expectation predicted significant
levels of variance in reported pain (Vase, Robinson, Verne & Price, 2005). Perhaps these
differential results are due to a study‟s focus on either trait anxiety (no relationship) vs.
treatment or symptom-specific anxieties (some relationship). Another possible
explanation for these differential results (which may work in conjunction with this first
suggestion) is the negative or positive valence of the treatment/ intervention. In the Vase
et al study (2005), participants were told to expect pain, whereas in the current study
participants were presented with a potentially beneficial treatment. Whereas the former
suggestion may understandably lead to increased anxiety, the latter would likely not.
Recently, neurobiological findings have revealed that at least in the context of placebo
hyperalgesia (or nocebo hyperalgesia) where one is told to expect pain, the expectation of
pain leads to anxiety itself, which then increases pain through neurobiological processes
of its own. In particular, anxiety regarding pain leads to increased activation of
cholecystokinin, a peptide hormone that facilitates pain transmission (Colloca &
Benedetti, 2007; Enck, Benedetti & Schedlowski, 2008). These recent findings suggest
that although anxiety and expectation may work together to influence outcome in
situations where outcomes are considered adverse, they may not necessarily be correlated
in situations where the outcomes themselves are not anxiety-producing.
The other potentially meaningful null result in the current study is the finding that
none of the measures of motivation (i.e., Desire for relief, Symptom severity, IBS:
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Interference with daily activities, or Socially desirable responding) were related to levels
of expectation to benefit from treatment. These findings are not necessarily inconsistent
with placebo research. In particular, previous research has documented that motivational
factors, such as desire for relief or desire to please the experimenter, contribute to
enhanced placebo responding. In one of these studies, expectations were not directly
measured, thus the authors could only speculate that the motivational element influenced
placebo responding through its interaction with outcome expectations. Specifically it was
suggested that when goals and expectations are in line there will be greater placebo
responding as opposed to when goals and expectations are out of line (Geers et al., 2005).
In three other studies where expectations were measured explicitly, although it was
reported that both expectancies and desire for relief (as well as their interaction) predicted
levels of placebo responding, it was not reported whether there was a significant
relationship between the two variables (Price et al., 2005; Vase et al., 2003; Vase et al.,
2005).
In the current study it was hypothesized that motivational factors might be related
to treatment expectancies as these previous studies have not indicated otherwise and this
hypothesis is in keeping with placebo theories wherein expectations (conscious or
unconscious) represent the final common pathway in placebo responding (Kirsch, 1985).
Other researchers, however, have suggested that motivational factors contribute to
placebo responding directly (Vase et al., 2003). The contribution of motivational factors
to placebo responding in earlier studies, combined with the null relationship between
motivation and treatment expectations in this study, together lend support to the theory
that such motivation factors work either independently or in concert with expectations to

161

contribute to placebo responding, as opposed to being mediated by expectations. Recent
brain imaging studies further support this view; it has been documented that there is
activation of expectations areas as well as motivation/emotion areas during placebo
responding (see Price et al., 2008).
M. Qualitative Findings
It is interesting to note that in the narrative responses, it was the contextdependent factors that were mentioned most frequently. Specifically, when asked to
comment on what personal factors may contribute to one‟s own expectations to benefit
from treatment, a great number of participants gave statements referring to aspects of the
treatment itself, and how this meshed with their perspectives/experiences/lifestyles. The
two most referenced pre-set categories were Treatment experience and Illness
attributions. Furthermore, all of the emergent categories were either extensions of these
themes of previous experience and illness attributions or referred directly to aspects of
the treatment (side effects, aversion, and convenience) that weren‟t manipulated or
measured in this study.
III. Summary and Implications
This research was designed to identify and quantify the relative contributions of
various personal psychosocial variables to expectations to benefit from treatment in an
IBS sample. In the pursuit of this end, this research has been successful in several ways.
For one, this research has successfully achieved its specific aims and answered its main
research questions focused on identifying a parsimonious set of psychosocial variables
that are associated with treatment expectancies in an IBS sample. Second, it has both
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supported and extended the conceptual models that together guided this research in its
aims. Importantly, it has provided valuable information that can be used to clinically in
the treatment of IBS. And lastly, it has highlighted areas of study that are in need of
more empirical investigation.
Consistent with Response Expectancy Model (Kirsch, 1985) and Olson et al.,
(1996) expectancy formation theory, past direct experience was an important contextdependent variable in this model predicting treatment expectancies. For one, previous
experiences with a specific treatment (i.e., previous satisfaction) were directly positively
associated with current treatment expectancies. Although Olson et al., outlined that prior
experience will have an important influences on one‟s beliefs, the current findings
regarding the moderating effect of prior treatment experience on the relationships of
various psychosocial variables to treatment expectancies add a unique and important
piece to our understanding of the role of previous experience in this model. Both Kirsch
and Olson et al. gave some consideration to the potential role for attributions in a model
predicting (treatment) expectations. The current research has made a contribution by
providing empirical support for this theorized association, namely by linking treatment
expectancies to individuals‟ perceptions of the somatic/ psychological focus of their
treatment. A strong inspiration for the current research, the Belief Activation Model
(Sirois, 2001, 2009) suggested that individual difference variables and health belief
variables have a role to play in influencing one‟s expectations regarding a proposed
intervention. The current research has supported and extended this model by a) providing
empirical support for the associations between TE and self-focused attention and
optimism, and b) identifying several health belief variables that contribute to treatment
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expectancies (control beliefs, coping self-efficacy, perceptions of current health). The
findings regarding the null relationships of motivation and anxiety to treatment
expectations may provide support for models of the placebo effect that suggest that these
variables influence placebo responding without being mediated by expectancies (e.g.,
Price, Finniss & Benedetti, 2008). Finally, although it is well accepted that contextual
factors are important variables in a model predicting treatment expectancies and placebo
responding, the current research has identified some further treatment-specific variables
reported to influence an individuals‟ positive expectations about treatment (e.g.,
convenience, aversion, side-effects). This research further contributes to our
understanding of why placebo research has been unable to identify a consistent placebo
responder, or to isolate the individual difference or personality traits that can be
consistently used to predict placebo responsiveness. In particular, this research highlights
that the treatment expectations that mediate placebo effects are influenced by a variety of
individual difference and health belief factors whose individual influences may vary
considerably according to the impact of important context-dependent psychosocial
factors. Truly it seems that expectations effects are influenced by a dynamic interaction
of person and context.
In terms of the implications of this research for the treatment of irritable bowel
syndrome, the current research findings are unique in that they specifically demonstrate
which psychosocial factors contribute to treatment expectancies in this sample (and their
relative contributions). This information can be translated into informing treatment
providers about psychosocial factors that should be addressed if one‟s goal is to
maximize the expectation effect in the therapeutic context of treating individuals with
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IBS. First these results highlight the importance of assessing patients‟ perceptions of the
extent to which the proposed treatment targets what are perceived as the somatic causes
of IBS symptoms. It has also been proposed herein that it may be relevant to assess and
understand a patient‟s preference for a more somatically or psychologically focused
treatment. These results also highlight the importance of assessing whether a patient has
had previous experiences with the proposed treatment(s), and if so, assessing how
successful they perceived the previous treatment to be.
This research has demonstrated that personal health beliefs do indeed have a role
in influencing one‟s expectations to benefit from treatment. Overall, specific health
beliefs, as opposed to more general health beliefs, seem to be more relevant to TE for
specific treatments. The results suggest that control beliefs, particularly beliefs about
one‟s ability to control and manage one‟s symptoms, are one of the more relevant health
beliefs to consider. Other research, guided by Leventhal‟s Common-Sense Model of
health (CSM; Nerenz & Leventhal, 1983; Meyer, Leventhal & Gutmann, 1985), has
demonstrated that control beliefs are an important aspect of one‟s illness representation
that can be ameliorated through intervention, resulting in improved health outcomes
(Petrie, Cameron, Ellis, Buick & Weinman, 2002). In the CSM, illness representations
are related to outcome via changes in people‟s coping actions and efforts. However,
accumulating research has suggested that illness representations may be associated with
outcomes independently of coping strategies (Hagger & Orbell, 2003). The current
research findings suggest that certain aspects of one‟s illness representation (e.g., control
beliefs and attributions) may influence outcomes through their positive influence on
expectations for treatment benefit.
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Another important individual difference factor to consider, according the results
of this study and others (i.e., Geers et al., 2006) is one‟s level of self-focused attention.
The present research found that among those with more previous treatment experience,
people with higher levels of self-focused attention also reported greater expectations to
benefit from treatment. Thus, contrary to the idea encountered in IBS literature that
increased bodily preoccupation is a pathological attribute of IBS treatment seekers, the
current findings suggest that people with more self-focus are more optimistic about their
ability to benefit from treatment. It makes sense that with more treatment experience,
people who are more internally-focused may become more skilled at monitoring their
IBS symptoms, discriminating them from non-IBS symptoms, and making useful
connections about how symptoms respond to different aspects of a treatment intervention.
It follows that such people would then report more confidence in their ability to benefit
from treatment. Although it may not always be easy or practical to assess a patient‟s
level of dispositional self-focused attention, other research studies have shown that
greater SFA can be induced (e.g., Geers et al., 2006). In fact, enhancing body/ somatic
awareness is an increasing popular component of treatment in several areas of healthcare.
The findings of this research also point to a role for some other health belief
variables that demonstrated a relationship to treatment expectancies. In particular, one
might consider assessing a patient‟s tendency to catastrophize about their bodily
symptoms, how many acute health problems they are dealing with, as well as the degree
to which they feel they can cope with the day-to-day aspects of their symptoms. This
research suggests that individuals with „stronger‟ initial expectancies (for example due to
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prior personal experience) and greater levels of self-focused attention may be more in
touch with these intrinsic health beliefs that can alter their expectations for treatment.
Another potential implication for the treatment of IBS concerns the treatment
preferences that were expressed by participants during the pilot study. Healthcare
providers should be aware that the majority of participants in the pilot sample expressed a
preference for a treatment that combined both pharmacological and psychological
approaches to the management of their IBS symptoms. This finding was further
supported by the qualitative data, wherein several participants made reference to a
preference for a holistic approach to treating their IBS, and/or discussed their symptom
attributions as having both physical and psychological components.
The implications for clinical practice that are suggested by these overall findings
are that it is important to provide patients with opportunities to enhance their sense of
control over their illness and their symptoms. For people with IBS, because of the
elusive etiology of symptoms and the range of treatment approaches that are available,
being able to make decisions regarding the choice of treatment may be a simple and
effective strategy to engender enhanced feelings of control. It is suggested that a clinical
interview include an exploration of a person‟s understanding of the success or failure of
previous treatments, attributions for symptom causes and management, preferences for
different treatment approaches, confidence for day-to-day coping and success with bodily
awareness. If available, cognitive-behavioural interventions could be used to address any
emergent maladaptive beliefs in the service of fostering a strengthened sense of control.
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IV. Limitations and Suggestions for Future Research
The present results add to existing literature by extending our knowledge of which
psychosocial variables display relationships to treatment expectancies in an IBS sample.
There are, however, limitations of the present work that should be highlighted. First,
several aspects of the design of the study limit the generalizability of these findings.
Although efforts were made to recruit participants from the community, and to offer
individuals the opportunity to complete a paper version of the study, the majority of the
data was collected online and the majority of participants were recruited from the
„volunteer‟ section of websites that host free online classified ads. One issue regarding
this type of sampling method is potential bias introduced as participants had to have
access to the Internet, be savvy to Internet classifieds sites and also be interested in
volunteering. This may have resulted in the generally higher level of education of the
sample, and may have contributed to the sample being predominantly Caucasian and
female. The ratio of female to males in this study (5.7:1) is higher than what would be
expected if sampling from the general IBS population (where prevalence estimates by
gender range from 2:1 female predominance to a ratio of 1:1 (Saito, Schoenfeld & Locke,
2002). It has been suggested that participants who volunteer to complete an online
survey may differ in systematic ways from those recruited from patient populations in the
community (Soetikno, Mrad, Pao & Lenert, 1997). Evidence from other studies suggests
that individuals with gastrointestinal disorders that are recruited from the Internet report
more serious symptomatology and less functionality than those recruited in the
community (Jones, Bratten & Keefer, 2007). However, some research on the
characteristics of participants from Internet studies suggest that such samples are more
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heterogeneous that their community based counterparts (Krantz & Dalal, 2000), and that
data collected online are of as good quality as community-collected data (Gosling,
Vazire, Srivastava & John, 2004). One advantage of conducting online research with
illness populations is that it provides an opportunity to reach individuals who may not
normally be recruited in the community because of limited mobility and other illness
related restrictions (Sirois, 2003).
The use of a cross-sectional design in the context of an Internet survey allowed
for the recruitment of a large sample of individuals with IBS over a relatively small
amount of time and with little financial investment. A limitation of this design, however,
was that the main dependent variable (expectation to benefit from treatment) was elicited
using fairly generic hypothetical treatment scenarios. It is possible that both the
significance and the magnitudes of the relationships found herein may not generalize to
an in vivo treatment scenario or to a real-world therapeutic context. For example, it is
presumed that the fairly weak relationship between TE and Patient-provider relationship
may be a function of the hypothetical nature of the provider (and thus the relationship).
In addition, the cross-sectional nature of the design certainly precludes any conclusions
regarding causality. It also may have limited this study‟s ability to identify a relationship
between TE and the psychosocial variables that are theorized to influence treatment
outcomes either after the administration of an intervention (e.g., self-focused attention,
anxiety) or by way of an interaction with TE (e.g., motivational factors). Future studies
may wish to explore these relationships in a more naturalistic environment using a
prospective design, which would allow for further clarification of the relationships and
relative roles of these variables in a real-life treatment context. It would certainly be of
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interest to see whether these more intrinsic psychosocial variables (e.g., health beliefs,
illness attributions) remain relevant predictors over and above the presumably powerful
influence of a strong patient-provider relationship.
Limiting this investigation to one illness population has allowed for increased
control over several possibly confounding sources of variance. It has also allowed for a
greater understanding of what may be the most relevant psychosocial variables for this
illness group, potentially contributing to improved management of this syndrome.
However, it does limit the generalizability of these results to other illness populations.
It may be that some of the relationships are relevant only in an IBS sample. For example,
catastrophizing about bodily complaints has been noted and studied primarily in IBS
samples (Gomborone et al., 1995; Kolowski et al 2005), and it may be that it is not a
relevant factor influencing TE in other illness groups. Furthermore, as suggested above,
certain variables such as control beliefs may show stronger relationships to TE among
illness groups where there is more treatment choice or where treatment adherence
requires more day-to-day personal effort (French & Weinman, 2008). Additional
research is needed to ascertain which of these relationships are confirmed in other illness
samples, both functional and organic. It may also be of interest to explore these
relationships in the context of the treatment of an acute illness or injury.
It is also important to take into account the fact that the majority of participants in
the pilot study chose the combined treatment (with both pharmacological and
psychological aspects), yet this treatment was not offered in the main study. As such, it
is possible that participants in the main study may have felt that they were being offered
the choice between two less-than-ideal treatments, as opposed to the type of treatment
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they would actually prefer. This situation could have contributed to low engagement
during survey completion, jeopardizing the validity of study findings. Although this is a
possibility, it should be noted that several efforts were made to increase the credibility
and acceptability of the treatment vignettes. For example, each proposed treatment
contained dietary components (consultation and specific recommendations), as this is
considered the most important line of treatment for the management of IBS symptoms.
In addition, each treatment plan involved a thorough assessment of personal triggers for
IBS symptoms as well as an educational component, and each treatment plan was based
on actual state-of-the-art treatment approaches.
This research also had some methodological limitations. The main problem that
arose with methodology was the weak psychometric properties of the original measure of
illness attributions. Although the analysis was unable to proceed as planned due to the
failure of this instrument, perceived somatic/psychological foci of treatment was
available for use as an approximation of a participant‟s illness attributions. Additional
work may be needed to develop and/or validate a sound measure of illness attributions.
Responses in the qualitative data also highlighted the need to measure a participant‟s
holistic illness attributions (mind-body interaction), and to a lesser extent, situational
symptom attributions. Future work should consider including these aspects of illness
attributions and assessing their contribution to treatment expectancies.
An additional methodological limitation is the failure to measure the „strength‟ of
one‟s expectation to benefit from treatment. This research was originally interested in
how „positive‟ one‟s treatment expectancies were, ranging from no expected benefit to
excellent expected benefit, as this is how treatment and outcome expectancies are

171

typically measured. However, it may be advisable for future researchers to include a
measure of the „certainty‟ or „strength‟ of an expectation, as this aspect of the expectation
has been proposed to play a role in the extent to which expectancies guide information
processing (Geers et al., 2006).
One further potential limit to the generalizability of some of these findings is that
the relationships of psychosocial variables to outcome expectancies were only examined
in the context of suggestions for positive outcomes (i.e., “This treatment will help with
those symptoms.”) It has been shown throughout the literature that some relationships
that stand in the context of positive suggestions may not hold up under conditions
including negative suggestions (e.g., Geers et al., 2007; Montgomery et al, 2003).
Further work investigating the correlates of expectations for negative outcomes in an IBS
sample would likely be clinically relevant, as most treatments (especially
pharmacological ones) are associated with negative side effects. Sensitivity to side
effects could potentially be reduced if contextual and psychosocial correlates of negative
expectations could be identified and managed.
V.

Conclusion

The placebo literature has clearly highlighted the important role that outcome
expectancies play in enhancing one‟s response to an intervention. As such, interest has
been growing in regards to identifying the factors that contribute to or interact with these
expectations. The current study was designed to identify, in particular, the salient
psychosocial variables that are relevant in influencing expectations to benefit from a
proposed treatment. This research has been successful in identifying a manageable set of
psychosocial variables that contribute to positive treatment expectancies in an IBS
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sample. In several instances this was the first time these variables had been linked in an
IBS sample. Two of the context-specific psychosocial variables identified as relevant in
this sample included previous satisfaction with similar treatments and the level of
perceived somatic focus of the treatment. In addition, control beliefs, self-focused
attention and optimism were identified as variables intrinsic to the individual that had an
influence on whether one expected to benefit from treatment. If the relevance of these
variables can be confirmed in a naturalistic IBS treatment context, the next steps would
be to assess whether these important variables can be addressed efficiently in a
therapeutic context. This work would ideally lead towards the development and
implementation of guidelines and interventions designed to target and utilize these
idiosyncratic beliefs and information-processing biases in an effort to maximize
expectations of treatment success and therefore the effectiveness of the therapeutic
intervention.
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APPENDICES
Appendix A. Letter of Information to Site Moderators
I am contacting you to request your assistance with recruiting participants for an on-line
research study on expectations of treatment for irritable bowel syndrome (IBS).
The purpose of this study is to investigate the personal factors that influence an
individual‟s expectations of benefiting from treatment. Previous research has shown that
expectations regarding treatment play an important role in treatment success, but little is
known about what individual factors contribute to the magnitude of positive expectations.
The main study will look closely at the individual factors that may influence treatment
expectations. We expect data collection to take approximately 12 months. Before we
conduct the main study, a pilot study will be conducted to validate the treatment vignettes
to be used in the main study. This pilot study will last approximately three weeks.
Individuals who participate in the first study would not be eligible to participate in the
second study.
A link placed on your message board to the following website mylinkhere would be of
great assistance. Interested participants would simply click on the link if you agree to
post it on your board, and then after reading the letter of information they can make an
informed decision about participating. The survey for the first study takes about 10
minutes to complete and the survey for the main study takes about 25 minutes to
complete. All information provided will be kept confidential. We will also produce a
brief on-line report of our findings for anyone interested by June 2009. More information
about the study is available on our web site.
As an incentive participants will be given a chance to win one of several gift certificates
from a major on-line bookseller.
This research has been approved by the University of Windsor Research Ethics Board.
If you have any questions or require more information about the study, please contact me
at (519) 256-2586, or by email at wilso2c@uwindsor.ca.
Please send a reply to this email, regardless of your intent to participate. Please check
below your participation interests:
Agreement to post recruitment message for main study ____
Agreement to post recruitment message for pilot study ____
No interest in participating
____
Thank you for your time and assistance.
Tobi Wilson, M.A.
Fushia Sirois, Ph.D.
Department of Psychology
University of Windsor
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Appendix B. Materials for Recruiting via Gastroenterology Clinics
Letter of Recruitment to Gastroenterologists
I am contacting you to request your assistance with recruiting participants for an on-line
research study on treatment expectations among individuals with irritable bowel
syndrome (IBS). The purpose of this study is to investigate the relationships between
individual difference factors (optimism, hope, anxiety, etc), health beliefs (beliefs of
vulnerability to illness, control over symptoms, health self-efficacy, catastrophizing, etc)
and treatment expectations among individuals with IBS. There is a considerable
literature supporting the link between treatment expectancies and treatment outcomes.
This study is designed to investigate whether certain psychosocial variables, unique to
each patient in a treatment situation, influence the strength of a patient‟s expectations of
treatment. Should this study be able to identify a parsimonious list of psychosocial
variables that are correlated to the strength of one‟s treatment expectancies, these
variables can then become potential targets of assessment and intervention in the service
of maximizing treatment effectiveness.
Posting our attached recruitment flyer in your clinic would be of great assistance.
Interested participants would simply go to the website listed on the flyer to access the
letter of information explaining the study, at which time they can make an informed
decision about participating. Should they decide to participate, they would read about
hypothetical IBS treatment scenarios, rate their expectations of each treatment, and
complete an online survey containing questionnaires designed to measure various
individual difference and health belief variables. The survey takes about 25 minutes to
complete and all information will be kept confidential. If preferred, participants can elect
to complete a paper version of the package.. More information about the study is
available on our web site.
As an incentive participants will be given a chance to win one of several gift certificates
from a major on-line book seller.
This research has been approved by the University of Windsor Research Ethics Board. If
you have any questions or require more information about the study, please contact me
by email at wilso2c@uwindsor.ca.
Please send a reply to this email, regardless of your intent to participate. Please check
below your participation interests:
Agreement to post recruitment message for study
____
No interest in participating
____
Thank you for your time and assistance,
Tobi Wilson, M.A.
Fuschia Sirois, Ph. D.
Department of Psychology
University of Windsor
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Recruitment Flyer for Gastroenterology Clinics

Would these Treatments Work for
You Too?
„IBS Treatment Study –Two‟
The University of Windsor is looking for
individuals age 16 and above with diagnosed
irritable bowel syndrome to participate
anonymously in an online survey study about
individual‟s thoughts and beliefs about IBS
treatments.
Your participation would take about 25 minutes,
and you would be entered into a draw to win one of
several $20 gift certificates. Please go to
mylinkhere.com for more information.
Please note that you may also complete a paper version of the study that
we will mail to you along with a postage paid return envelope. Go to
mylinkhere.com for more information.
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Appendix C. Recruitment Messages
1. Pilot Recruitment Message

Would these IBS Treatments Work for You?
The University of Windsor „IBS Treatment Study - One‟ is looking for individuals
age 16 and above with diagnosed IBS to participate in an online survey study about
individual‟s thoughts and beliefs about IBS treatments. Your participation would
take about 10 minutes, and you would be entered into a draw to win one of several
$20 gift certificate. Please click on the following link for more information:
mylinkhere

2. Main Study Recruitment Message

Would these IBS Treatments Work for You Too?
The University of Windsor „IBS Treatment Study –Two‟ is looking for individuals
age 16 and above with diagnosed IBS to participate in an online survey study about
individual‟s thoughts and beliefs about IBS treatments. Your participation would
take about 25 minutes, and you would be entered into a draw to win one of several
$20 gift certificates. Please click on the following link for more information:
mylinkhere
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Appendix D. Rome III IBS Criteria
IBS Symptom Questionnaire
For each question, please „check‟ the number that applies best to you:
___ 0 Never
___ 1 Less than one day a month
1. In the last 3 months, how often did
___ 2 One day a month
you have discomfort or pain anywhere
___ 3 Two to three days a month
in your abdomen?
___ 4 One day a week
___ 5 More than one day a week
___ 6 Everyday
If you answered ‘never’ to the above questions, please skip remaining questions
___ 0 No
2. For women: Did this discomfort or
___ 1 Yes
pain occur only during your menstrual
___ 2 Does not apply to me because
bleeding and not at other times?
I have had the change of life
3. Have you had this discomfort or pain
___ 0 No
6 months or longer?
___ 1 Yes
___ 0 Never or rarely
4. How often did this discomfort or pain
___ 1 Sometimes
get better or stop after you had a bowel
___ 2 Often
movement?
___ 3 Most of the time
___ 4 Always
___ 0 Never or rarely
5. When this discomfort or pain started,
___ 1 Sometimes
did you have more frequent bowel
___ 2 Often
movements?
___ 3 Most of the time
___ 4 Always
___ 0 Never or rarely
6. When this discomfort or pain started,
___ 1 Sometimes
did you have less frequent bowel
___ 2 Often
movements?
___ 3 Most of the time
___ 4 Always
___ 0 Never or rarely
7. When this discomfort or pain started,
___ 1 Sometimes
were your stools (bowel movements)
___ 2 Often
looser?
___ 3 Most of the time
___ 4 Always
___ 0 Never or rarely
___ 1 Sometimes
8. When this discomfort or pain started,
___ 2 Often
how often did you have harder stools?
___ 3 Most of the time
___ 4 Always
___ 0 Never or rarely
9. In the last 3 months, how often did
___ 1 Sometimes
you have hard or lumpy stools?
___ 2 Often
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10. In the last 3 months, how often did
you have loose, mushy or watery stools?

___
___
___
___
___
___
___
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3
4
0
1
2
3
4

Most of the time
Always
Never or rarely
Sometimes
Often
Most of the time
Always

Appendix E. Rome III Diagnostic Criteria & Scoring Criteria
Diagnostic Criteria


Recurrent abdominal pain or discomfort at least 3 days/ month in the last 3 months
associated with two or more of criteria #1 - #3 below:

Pain or discomfort at least 2-3 days / month (Question 1 > 2)
For women, does pain occur only during menstrual bleeding? (Question 2 = 0 or 2)
1.

Improvement with defecation

Pain or discomfort gets better after BM at least sometimes (Question 4 > 0)
2.

Onset associated with a change in frequency of stool.

Onset of pain or discomfort associated with more stools at least sometimes
(Question 5 > 0) OR
Onset of pain or discomfort associated with fewer stools at least sometimes
(Question 6 > 0)
3.

Onset associated with a change in form (appearance) of stool.

Onset of pain or discomfort associated with looser stools at least sometimes
(Question 7 > 0) OR
Onset of pain or discomfort associated with harder stools at least sometimes
(Question 8 > 0)
 Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to
diagnosis.
(Question 3 = 1)
Criteria for IBS- C: (Question 9 > 0) and (Question 10 = 0)
Criteria for IBS- D: (Question 9 = 0) and (Question 10 > 0)
Criteria for IBS- A: (Question 9 > 0) and (Question 10 > 0)
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Appendix F.

Informed Consent Forms

LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN
RESEARCH
IBS Treatment Study
Study One
You are asked to participate in a research study conducted by Tobi Wilson, graduate
student, and Dr. Fuschia Sirois, research supervisor, from the Department of Psychology
at the University of Windsor. The results of this research will contribute to Ms. Wilson‟s
doctoral dissertation.
If you have any questions or concerns about the research, please feel free to contact Dr.
Fuschia Sirois at 519-253-3000 X 2224.
PURPOSE OF THE STUDY
The purpose of this study is to look at what people with irritable bowel syndrome (IBS)
think about some of the options that are available for treating IBS. Specifically, this
study is interested in people‟s thoughts about whether different treatments will work for
them.
PROCEDURES
If you volunteer to participate in this study, we would ask you to do the following things:
First you would be asked to read about some hypothetical treatment options for IBS.
Then you would be asked to rate how much you thought each treatment would work for
you, and pick the one you would prefer. You would also be asked some questions about
whether you found these treatments credible, and would be given the opportunity to tell
us your thoughts about these treatment options.
If you volunteer to participate in this study, you would click on the I AGREE button
below and would be directed to the study webpage to complete the study online. It would
take about ten minutes to complete, and you would only be asked to participate once. A
similar study will be conducted again in the near future, but you would only be asked to
participate in this study.
POTENTIAL RISKS AND DISCOMFORTS
Participating in this study may make you feel slightly uncomfortable. We have tried to
minimize this risk by making your participation anonymous, and by only asking you to
provide your opinions.
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR SOCIETY
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Participating in this study will be of no direct benefit to you.
We think that the results of this study could potentially be of benefit to society. For
example, we think that IBS treatments could be improved if we had more knowledge
about what people with IBS think about different treatment options.
PAYMENT FOR PARTICIPATION
In return for your participation, at the end of the study you will have the option to be
entered into a draw for one of several gift certificates from a major international
bookseller. The value of these gift certificates is 18 USD (20 CAD, 14 EUR or 10
GBP).
CONFIDENTIALITY
The information you provide in this study will remain anonymous. This means that you
will NOT be asked to provide your name. If you choose to be contacted by regular mail
in the case that you win a gift certificate, your address will be stored separately from your
study information so that your information cannot be linked to you. All data will be
stored securely and may only be accessed by the main investigator and faculty supervisor.
Data will be stored securely for a period of 10 years, as required, at which time it will be
destroyed.
PARTICIPATION AND WITHDRAWAL
You can choose whether to be in this study or not. If you volunteer to be in this study,
you may withdraw at any time without consequences of any kind. You may also refuse
to answer any questions you don‟t want to answer and still remain in the study.
The investigators may withdraw you from this research if circumstances arise which
warrant doing so. Your information would be withdrawn from the study if you do not
complete at least 80% of the survey items. As this study is interested only with
individuals who have been diagnosed with IBS, your information could be withdrawn if
you do not currently meet criteria for a diagnosis of IBS.
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS
The results of this study will be available to the participants in May 2007 on the
following website: http://athena.uwindsor.ca/fsirois
SUBSEQUENT USE OF DATA
This data will not be used in subsequent studies.
RIGHTS OF RESEARCH SUBJECTS

210

You may withdraw your consent to participate at any time and discontinue participation
without penalty. If you have questions regarding your rights as a research subject,
contact: Research Ethics Coordinator, University of Windsor, Windsor, Ontario, CA,
N9B 3P4; telephone 519-253-3000, ext. 3916; e-mail: lbunn@uwindsor.ca
SIGNATURE OF INVESTIGATOR
These are the terms under which I will conduct research.
Tobi Wilson, M.A.
Department of Psychology
University of Windsor
It is recommended that you print out a copy of this letter of information for your
records.
Pass it on: Feel free to send this page to other people you know with IBS who might be
interested in completing the survey
Do you wish to continue? To acknowledge that you have read and understood this
information and would like to continue with the survey, please click on “I agree.”

I AGREE

LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN
RESEARCH
IBS Treatment Study
Study Two
(online version)
You are asked to participate in a research study conducted by Tobi Wilson, graduate
student, and Dr. Fuschia Sirois, research supervisor, from the Department of Psychology
at the University of Windsor. The results of this research will contribute to Ms. Wilson‟s
doctoral dissertation.
If you have any questions or concerns about the research, please feel free to contact Dr.
Fuschia Sirois at 519-253-3000 X 4447 or email sirois12@uwindsor.ca.
PURPOSE OF THE STUDY
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The purpose of this study is to look at what people with irritable bowel syndrome (IBS)
think about some of the options that are available for treating IBS. Specifically, this
study is interested in people‟s thoughts about whether different treatments will work for
them. In addition, this study is designed to assess how individual‟s expectations and
preferences for different treatments vary due to individual‟s unique personal
characteristics.
PROCEDURES
If you volunteer to participate in this study, we would ask you to do the following things:
First you would be asked to read about some hypothetical treatment options for IBS.
Then you would be asked to rate how much you thought each treatment would work for
you, and pick the one you would prefer. You would be asked to provide some basic
demographic information about yourself and your experience of IBS symptoms and
treatments. You would then complete a survey that asks questions about your unique
characteristics. Finally, you would be given the opportunity to tell us your thoughts
about these treatment options.
If you volunteer to participate in this study, you would click on the I AGREE button
below and would be directed to the study webpage to complete the study online. It would
take about 25 minutes to complete, and you would only be asked to participate once. A
similar study has been conducted not long ago, (IBS Treatment Expectations – Study
One) and if you participated in that study, we ask that you do not participate in this one.
POTENTIAL RISKS AND DISCOMFORTS
Some people may experience some mild distress when asked to think about their IBS. We
have tried to minimize this risk by making your participation anonymous, and by only
asking you to provide your opinions.
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR SOCIETY
Participating in this study will be of no direct benefit to you.
We think that the results of this study could potentially be of benefit to society. For
example, we think that IBS treatments could be improved if we had more knowledge
about what people with IBS think about different treatment options, and what individual
factors affect these expectations.
PAYMENT FOR PARTICIPATION
In return for your participation, you will have the option to be entered into a draw for one
of several gift certificates from a major international bookseller. The value of these gift
certificates is 18 USD (20 CAD, 14 EUR or 10 GBP).
CONFIDENTIALITY
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The information you provide in this study will remain anonymous. This means that you
will NOT be asked to provide your name. If you choose to be contacted by regular mail
in the case that you win a gift certificate, your address will be stored separately from your
study information so that your information can be linked to you. All data will be stored
securely and may only be accessed by the main investigator and faculty supervisor. Data
will be stored securely for a period of 10 years, as required, at which time it will be
destroyed.
PARTICIPATION AND WITHDRAWAL
You can choose whether to be in this study or not. If you volunteer to be in this study,
you may withdraw at any time without consequences of any kind. You may also refuse
to answer any questions you don‟t want to answer and still remain in the study.
The investigators may withdraw you from this research if circumstances arise which
warrant doing so. Your information would be withdrawn from the study if you do not
complete at least 80% of the survey items. As this study is interested only with
individuals who have been diagnosed with IBS, your information could be withdrawn if
you do not currently meet criteria for a diagnosis of IBS.
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS
The results of this study will be available to the participants in June 2009 on the
following website: http://athena.uwindsor.ca/fsirois
SUBSEQUENT USE OF DATA
The data for this study may be used in subsequent research on treatment expectations. By
completing and submitting the survey package you agree that this data can be used in
subsequent studies.
RIGHTS OF RESEARCH SUBJECTS
You may withdraw your consent to participate at any time and discontinue participation
without penalty. If you have questions regarding your rights as a research subject,
contact: Research Ethics Coordinator, University of Windsor, Windsor, Ontario, CA,
N9B 3P4; telephone 519-253-3000, ext. 3916; e-mail: lbunn@uwindsor.ca
SIGNATURE OF INVESTIGATOR
These are the terms under which I will conduct research.
Tobi Wilson, M.A.
Department of Psychology
University of Windsor
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It is recommended that you print out a copy of this letter of information for your
records.
Pass it on: Feel free to send this page to other people you know with IBS who might be
interested in completing the survey
Do you wish to continue? To acknowledge that you have read and understood this
information and would like to continue with the survey, please click on “I agree.”

I AGREE
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CONSENT TO PARTICIPATE IN RESEARCH
IBS Treatment Study
Study Two
(Paper version)
You are asked to participate in a research study conducted by Tobi Wilson, graduate
student, and Dr. Fuschia Sirois, research supervisor, from the Department of Psychology
at the University of Windsor. The results of this research will contribute to Ms. Wilson‟s
doctoral dissertation.
If you have any questions or concerns about the research, please feel free to contact Dr.
Fuschia Sirois at 519-253-3000 X 4447 or email sirois12@uwindsor.ca.
PURPOSE OF THE STUDY
The purpose of this study is to look at what people with irritable bowel syndrome (IBS)
think about some of the options that are available for treating IBS. Specifically, this
study is interested in people‟s thoughts about whether different treatments will work for
them. In addition, this study is designed to assess how individual‟s expectations and
preferences for different treatments vary due to individual‟s unique personal
characteristics.
PROCEDURES
If you volunteer to participate in this study, we would ask you to do the following things:
First you would be asked to read about some hypothetical treatment options for IBS.
Then you would be asked to rate how much you thought each treatment would work for
you, and pick the one you would prefer. You would be asked to provide some basic
demographic information about yourself and your experience of IBS symptoms and
treatments. You would then complete a survey that asks questions about your unique
characteristics. Finally, you would be given the opportunity to tell us your thoughts
about these treatment options.
If you volunteer to participate in this study, it would take about 25 minutes to complete,
and you would only be asked to participate once. You would then be asked to seal the
completed study materials (consent form and survey package) in the postage-paid
envelope provided, and place the package in the mail. A similar study has been conducted
not long ago, (IBS Treatment Expectations – Study One) and if you participated in that
study, we ask that you do not participate in this one.
POTENTIAL RISKS AND DISCOMFORTS
Some people may experience some mild distress when asked to think about their IBS.
We have tried to minimize this risk by making your participation anonymous, and by
only asking you to provide your opinions.
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POTENTIAL BENEFITS TO PARTICIPANTS AND/OR SOCIETY
Participating in this study will be of no direct benefit to you.
We think that the results of this study could potentially be of benefit to society. For
example, we think that IBS treatments could be improved if we had more knowledge
about what people with IBS think about different treatment options, and what individual
factors affect these expectations.
PAYMENT FOR PARTICIPATION
In return for your participation, when you return your package by mail, you will be
entered into a draw for one of several gift certificates from a major international
bookseller. The value of these gift certificates is 20 CAD (18 USD, 14 EUR or 10 GBP).
CONFIDENTIALITY
The information you provide in this study will remain anonymous. This means that you
will NOT be asked to provide your name. If you choose to be contacted by regular mail
in the case that you win a gift certificate, your address will be stored separately from your
study information so that your information cannot be linked to you. All data will be
stored securely and may only be accessed by the main investigator and faculty supervisor.
Data will be stored securely for a period of 10 years, as required, at which time it will be
destroyed.
PARTICIPATION AND WITHDRAWAL
You can choose whether to be in this study or not. If you volunteer to be in this study,
you may withdraw at any time without consequences of any kind. You may also refuse
to answer any questions you don‟t want to answer and still remain in the study.
The investigators may withdraw you from this research if circumstances arise which
warrant doing so. Your information would be withdrawn from the study if you do not
complete at least 80% of the survey items. As this study is interested only with
individuals who have been diagnosed with IBS, your information could be withdrawn if
you do not currently meet criteria for a diagnosis of IBS.
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS
The results of this study will be available to the participants in June, 2009 on the
following website: http://athena.uwindsor.ca/fsirois
SUBSEQUENT USE OF DATA
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The data for this study may be used in subsequent research on treatment expectations. By
completing and submitting the survey package you agree that this data can be used in
subsequent studies.
RIGHTS OF RESEARCH SUBJECTS
You may withdraw your consent to participate at any time and discontinue participation
without penalty. If you have questions regarding your rights as a research subject,
contact: Research Ethics Coordinator, University of Windsor, Windsor, Ontario, CA,
N9B 3P4; telephone 519-253-3000, ext. 3916; e-mail: lbunn@uwindsor.ca
SIGNATURE OF RESEARCH SUBJECT/LEGAL REPRESENTATIVE
I understand the information provided for the study IBS Treatment Study - Two as
described herein. My questions have been answered to my satisfaction, and I agree to
participate in this study. I have been given a copy of this form.
____________________________________
Signature
SIGNATURE OF INVESTIGATOR
These are the terms under which I will conduct research.

_______________________________________
Tobi Wilson, M.A.
Department of Psychology
University of Windsor
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________________
Date

Appendix G. Demographic & Background Questions
We would like to know a little bit about you. Please fill in the information below.
Age: _____________
Date of Birth: Day _____ Month ______ Year _______
Recruited by: ___ IBS website ___ Research website ___ Other
Ethnicity: (check one)
Asian
___
Black
___
East Indian ___
Hispanic
___
Mixed
___
Native ___
White
___
Employment Status: (check one)
Employed Full-time ___
Employed Part-time ___
Unemployed
___
Disabled
___
Retied
___
Student
___
Education (check one)
Some high school
___
High school graduate
___
Some college/ university
___
College / university graduate
___
Graduate / professional school
___
Marital Status: (check one)
Never married
___
Married/ Common law
___
Separated / Divorced
___
Widowed
___
About your IBS:
Diagnosed IBS?
Yes ___
No ___
By: Physician _____ Self ___
Have you ever been misdiagnosed? Yes ___ No ___
Time since diagnosis (years) ________
Time experiencing symptoms (years) ________
IBS subtype?
Constipation predominant
___
Alternating subtype
___
Diarrhea predominant
___
Unknown
___
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Appendix H. Letter of Explanation

EXPLANATION OF THE STUDY
IBS Treatment Study - One
Research has found that a person‟s beliefs about a treatment can have an
important effect on his or her response to that treatment. For example, if someone
believes that a treatment will be of benefit, he/she is more likely to actually benefit from
that treatment than is someone with less positive beliefs. There has been a lot of interest
in this relationship between beliefs and health outcomes. So far, however, very little is
known about what how someone‟s personal characteristics may influence one‟s beliefs
about treatment. This study was designed to be followed by a larger study that will look
at how strongly one‟s personality and thoughts about health influence one‟s beliefs about
treatment. For example, the larger study may find that, on average, those with higher
levels of anxiety show less positive beliefs about treatment. Or maybe people who think
of themselves as generally pretty healthy (despite having an illness) have more positive
beliefs about treatment, compared to people who think of themselves as generally
unhealthy.
Before doing the larger study, we had to make sure that the hypothetical treatment
scenarios that we had written were credible. Also, we wanted to check that not everyone
had the same beliefs about these treatments, as we want to know whether certain personal
characteristics or thoughts strengthen or weaken someone‟s beliefs about treatment.
In order to make sure that the treatment scenarios were reasonable, we conducted
this small study that you have just participated in. This study will provide some
important information that we will use in the larger study. For example, this study was
interested in your thoughts about the different treatment options. Based on the reactions
of all participants in this small study, we will be able to figure out if these treatment
scenarios are OK or if they need to be changed. This study may also provide some
important information about IBS treatment. For example, we were also interested in your
comments about the treatments and your beliefs about whether the treatments would be a
benefit to you. Knowing what types of treatments people prefer, and whether these
preferences are related to their history of treatment, their diagnosis, or the severity of
their symptoms, can be potentially useful information for those health care providers that
want to offer the best IBS treatment to their patients.
Thank you so much for participating in this research. We greatly appreciate your
time and effort!
Tobi Wilson, M.A.
Fuschia Sirois, Ph. D
Department of Psychology, University of Windsor
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EXPLANATION OF THE STUDY
IBS Treatment Study - Two
Research has found that a person‟s expectations about a treatment can have an
important effect on his or her response to that treatment. For instance, if an individual
expects that a treatment will be of great benefit, he/she is more likely to actually benefit
from that treatment than is an individual with less positive expectations. Although this
finding has been well established, very little is known about what sort of personal
characteristics may influence one‟s expectations of treatment. This study was designed
to investigate how strongly one‟s personality and beliefs influence one‟s treatment
expectations. For example, we may find that, on average, those with higher levels of
anxiety show less positive treatment expectations. Perhaps people who think of
themselves as generally pretty healthy (despite having a particular illness) have more
positive expectations about the outcomes of treatment. The questionnaires you have just
completed are designed to measure certain aspects of your personality (e.g., level of
hope, optimism, anxiety, motivation), as well as aspects of your beliefs about health and
illness (e.g., your general health, sense of control over your symptoms, belief in your own
ability to manage your illness). Your responses will help us to figure out whether on
average, certain personality traits or beliefs are strongly related to treatment expectations.
With this information, we can develop ways to boost people‟s expectations about their
treatment. For example, if it turns out that anxiety really interferes with treatment
expectations, then we will encourage treatment providers to assess a person‟s anxiety and
address it, in order to help that person get the most out of treatment.
Thank you so much for participating in this research. We greatly appreciate your
time and effort!
Tobi Wilson, M.A.
Fuschia Sirois, Ph. D
Department of Psychology
University of Windsor
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Appendix I.

Treatment Vignettes

Please read the following treatment vignettes and imagine that you are participating in
this scenario.
(Note that this treatment scenario is hypothetical; your participation in the
current study will not involve participating in any treatments).
Please imagine that these treatment scenarios would occur free of charge and at a location
convenient for you.
In this treatment scenario, first you would be invited into a local clinic…
An interview will be conducted by a gastroenterologist (IBS specialist) to
assess:
a) Your IBS symptomotology (severity, IBS subtype, history of symptoms and
treatment, and how much your IBS gets in way of your life);
b) Potential contributors (dietary habits, personal trigger factors, stress
management knowledge and behaviours);
c) Other health concerns; and
d) Differential diagnosis (Your family history of health problems, and symptoms
associated with organic diseases will be assessed via interview to ensure that a
diagnosis of IBS is appropriate for you.
If necessary you will be referred for physical tests to aid in this differential
diagnosis or asked to track potential contributors in a daily diary for the
period of one week. This supplemental information will be reviewed in a
follow-up clinical interview.
If you do not meet diagnostic criteria for IBS, you will no longer be eligible to
participate in this treatment scenario. You would be provided with an external
follow-up referral if indicated.
Based on the information provided in the interview(s), you will be assigned to
one of three treatment options:
a) Treatment A
o You would receive a dietary consult, and be provided with specific
dietary recommendations as well as other suggestions regarding
lifestyle factors known to affect global symptom reporting in
individuals with IBS
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o You would be prescribed a pharmaceutical drug, specific to your IBS
subtype (IBS-D or IBS C/A) that is designed to provide global IBS
symptom improvement
o
Both drugs have been shown in clinical trials to improve global
symptom reports in both men and women, as compared to
placebo treatments.
o
Specifically, both drugs have been shown to significantly
improve pain/discomfort, abnormal bowel habits, and bloating.
o
After extensive clinical testing, neither drug has been
associated with serious health consequences
o Both drugs are associated with mild-moderate side-effects in some
people.
o
The most common side-effect for the IBS-D drug is constipation
(in about 15% of participants). For the IBS-C/A
drug, the most
common side-effect is diarrhea (in about 10% of
participants)
o
Other, less common side effects associated with these drugs
include headache, abdominal pain, nausea or flatulence.
o If prescribed the IBS-D drug, you would take the drug three times a
day in tablet form. If prescribed the IBS-C/A drug, you would take the
drug twice a day, in tablet form.
o Once per week, for eight weeks, you would be asked to visit the local
clinic to talk with the gastroenterologist for 20 minutes about your IBS
symptoms and any side-effects.

b) Treatment B
o You would first receive a dietary consult, and be provided with
specific dietary recommendations as well as other suggestions
regarding lifestyle factors known to affect global symptom reporting in
individuals with IBS.
o You will then be prescribed a short course of individual therapy with a
professional, designed to provide global IBS symptom improvement.
o The therapy will involve cognitive-behavioural therapy for IBS
combined with guided relaxation.
o
This type of treatment has been shown in clinical trials to
improve global symptom reports in both men and women, as
compared to placebo treatments.
o
This treatment has been found to improve bowel symptoms
and quality of life significantly for IBS sufferers.
o
The cognitive-behavioural component involves the identification
of environmental triggers and the modification of
self-defeating
patterns of thought and behaviour underlying IBS symptoms.
o
The relaxation component uses guided imagery to promote
relaxation, reduce pain and regulate bowel function.
o Neither component has been associated with serious side-effects
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o You would be asked to attend a 50-minute therapy session once per
week and to complete approximately one hour of homework per week
o You would meet with the professional for therapy at the local clinic for
8 weeks.
c)

Treatment C
o You would first receive a dietary consult, and be provided with
specific dietary recommendations as well as other suggestions
regarding lifestyle factors known to affect global symptom reporting in
individuals with IBS.
o You will then be prescribed a short course of individual therapy with a
professional, as well as a pharmaceutical drug, both designed to
provide global IBS symptom improvement.
o Both types of treatment have been shown in clinical trials to contribute
to global symptoms improvements in both men and women
o In this treatment, you will prescribed the same drug as above (specific
to your IBS subtype), except that the dose will be reduced to 50% of
the dose for the above treatment
o In this treatment, you will be prescribed a 6 - week course of therapy,
and will only receive the cognitive-behavioural component of the
therapy
o The cognitive-behavioural component involves the identification of
environmental triggers and the modification of self-defeating patterns
of thought and behaviour underlying IBS symptoms
o The drug treatment has been associated with mild-moderate sideeffects (described above)
o The cognitive-behavioural therapy has not been associated with any
side-effects
o You would be asked to attend a 40 – minute therapy session once per
week for 6 weeks, and to complete approximately one hour of
homework per week
o Once per week, for 8 weeks, you would talk with the
gastroenterologist for 10 minutes about your IBS symptoms and any
side-effects.
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Appendix J.

Expectancy Rating Scales

Think back to the treatments in the vignettes. We are
interested in how much you think each treatment would work
for you and your IBS symptoms, if you were in the
hypothetical treatment situation.
This is no right or wrong answer; we are just interested in
your opinion.
Think about the treatment that offered a drug specific to
your IBS subtype.
How much do you expect that this treatment would work for
you and your symptoms of IBS?
On the line below, please show how much you expect this
treatment to work, by making a mark along the line
somewhere between „No Expected Benefit‟ and „Excellent
Expected Benefit.‟
No
Excellent
Expected
Expected
Benefit
Benefit
_____________________________________________________________________________
0
25
50
75
100

Think about the treatment that offered both cognitivebehavioural therapy and guided relaxation.
How much do you expect that this treatment would work for
you and your symptoms of IBS?
On the line below, please show how much you expect this
treatment to work, by making a mark along the line
somewhere between „No Expected Benefit‟ and „Excellent
Expected Benefit.‟
No
Excellent
Expected
Expected
Benefit
Benefit
_____________________________________________________________________________
0
25
50
75
10
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Appendix K. Treatment Credibility Questions
Think back again to the treatments in the vignettes. We are also interested in how
credible you think each treatment description was.
There is no right or wrong answer; we are just interested in your opinion.
Think about the treatment that offered a drug specific to your IBS subtype.
How credible is this treatment for IBS?
On the line below, please show how much you thought this specific treatment was
credible for IBS, by making a mark along the line somewhere between „Not At All
Credible‟ and „Completely Credible.‟
Not
At All
Completely
Credible
Credible
_____________________________________________________________________
0
2.5
5
7.5
11

Think about the treatment that offered both cognitive-behavioural therapy and guided
relaxation.
How credible is this treatment for IBS?
Not
At All
Completely
Credible
Credible
_______________________________________________________________________
0
2.5
5
7.5
11

Think about the treatment that offered a drug specific to your IBS subtype as well as
cognitive-behavioural therapy.
How credible is this treatment for IBS?
Not
At All
Completely
Credible
Credible
_______________________________________________________________________
0
2.5
5
7.5
11
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Appendix L. The Private Self- Consciousness Scale
Please indicate how much each of these statements describes
you, by checking the appropriate box.

Not at all
like me

I‟m always trying to figure myself out.

I think about myself a lot.

I often daydream about myself.

I generally pay attention to my inner
feelings.

I‟m constantly thinking about my reasons
for doing things.

I sometimes step back (in my own mind)
in order to examine myself from a
distance.

I‟m quick to notice changes in my mood.
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Kind of
like me

Much
like me

A lot
like me

Appendix M. Trait Anxiety Measures
Anxious Arousal subscale of the Mood and Anxiety Symptoms Questionnaire
Below is a list of feelings, sensations, problems and experiences
that people sometimes have. Read each item and then mark the
appropriate choice in the space next to that item. Use the
choice that best describes how much you have feel or experience
things this way generally.
Not at
all

A
Little
Bit

Moderatel
y

Startled
Easily
Faint
Numbness or
tingling in
my body
Pain in my
chest
Hot or cold
spells
Dizzy or
lightheaded
Short of
breath
Unable to
relax
Like I was
choking
A very dry
mouth
Afraid I
was going
to die
Heart
racing or
pounding
Trembling
or shaking
Need to
urinate
frequently
Trouble
swallowing
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Quite a
Bit

Extremel
y

Cold or
sweaty
hands

Penn State Worry Questionnaire
Enter the number that best describes how typical or characteristic each item is of you:
1
Not at all typical

2

3
Somewhat typical

1. If I do not have enough time to do everything,
I do not worry about it.
2. My worries overwhelm me.
3. I do not tend to worry about things.
4. Many situations make me worry.
5. I know I should not worry about things,
but I just cannot help it.
6. When I am under pressure I worry a lot.
7. I am always worrying about something.
8. I find it easy to dismiss worrisome thoughts.
9. As soon as I finish one task, I start to worry
about everything else I have to do.
10. I never worry about anything.
11. When there is nothing more I can do about a concern,
I do not worry about it anymore.
12. I have been a worrier all my life.
13. I notice that I have been worrying about things.
14. Once I start worrying, I cannot stop.
15. I worry all the time.
16. I worry about projects until they are all done.
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4

____
____
____
____
____
____
____
____
____
____
____
____
____
____
____
____

5
Very Typical

Appendix N. The Life Orientation Scale – Revised
Please indicate how much you agree with each of the
statements below by checking the appropriate box. Try to
be as honest and accurate as your can, and try not to let
your answer to one question influence your answer to other
questions. There are no right or wrong answers.
Strongly
Disagree
In uncertain times, I
usually expect the
best
It‟s easy for me to
relax
If something can go
wrong for me, it will
I‟m always optimistic
about my future
I enjoy my friends a
lot
It‟s important for me
to keep busy
I hardly ever expect
things to go my way
I don‟t get upset too
easily
I rarely count on good
things happening to me
Overall, I expect more
good things to happen
than bad
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Disagree

Agree

Strongly
Agree

Appendix O. The Adult Hope Scale
Directions: Read each tem carefully. Using the scale
shown below, please select the number that best
describes YOU and put that number in the blank
provided.
1.
2.
3.
4.
5.
6.
7.
8.
___
___
___
___
___
___
___
___
___
___
___
___

=
=
=
=
=
=
=
=

Definitely False
Mostly False
Somewhat False
Slightly False
Slightly True
Somewhat True
Mostly True
Definitely True

1. I can think of many ways to get out of a jam.
2.
I energetically pursue my goals.
3.
I feel tired most of the time.
4. There are lots of ways around any problem.
5. I am easily downed in an argument.
6. I can think of many ways to get the things in
life that are important to me.
7. I worry about my health.
8. Even when others get discouraged, I know I can
find a way to solve the problem.
9. My past experiences have prepared me well for
my future.
10. I‟ve been pretty successful in life.
11. I usually find myself worrying about
something.
12. I meet the goals that I set for myself.
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Appendix P. Perception of Health items
These questions are about how healthy you perceive your
self to be. Please read each question and indicate your
response by checking the appropriate box. There are no
right or answers; we are interested in your opinion.
Very
Poor

Compared to other
people your age, how
would you rate your
health?
Compared to other
people with IBS, how
would you rate your
health?
In general, how would
you rate your health?
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Poor

Average

Good

Excellent

Appendix Q. Brief Health History Checklist
This section deals with health issues you have experienced that
are either temporary or over a short period of time (acute).
ACUTE HEALTH PROBLEMS:
Please indicate which ones you are currently experiencing, or can
remember experiencing within the past six months. – please check
all that apply

Back problems

Insomnia

Skin

Sprains or muscle

Infections

strains

Headache

Allergies

problems/r
ashes

Flu, cold or fever

Reproducti
ve/
menstrual
problems

Dental problems

Other
acute
health
problems

Acute digestive
problems
(constipation,
heartburn, etc.)
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Appendix R. Control Beliefs Inventory
The following statements concern the different ideas that people have about their health.
Some of these statements refer to your general state of health and others refer to specific
times when you are experiencing illness symptoms. Please read each statement carefully
and answer according to how much you agree with each statement by circling a number
from 1 to 6. Please answer according to the following scale:
1

2

3

4

5

6

STRONGLY
DISAGREE

DISAGREE

MILDLY
DISAGREE

MILDLY
AGREE

AGREE

STRONGLY
AGREE

Control Over Health Items
1. My health depends on how I take care of myself.
2. It is my own actions that determine how healthy I am.
3. People who take care of themselves stay healthy.
4. How soon I recover from an illness depends on how I look after myself.
5. My current state of health is a reflection of how I look after myself.
6. If I make the effort, I can manage my illness.
Control Over Symptoms Items
7. If I do the right things I can make my symptoms more manageable.
8. If I make the effort, I can manage my symptoms.
9. There are things that I can do to make my symptoms easier to deal with.
10. I believe that I can do more to control my symptoms
11. I can take control of my health by managing my day-to-day symptoms.
Health Self-Efficacy Items
12. Even though there are things I can do to improve my health, I don‟t feel that I can do
them.
13. I am able to meet the challenge of following a healthy routine
14. When facing a health problem, I often feel overwhelmed about what to do.
15. I am certain that with effort I can improve my health.
16. I am confident that I could deal with any unexpected health problems.
17. When it comes to my health, I often feel unable to do what I know should be done.
18. I am confident in my ability to make the right decisions about my health.
19. Regardless of circumstances, there are things I can do to improve my health.
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Appendix S. Coping Self-Efficacy Scale
Please indicate how well you feel you have been dealing with the different
aspects of your condition in general by checking a box for each question.
Strongly
Disagree

Disagree

a) I am successfully
coping with the
symptoms of my
condition
b) I am successfully
coping with the
day to day
problems that
living with my
condition creates
c) I am successfully
coping with the
emotional aspects
of my condition
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Neither
Agree nor
Disagree

Agree

Strongly
Agree

Appendix T. Resistance to Illness Subscale
Please read each of the following statements carefully and indicate how true is statement
is for you by checking the appropriate box.
Definitely
False

I seem to get sick a little
easier than other people
Most people get sick a little
easier than I do
My body seems to resist
illness very well
When there is something
going around I usually catch it
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Mostly
False

Don’t
Know

Mostly
True

Definitely
True

Appendix U. Catastrophizing Interpretation of Bodily Complaints Subscale
Completely
Wrong
A suddenly appearing joint pain
can be a sign of a beginning
paralysis
I‟m healthy when I don‟t have any
bodily sensations
My doctor or I must be capable of
finding an explanation for all my
bodily complaints.
When suffering from constipation,
one should consult an expert
immediately to be certain that one
doesn‟t have intestinal cancer.
Bodily complaints are always a
sign of disease.
Red blotches on the skin are a
threatening sign of skin cancer
When suffering from joint pain,
one should take good care of
oneself.
When one sweats a lot, it can be
due to an overburdened heart.
The most common reason for
discomfort is a serious illness.
If a doctor refers me for further
examinations, then he is
convinced that there is a serious
problem.
Only persons who do not exert
themselves physically stay healthy
in the long run.
A healthy body doesn‟t cause
complaints.
A tingling sensation in the legs
can be a serious sign of a nerve
disorder.
The most serious diseases develop
unnoticed and then break out at
some time or other.
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Mostly
Wrong

Mostly
Right

Completely
Right

Appendix V. Treatment Experience Questions
Think about the treatment that offered a drug specific to
your IBS subtype.
Do you have experience with this type of treatment? ___ Yes ___ No (Check One)
If Yes, Please rate how successful that treatment was for you (by making a mark on the line
below):
0
10
__________________________________________________________________________
Not at all
Completely
Successful
Successful

Think about the treatment that offered both cognitivebehavioural therapy and guided relaxation.
Do you have experience with this type of treatment? ___ Yes ___ No (Check One)
If Yes, Please rate how successful that treatment was for you (by making a mark on the line
below):
0
10
__________________________________________________________________________
Not at all
Completely
Successful
Successful
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This section deals with your current and past IBS treatment
experiences, as well as how successful they were for
helping with your symptoms.
Please check off any treatments that you are CURRENTLY
using to treat your symptoms of IBS. For treatment that
you are using, rate your satisfaction with this treatment
by checking the appropriate box.
very
dissatisfied

YES

dissatisfied

Diet Changes
Relaxation
Training
Biofeedback
Training
Laxatives /
Antidiarrheals
Herbal / Mineral
/Vitamin
Supplements
Probiotics
Acupuncture
Antispasmotics
Serotonin
Agonists/
Antagonists
Hypnotherapy
Psychotherapy
Antidepressants
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mildly
dissatisfied

mildly
satisfied

satisfied

very
satisfied

Please check off any treatments that you have used in the
PAST to treat your symptoms of IBS. For treatment(s) that
you have used, rate your satisfaction with this treatment
by checking the appropriate box.
very
dissatisfied

YES

dissatisfied

mildly
dissatisfied

mildly
satisfied

satisfied

very
satisfied

Diet Changes
Relaxation
Training
Biofeedback
Training
Laxatives /
Antidiarrheals
Herbal / Mineral
/Vitamin
Supplements
Probiotics
Acupuncture
Antispasmotics
Serotonin
Agonists/
Antagonists
Hypnotherapy
Psychotherapy
Antidepressants

Please indicate below if you have been treated by a
gastroenterologist before, as well as your satisfaction
with this treatment.
YES

not satisfied

mildly
satisfied

Treated by
Gastroenterologist
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moderately
satisfied

very much
satisfied

extremely
satisfied

Appendix W. Symptom Attribution Questions
Listed below are symptoms you may or may not have ever experienced. Below each
symptom are three possible reasons for this symptom. For each reason, please indicate
how much the reason might explain your symptom, by making a mark along the line
beside the reason. Please mark every item for each symptom.
If I had trouble sleeping, I would probably think that is because:
Not true
At all
Some kind of pain or physical
discomfort is keeping me awake
I'm not tired or I had too much coffee
I'm worrying too much or I must be
nervous about something

Very
Much
True

0_______________________________10
0_______________________________10
0_______________________________10

If I were constipated or irregular, I would probably think that it is because:
Not true
At all

Very
Much
True

There is not enough fruit or fiber
in my diet

0_______________________________10

Nervous tension is keeping me from
being regular

0_______________________________10

There is something wrong with my
Bowels or intestines

0_______________________________10

If I were sweating a lot, I would probably think that it is because:
Not true
At all

Very
Much
True

I must have a fever or infection

0_______________________________10

I‟m too anxious or nervous

0_______________________________10

The room is too warm, I‟m
Overdressed or working too hard

0_______________________________10
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If I had abdominal pain or discomfort, I would probably think that it was because:
Not true
At all

Very
Much
True

I‟ve worried myself sick

0_______________________________10

I have the flu or stomach irritation

0_______________________________10

I‟ve had something to eat
that did not agree with

0_______________________________10
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Appendix X. Perception of Treatment Focus Rating Scales
Think back to the treatment that you said you would hypothetically prefer.
While thinking about the treatment that you chose, consider how true the following
statements are.
This is no right or wrong answer; we are just interested in your opinion.
“This treatment targets the physical causes of IBS.”
On the line below, please show how much you feel this statement is true, by making a
mark along the line somewhere between „Not at All True‟ to „Very Much True.‟

Not at
Very
All
Much
True
True
______________________________________________________________
0
2.5
5
7.5
10

“This treatment targets the psychological causes of IBS.”
On the line below, please show how much you feel this statement is true, by making a
mark along the line somewhere between „Not at All True‟ to „Very Much True.‟
Not at
Very
All
Much
True
True
______________________________________________________________
0
2.5
5
7.5
10
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Think back to the other treatment that was offered, the one you did not choose as your
preferred treatment.
While thinking about the treatment that you did not choose as preferred, consider how
true the following statements are.
This is no right or wrong answer; we are just interested in your opinion.
“This treatment targets the physical causes of IBS.”
On the line below, please show how much you feel this statement is true, by making a
mark along the line somewhere between „Not at All True‟ to „Very Much True.‟

Not at
Very
All
Much
True
True
______________________________________________________________
0
2.5
5
7.5
10

“This treatment targets the psychological causes of IBS.”
On the line below, please show how much you feel this statement is true, by making a
mark along the line somewhere between „Not at All True‟ to „Very Much True.‟

Not at
Very
All
Much
True
True
______________________________________________________________
0
2.5
5
7.5
10
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Appendix Y. Current IBS Symptom Severity Scale
Current Symptoms Questionnaire
For each question, please „check‟ the number that best
describes your symptoms over this past week. Please answer
all questions.
1. ABDOMINAL PAIN
No symptoms

1

2

3

4

5

6

7

8

Extremely
severe

1

2

3

4

5

6

7

8

Extremely
severe

1

2

3

4

5

6

7

8

Extremely
severe

2. CONSTIPATION
No symptoms

3. DIARRHEA
No symptoms

4. INCOMPLETE EVACUATION AFTER A BOWEL MOVEMENT
No symptoms

1

2

3

4

5

6

7

8

Extremely
severe

1

2

3

4

5

6

7

8

Extremely
severe

1

2

3

4

5

6

7

8

Extremely
severe

7

8

Extremely
severe

5. BLOATING
No symptoms

6. FLATULENCE
No symptoms

7. URGENCY WHEN NEEDING A BOWEL MOVEMENT
No symptoms

1

2

3

4

5

6

To what extent has IBS affected your daily activities? (check one):
Not at all

A little

Somewhat
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A lot
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Appendix Z. The Social Desirability Scale -17
Below you will find a list of statements. Please read each
statement carefully and decide if this statement describes
you or not. It if describes you, check the “true”; if not,
check the word “false.”
TRUE
I sometimes litter
I always admit my mistakes openly and
face the potential negative consequences
In traffic I am always polite and
considerate of others
I sometimes only help because I expect
something in return
I always accept others‟ opinions, even
when they don‟t agree with my own
I take out my bad moods on others now
and then
There has been an occasion when I took
advantage of someone else
In conversations I always listen
attentively and let others finish their
sentences
I never hesitate to help someone in case
of emergency
When I have made a promise, I keep it –
no ifs, ands or buts
I occasionally speak badly of others
behind their back
I would never live off other people
I always stay friendly and courteous
with other people, even when I am
stressed out
During arguments I always stay objective
and matter-of-fact
There has been at least one occasion
when I failed to return an item I
borrowed
I always eat a healthy diet
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FALSE
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Appendix AA.

Modified Patient Reactions Assessment

Please think back to the treatment vignettes that you read. Imagine that you were actually
involved in the treatment scenario, having a clinical interview with a gastroenterologist
who later referred you to a particular treatment. Imagine yourself interacting with the
treatment provider. Please keep this in mind while reading the following statements and
indicate your level of agreement (hypothetically) by checking the appropriate box.
Strongly
Disagree
I understand the treatment
side-effects
I have been told what the
treatment would do
I understand the treatment plan
for me
I have a good idea about the
changes to expect in my health
The treatment procedure has
been clearly explained
It is difficult to get conflicting
information straightened out
I have difficulty asking about
something I don‟t understand
It is hard for me to tell about
new symptoms
It is difficult asking the
provider questions
The provider is warm and
caring towards me
The provider makes me
comfortable discussing
personal issues
This person really respects me
I sometimes feel insulted when
talking to this person
The provider doesn‟t seem
interested in me as a person
It is hard for me to ask how
treatment is going
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Disagree

Neutral

Agree Strongly
Agree

Appendix AB.

Qualitative Data Coding Manual
Pre-set categories

Self-focused attention.
Definition: a tendency to tendency to focus on attending to inner thoughts,
feelings and sensations.
Examples:
I‟m always checking in with what is going on in my body.
I pay a lot of attention to whether I‟m feeling stressed.
Anxiety.
Definition: a tendency towards feeling apprehensive about situations and
potentialities, accompanied by worries, negative affect and
physiological feelings of anxiety.
Examples:
I‟ve always been a worrier.
When I get to feeling anxious…
Optimism/ Pessimism.
Definition: a tendency to expect good things will happen; a tendency to expect
bad things will happen.
Example:
I tend to look on the bright side.
If something bad could happen, it usually will.
Hope.
Definition: a cognitive set based on reciprocally derived sense of successful
agency (goal-directed determination) and pathways (ways to meet
goals).
Example:
Any mention of the word „hope.‟
Current Health: Perception of health.
Definition: beliefs about one‟s general level of overall health
Examples:
I‟m pretty healthy overall.
My health is not what I‟d call good.
Current Health: Acute health problems.
Definition: current health problems other than IBS
Example:
Any mention of any other health condition.
Control Beliefs: Health.
Definition: a belief that one generally knows how to manage their health.
Example:
It‟s up to me to get healthy.
Control Beliefs: Symptoms.
Definition: a belief that one can manage their symptoms of IBS
Example:
I‟ve always been aware of how I affect my IBS symptoms…
Health self-efficacy.
Definition: a belief that one has the ability to be healthy, to reduce
symptomatology, to recover from illness, etc.
Example:
I can do what it takes to get control of my health.
Vulnerability to illness.
Definition: a belief that one is more susceptible to illness or poor health
Example:
If it‟s going around, I‟ll catch it for sure.
Catastrophizing.
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Definition: a belief that bodily sensations and symptoms are indicative of a
serious illness or problem.
Example:
I tend to get really worried when my body feels differently.
Treatment experience: Previous experience with similar treatment.
Definition: having tried or been offered a similar in the past.
Example:
I‟ve tried therapy for my IBS and it did nothing.
Treatment experience: Number of treatments attempted.
Definition: having tried any number of treatments in the past.
Example:
I‟ve tried so many treatments already….
Illness attributions: Somatic.
Definition: a perception that one‟s symptoms are caused by organic factors or that
the treatment is targeting the somatic aspects of one‟s symptoms.
Example:
The drug treatment really gets at the root of my problem
Illness attributions: Psychological.
Definition: a perception that one‟s symptoms are caused by psychological factors
or that the treatment is targeting the psychological aspects of one‟s
symptoms.
Example:
I know that stress really affects my IBS symptoms…
Motivation: Desire for relief.
Definition: a state of wanting to see relief
Example:
I have to see some sort of improvement!
Motivation: Symptom severity.
Definition: a state of varying severity of symptoms
Example:
My symptoms aren‟t so bad these days anyways
Motivation: Socially desirable responding.
Definition: a tendency to present oneself in the most favourable light
Example:
I always adhere to all treatment recommendations
Patient-provider relationship.
Definition: any aspect of the provider that is salient to the patient
Example:
If my doctor recommends it, I trust him
Emergent Categories
Aversion.
Definition: a preference against / dislike of something
Examples:
I prefer to treat my symptoms without drugs.
I don‟t do for that therapy stuff
Side effects.
Definition: undesirable consequences of a therapeutic agent
Example:
It sounds like the side effects would be as bad as my symptoms
Illness attributions: Holistic.
Definition: a perception that one‟s symptoms are caused by a combination of
somatic and psychological factors or that the treatment is targeting the somatic
and psychological aspects of one‟s symptoms.
Example:
I really think one needs to address the mind and the body together
Illness attributions: Situational.
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Definition: a perception that one‟s symptoms are caused by factors that are neither
somatic nor psychological factors.
Example:
My IBS is due to my poor lifestyle
Convenience.
Definition: a perception that a treatment may or may not be best due to lifestyle,
personality, financial, or social factors
Example:
I don‟t have the time to do relaxation
Weekly therapy would be too expensive for me
Treatment experience: Vicarious.
Definition: having known someone who has tried something similar in the past
Example:
Therapy has done very little to help my mom with her symptoms
Treatment experience: Inexperience.
Definition: having not tried something in the past
Example:
I haven‟t yet tried that approach…
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Appendix AC.

Testing for Moderation

1. Summary of Hierarchical Regression Analysis to Test Moderation of Self-focused
Attention to Treatment Expectanciesa by Treatment Experience (N = 227)
R2
R2

Variable
B
SE B
Step 1

.02

Experience

.08

.06

.08

Self-focused attention

.01

.01

.12

Step 2

.06** .04**

Experience

.76

.24

.76**

Self-focused attention

.00

.01

.03

Experience*Self-focused attention

.04

.01

.77**

a

Transformed. Adjusted R2 after step 1 = .01, after step 2 = .04.
*p < .05. **p < .01.

2. Summary of Hierarchical Regression Analysis to Test Moderation of Optimism to
Treatment Expectanciesa by Treatment Experience (N = 227)
R2
R2

Variable
B
SE B
Step 1

.04*

Experience

.05

.06

.05

Optimism

.05

.02

.18**

Step 2

.05*

Experience

.40

.26

.41

Optimism

.03

.02

.10

Experience*Optimism

.05

.03

.38

a

Transformed. Adjusted R2 after step 1 = .03, after step 2 = .03.
*p < .05. **p < .01.
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3. Summary of Hierarchical Regression Analysis to Test Moderation of Hope to
Treatment Expectanciesa by Treatment Experience (N = 227)
R2
R2

Variable
B
SE B
Step 1

.01

Experience

.06

.06

.06

Hope

.00

.00

.01

Step 2

a

.03

Experience

.61

.31

.63

Hope

.00

.00

.02

Experience*Hope

.01

.01

.59

.01

Transformed. Adjusted R2 after step 1 = .03, after step 2 = .03.

4. Summary of Hierarchical Regression Analysis to Test Moderation of Acute Health
Problems to Treatment Expectanciesa by Treatment Experience (N = 227)
R2
R2

Variable
B
SE B
Step 1

.01

Experience

.05

.06

.06

Acute health problems

.02

.01

.09

Step 2

.03

Experience

.05

.06

.05

Acute health problems

.00

.02

.01

Experience*Acute health problems

.04

.02

.16

a

Transformed. Adjusted R2 after step 1 = .00, after step 2 = .01.
*p < .05. **p < .01.
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.01

5. Summary of Hierarchical Regression Analysis to Test Moderation of Coping selfefficacy to Treatment Expectanciesa by Treatment Experience (N = 227)
R2
R2

Variable
B
SE B
Step 1

.03*

Experience

.08

.06

.08

Coping self-efficacy

.03

.01

.16*

Step 2

.09** .06**

Experience

.84

.21

.87**

Coping self-efficacy

.01

.01

.04

Experience* Coping self-efficacy

.08

.02

.88**

a

Transformed. Adjusted R2 after step 1 = .02, after step 2 = .08.
*p < .05. **p < .01.

6. Summary of Hierarchical Regression Analysis to Test Moderation of Control over
Symptomsa to Treatment Expectanciesa by Treatment Experience (N = 227)
R2
R2

Variable
B
SE B
Step 1

.10**

Experience

.05

.06

.05

Control over symptoms

.14

.03

.30**

Step 2

.11**

Experience

.05

.06

.05

Control over symptoms

.09

.04

.20*

Experience* Control over symptoms

.12

.06

.16

a

Transformed. Adjusted R2 after step 1 = .09, after step 2 = .10.
*p < .05. **p < .01.
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.02

7. Summary of Hierarchical Regression Analysis to Test Moderation of Perceived
Somatic Focus of Treatmenta to Treatment Expectanciesa by Treatment Experience (N =
227)
R2
R2

Variable
B
SE B
Step 1

.23**

Experience

.08

.06

.08

Perceived somatic focus of tx

.37

.05

.48**

Step 2

.23**

Experience

.22

.18

.23

Perceived somatic focus of tx

.41

.06

.52**

Experience* Perceived somatic focus of tx

.08

.09

.16

a

Transformed. Adjusted R2 after step 1 = .22, after step 2 = .22.
**p < .01.
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